document incorporate reference document proxy statement annual meeting shareholder hold iii file securities exchange commission day close fiscal year cover reporttable content table content item business item risk factor cautionary factor affect future result item unresolved staff comment item property item legal proceeding item safety disclosure executive officer registrant item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum afinancial statement note consolidated financial statement report independent register public accounting firm bsupplementary datum item change disagreement accountant account financial disclosure item control procedure management report item information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service item exhibit financial statement schedule item summary signature table content item business merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product company operation principally manage product basis include operating segment pharmaceutical animal health healthcare service alliance segment pharmaceutical segment reportable segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity sale vaccine major european market market company sanofi pasteur msd joint venture termination december begin merck record vaccine sale european market previously joint venture company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer companys healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient merck alliance segment primarily include result company relationship astrazeneca termination relationship june october company divest consumer care segment develop manufacture market overthecounter foot care sun care product company incorporate new jersey financial information information company segment item management discussion analysis financial condition result operation item financial statement supplementary datum product service mark appear type form different surround text trademark service mark own license promote distribute merck subsidiary affiliate note trademark service mark respective owner product sale total company sale include sale company pharmaceutical product total sale animal health product follow million total sale pharmaceutical januviajanumet zetiavytorin gardasilgardasil proquadmmr iivarivax keytruda isentress remicade cubicin singulair pneumovax animal health consumer care revenue october company divest consumer care segment develop manufacture market overthecounter foot care sun care product revenue primarily comprise miscellaneous corporate revenue include revenue hedging activity thirdparty manufacture sale table content pharmaceutical company pharmaceutical product include therapeutic preventive agent generally sell prescription treatment human disorder certain product company franchise follow primary care women health cardiovascular zetia ezetimibe market ezetrol country outside united states vytorin ezetimibesimvastatin market inegy outside united states atozet ezetimibe atorvastatin market certain country outside united states cholesterol modifying medicine diabete januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabete general medicine women health nuvare etonogestrelethinyl estradiol vaginal ring vaginal contraceptive product implanon etonogestrel implant singlerod subdermal contraceptive implantnexplanon etonogestrel implant single radiopaque rodshape subdermal contraceptive implant dulera inhalation aerosol mometasone furoateformoterol fumarate dihydrate combination medicine treatment asthma follistim follitropin beta injection market puregon country outside united states fertility treatment hospital specialty hepatitis zepatier elbasvir grazoprevir treatment adult patient chronic hepatitis virus hcv genotype infection ribavirin certain patient population pegintron peginterferon alphab victrelis boceprevir medicines treatment chronic hcv hiv isentress raltegravir hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection hospital acute care cubicin daptomycin injection antibiotic complicated skin skin structure infection bacteremia cause designate susceptible organism noxafil posaconazole prevention invasive fungal infection invanz ertapenem sodium treatment certain infection cancida caspofungin acetate antifungal product bridion sugammadex injection medication reversal type neuromuscular block agent surgery primaxin imipenem cilastatin sodium antibacterial product immunology remicade infliximab treatment inflammatory disease simponi golimumab oncemonthly subcutaneous treatment certain inflammatory disease company market europe russia turkey oncology keytruda pembrolizumab treatment previously untreated metastatic nonsmallcell lung cancer nsclc patient tumor express high level pdl tumor proportion score tps previously treat metastatic nsclc patient tumor express pdl tps advanced melanoma previously treat recurrent metastatic head neck cancer emend aprepitant prevention chemotherapy induce postoperative nausea vomit temodar temozolomide market temodal outside united states treatment certain type brain tumor diversify brand respiratory singulair montelukast medicine indicate chronic treatment asthma relief symptom allergic rhinitis nasonex mometasone furoate monohydrate inhaled nasal corticosteroid treatment nasal allergy symptom cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide treatments hypertension arcoxia etoricoxib treatment arthritis pain company market outside united states fosamax alendronate sodium market fosamac japan treatment prevention osteoporosis zocor simvastatin statin modifying cholesterol table content vaccine gardasil human papillomavirus quadrivalent type vaccine recombinantgardasil human papillomavirus valent vaccine recombinant vaccine help prevent certain disease cause certain type human papillomavirus hpv proquad measle mump rubella varicella virus vaccine live pediatric combination vaccine help protect measle mump rubella varicella mmr measles mumps rubella virus vaccine live vaccine help prevent measle mump rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella zostavax zoster vaccine live vaccine help prevent shingles herpe zoster rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infant child pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease animal health animal health segment discover develop manufacture market animal health product include vaccine principal product segment include livestock product nuflor florfenicol antibiotic range use cattle swine bovilisvista vaccine line infectious disease cattle banamine flunixin meglumine bovine swine antiinflammatory estrumate cloprostenol sodium treatment fertility disorder cattle matrix altrenogest fertility management swine resflor florfenicol flunixin meglumine combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zuprevo tildipirosin bovine respiratory disease zilmax zilpaterol hydrochloride revalor trenbolone acetate estradiol improve production efficiency beef cattle safeguard fenbendazole dewormer cattle mpac mycoplasma hyopneumoniae bacterin swine pneumonia vaccine porcilis lawsonia intracellularis baterin circumvent porcine circovirus vaccine type kill baculovirus vector vaccine line infectious disease swine poultry product nobilisinnovax live marek disease vector vaccine line poultry paracox coccivac coccidiosis vaccine companion animal product bravecto fluralaner line product kill flea tick dog week nobivac vaccine line flexible dog cat vaccination otomax gentamicin sulfate usp betamethasone valerate usp clotrimazole usp ointmentmometamax gentamicin sulfate usp mometasone furoate monohydrate clotrimazole usp otic suspensionposatex orbifloxacin mometasone furoate monohydrate posaconazole suspension ear ointments acute chronic otitis caninsulinvetsulin porcine insulin zinc suspension diabete mellitus treatment dog cat panacur fenbendazolesafeguard fenbendazole broadspectrum anthelmintic dewormer use animal regumate altrenogest fertility management horse prestige vaccine line horse activyl indoxacrbscalibor deltamethrinexspot protect bite flea tick mosquitoe sandfly aquaculture product slice emamectin benzoate parasiticide sea lice salmon aquavac avirulent live culturenorvax vaccine bacterial viral disease fish compact vaccine salmon aquaflor florfenicol antibiotic farmraise fish discussion sale company product item management discussion analysis financial condition result operation product approval january merck announce food drug administration fda approve zepati treatment adult patient chronic hcv infection ribavirin certain patient population february merck announce fda approve supplemental new drug application singledose emend injection prevention delay nausea vomit adult receive initial repeat course moderately emetogenic chemotherapy company receive marketing approval european medicine agency ema bravecto spoton solution cat dog july company receive approval united states market product tradename bravecto topical table content july european commission approve zepati oncedaily single tablet combination therapy treatment chronic hcv infection ribavirin certain patient population august merck announce fda approve keytruda treatment patient recurrent metastatic head neck cancer disease progression platinumcontaine chemotherapy october merck announce fda approve keytruda firstline treatment patient nsclc tumor high pdl expression tps determine fdaapprove test egfr alk genomic tumor aberration addition october merck announce fda approve zinplava injection mgml zinplava indicate reduce recurrence clostridium difficile infection cdi patient year age old receive antibacterial drug treatment cdi high risk cdi recurrence january merck announce approve keytruda firstline treatment metastatic nsclc adult tumor high pdl expression tps egfr alk positive tumor mutation joint venture sanofi pasteur msd december merck sanofi pasteur sanofi terminate equallyowne joint venture form company develop market human vaccine europe license subsidiary scheringplough corporation scheringplough enter licensing agreement centocor ortho biotech inc centocor johnson johnson company market remicade prescribe treatment inflammatory disease scheringplough subsidiary exercise option contract centocor license right develop commercialize simponi fully human monoclonal antibody company marketing right product europe russia turkey remicade lose market exclusivity major european market february company long market exclusivity marketing territory company continue market exclusivity simponi marketing territory profit derive merck distribution product country equally divide merck competition health care environment competition market company conduct business pharmaceutical industry general highly competitive highly regulate company competitor include worldwide researchbase pharmaceutical company small research company limit therapeutic focus generic drug manufacturer animal health care company companys operation adversely affect generic biosimilar competition company product mature technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor generic availability competitor brand product new information clinical trial market product postmarkete surveillance addition patent right increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result payment royalty recognition impairment charge respect intangible asset associate certain product competitive pressure intensify pressure industry grow pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively long stand emphasis research development company position compete search technological innovation additional resource require meet market challenge include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product external alliance license arrangement refine sale marketing effort address table content change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number compound available treat particular disease typically increase time result slow sale growth reduce sale company product therapeutic category highly competitive animal health business affect factor include regulatory legislative issue scientific technological advance product innovation quality price company product effective promotional effort frequent introduction generic product competitor health care environment government regulation global effort health care cost containment continue exert pressure product pricing market access united states federal state government year pursue method reduce cost drug vaccine pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity hospital serve disproportionate share low income uninsured patient backdrop united states enact major health care reform legislation patient protection affordable care act aca begin implement insurance market reform advance state federal insurance exchange launch respect effect law pharmaceutical industry law increase mandate medicaid rebate expand rebate medicaid manage care utilization increase type entity eligible federal drug discount program law require pharmaceutical manufacturer pay point service discount medicare beneficiary medicare coverage gap socalle donut hole approximately million million million record merck reduction revenue respectively relate donut hole provision pharmaceutical manufacturer require pay annual nontax deductible health care reform fee total annual industry fee billion increase billion fee assess company proportion share prior year brand pharmaceutical sale certain government program medicare medicaid company record million million million cost marketing administrative expense respectively annual health care reform fee high expense reflect final regulation annual health care reform fee issue internal revenue service irs july final irs regulation accelerate recognition criterion fee obligation year year underlie sale allocate fee occur year fee pay result change merck record additional year expense million february center medicare medicaid services cms issue medicaid rebate final rule implement provision aca effective april rule provide comprehensive guidance calculation average manufacturer price good price metric utilize determine rebate drug manufacturer require pay state medicaid programs impact change result issuance rule material merck time company await guidance cms aspect rule defer later implementation include definition constitute product line extension delay participation territory medicaid drug rebate program april company evaluate financial impact element effective significant uncertainty future aca particular healthcare law general united states company participate debate monitoring propose change affect business company unable predict likelihood change aca depend nature repeal replacement aca action material adverse effect company result operation financial condition business vermont legislature pass pharmaceutical cost transparency law law require manufacturer identify vermont green mountain care board report certain product price information vermont attorney general attorney general require submit report legislature number state introduce legislation kind company expect state continue focus pharmaceutical price transparency extent proposal pass law unknown time company face increase pricing pressure globally manage care organization government agency program negatively affect company sale profit margin united states table content include practice manage care organization federal state exchange institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act aca change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure example health care reform contribute increase number patient medicaid program sale pharmaceutical product subject substantial rebate addition effort contain federal deficit pharmaceutical industry consider potential source saving legislative proposal debate enact type revenue generating cost saving proposal include additional direct price control medicare prescription drug program addition congress consider proposal allow certain condition importation medicine country remain uncertain proposal include future federal budget deficit reduction proposal directly indirectly affect company private sector consolidation integration healthcare provider major factor competitive marketplace pharmaceutical product health plan pharmacy benefit manager consolidate few large entity enhance purchasing strength importance private thirdparty insurer government increasingly employ formulary control cost negotiate discount price exchange formulary inclusion failure obtain timely adequate pricing formulary placement merck product obtain pricing placement unfavorable pricing adversely impact revenue addition formulary tier copay differential private health insurance company selfinsure employer raise copayment require beneficiary particularly brand pharmaceutical biotechnology product private health insurance company increasingly impose utilization management tool clinical protocol require prior authorization brand product generic product available require patient fail generic product permit access brand medicine utilization management tool treatment area payer take position multiple brand product therapeutically comparable payer market concentrate drug available generic form pharmaceutical company face great pricing pressure private thirdparty payer order provide information company pricing practice company recently post website pricing action transparency report united states year report provide company average annual list price net price increase company portfolio date report show company average annual net price increase take sale deduction rebate discount return account human health portfolio low midsingle digit additionally weight average annual discount rate steadily increase time reflect competitive market brand medicine impact aca company gross sale reduce result rebate discount return effort health care cost containment remain intense european country company face competitive pricing pressure result generic biosimilar drug addition majority country europe attempt contain drug cost engage reference pricing authority examine predetermine market publish price drug brand authority use price data market set new local price brandname drug include company guideline examine reference pricing usually set local market change pursuant local regulation addition japan pharmaceutical industry subject governmentmandate biennial price reduction pharmaceutical product certain vaccine occur furthermore government order repricing class drug determine appropriate applicable rule certain market outside united states implement cost management strategy health technology assessment hta require additional data review administrative process increase complexity timing cost obtain product reimbursement exert downward pressure available reimbursement united states htas government private payer company focus emerge market continue government emerge market focus constrain health care cost enact price control relate measure compulsory table content license aim pressure price pharmaceutical constrain market access company anticipate pricing pressure market access challenge continue vary degree emerge market price market access challenge condition emerge market country affect company effort continue grow market include potential political instability significant currency fluctuation control financial crisis limit change availability funding health care development adversely impact business environment company company engage thirdparty agent assist operate emerge market country affect ability realize continued growth increase company risk exposure address cost containment pressure company engage public policy advocacy policymaker continue work demonstrate medicine provide value patient pay health care company advocate government policymaker encourage longterm approach sustainable health care financing ensure access innovative medicine disproportionately target pharmaceutical source budget saving market historically low rate health care spending company encourage government increase investment adopt market reform order improve citizen access appropriate health care include medicine operating condition challenge global pressure competition industry regulation cost containment effort predict effect factor company business company continually take measure evaluate adapt improve organization business practice well meet customer need believe position respond evolve health care environment market force pharmaceutical industry subject regulation regional country state local agency world focus standard process determine drug safety effectiveness condition sale reimbursement particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement practice increase time resource necessary develop new product bring market united states time fda commit expedite development review product bear breakthrough therapy designation accelerate regulatory review process medicine designation european union adopt directive legislation concern classification label advertise wholesale distribution integrity supply chain enhance pharmacovigilance monitor approval marketing medicinal product human use provide mandatory standard supplemented implement additional regulation member states company policy procedure consistent substance directive consequently believe material effect company business company believe continue able conduct operation include launch new drug regulatory environment research development discussion regulatory approval process access medicine global health care company merck primary role discover develop innovative medicine vaccine company recognize important role play helping improve access product world company effort regard wideranging include set principle company strive embed operation business strategy guide company worldwide approach expand access health care addition company farreache philanthropic program merck patient assistance program provide medicine adult vaccine free people united states prescription drug health insurance coverage company assistance afford merck medicine vaccine merck launch merck mother longterm effort global health partner end preventable death complication pregnancy childbirth merck provide fund merck foundation independent organization partner variety organization dedicate improve global health table content privacy datum protection company subject significant number privacy datum protection law regulation globally place restriction company ability transfer access use personal datum business legislative regulatory landscape privacy datum protection continue evolve increase attention privacy datum protection issue develop emerge market potential affect directly company business include new general data protection regulation effective impose penalty global revenue additional law regulation enact united states europe asia latin america increase enforcement litigation activity united states develop market increase regulatory cooperation privacy authority globally company adopt comprehensive global privacy program manage evolve risk certify compliant approve asia pacific economic cooperation crossborder privacy rule system euus privacy shield program bind corporate rule distribution company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine sell primarily physician wholesaler physician distributor government entity company professional representative communicate effectiveness safety value company pharmaceutical vaccine product health care professional private practice group practice hospital manage care organization company sell animal health product veterinarian distributor animal producer raw material raw material supply generally available multiple source purchase worldwide normally available quantity adequate meet need company business patent trademark license patent protection consider aggregate material importance company marketing product united states major foreign market patent cover product pharmaceutical formulation process intermediate useful manufacture product use product protection individual product extend vary period accordance legal life patent country protection afford vary country country depend type patent scope coverage food drug administration modernization act include pediatric exclusivity provision provide additional month market exclusivity united states indication new currently market drug certain agree pediatric study complete applicant current patent law provide additional patent term period patent product regulatory review fda provide additional month pediatric market exclusivity attach product supplementary protection certificate spc japan provide additional term pediatric study attach market exclusivity unrelated patent right table content patent portfolio develop product introduce company normally provide market exclusivity company follow key patent protection united states japan include potential patent term extension pte spc indicate follow market product product year expiration year expiration year expiration japan invanz composition arcoxia market market cancidas formulation zostavax expire use dulera formulation combination zetia vytorin asmanex formulation formulation formulation nuvare delivery system delivery system emend injection follistim formulation formulation formulation noxafil rotateq expire expire recombivax method making expire expire januvia janumet janumet isentress simponi bridion pende pte nexplanon device device market bravecto pende pte patent spc gardasil gardasil patent spc keytruda patent spc pende pte zerbaxa pende pte patent spc sivextro patent spc zinplava pende pte belsomra zepati patent spc currently market approval note compound patent note certain product list subject patent litigation item financial statement supplementary datum note contingency environmental liability date represent expiration date follow country france germany italy spain major market spc grant major markets patent expiry date spc expiry date list agreement generic manufacturer launch generic version zetia united states december august district court decision find invalid company patent claim nuvaring delivery system decision currently appeal eligible month pediatric exclusivity pte system japan allow patent extend provide later approval direct different indication previous approval result multiple pte approval give patent expiration date company marketing right japan spc application file july expect expiry eligible pediatric exclusivity expiration product patent normally result loss market exclusivity cover pharmaceutical product commercial benefit continue derive latergrante patent process intermediate relate economical method manufacture active ingredient product patent relate use product iii patent relate novel composition formulation united states certain country market exclusivity available relevant law effect product patent expiration pharmaceutical product depend factor nature market position product growth market complexity economic process manufacture active ingredient product requirement new drug provision federal food drug cosmetic act similar law regulation country table content addition market exclusivity seek united states country relevant law include law increase patent life benefit increase patent life partially offset increase number incentive use generic product additionally improvement intellectual property law seek united states country reform patent relevant law implementation international treaty company follow key patent protection drug candidate review united states fda additional patent term provide pipeline candidate base patent term restoration pediatric exclusivity currently anticipate review year expiration pediatric hexavalent combination vaccine method make company follow key patent protection drug candidate phase development currently anticipate phase drug candidate year expiration ebola vaccine letermovir anacetrapib mka relebactam imipenemcilastatin verubecestat doravirine ertuglifozin mka ertuglifozin sitagliptin mkb ertuglifozin metformin vericiguat note patent chart compound patent patent subject future patent term restoration year month pediatric market exclusivity available addition depend circumstance surround final regulatory approval compound list patent patent application pende relevance product finally approve relevance application depend claim ultimately grant nature final regulatory approval product regulatory exclusivity tie protection clinical data complementary patent protection case provide effective long last marketing exclusivity compound patent estate united states data protection generally run year marketing approval new chemical entity extend seven year orphan drug indication year marketing approval biological product information respect company patent item risk factor item financial statement supplementary datum note contingency environmental liability worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely royalty income patent knowhow license right amount million merck incur royalty expense amount billion patent knowhow license hold research development company business characterize introduction new product new use exist product strong research development program approximately people employ company research activity research development expense billion billion billion include restructuring cost acquisition divestiturerelated cost year company prioritize research development effort focus candidate believe represent breakthrough science difference patient payer table content company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource candidate company believe capable provide unambiguous promotable advantage patient payer deliver maximum value approve medicine vaccine new indication new formulation merck pursue emerge product opportunity independent therapeutic area modality small molecule biologic vaccine build biologic capability company commit make externally source program great component pipeline strategy focus supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound access new technology company review pipeline examine candidate provide value outlicense company continue evaluate certain latestage clinical development platform technology asset determine outlicense sale potential company clinical pipeline include candidate multiple disease area include atherosclerosis cancer cardiovascular disease diabete infectious disease inflammatoryautoimmune disease neurodegenerative disease respiratory disease development human health product industry practice government regulation united states foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug vaccine marketed united states record datum preclinical clinical experience include new drug application nda drug biologic license application bla vaccine biologic submit fda require approval company scientist discover new small molecule compound biologic believe promise treat medical condition company commence preclinical testing compound preclinical testing include laboratory testing animal safety study gather data chemistry pharmacology immunogenicity toxicology pende acceptable preclinical datum company initiate clinical testing accordance establish regulatory requirement clinical testing begin phase study design assess safety tolerability pharmacokinetic preliminary pharmacodynamic activity compound human favorable additional large phase study initiate determine efficacy compound affect population define appropriate dosing compound identify adverse effect limit compound usefulness situation clinical program incorporate adaptive design methodology use accumulate datum decide modify aspect ongoing clinical study continue undermine validity integrity trial type adaptive clinical trial adaptive phase trial design twostage trial design consist phase proofofconcept stage phase doseoptimization finding stage datum phase trial satisfactory company commence largescale phase trial confirm compound efficacy safety type adaptive clinical trial adaptive phase trial design study include interim analysis adaptation change trial feature common phase study multiple dose group design similar phase trial adaptive phase trial design reduce timeline eliminate activity require start separate study completion phase trial satisfactory company submit regulatory filing appropriate regulatory agency world product candidate approve marketing assurance compound result particular program obtain regulatory approval necessary market vaccine development follow general pathway drug preclinical testing focus vaccine safety ability elicit protective immune response immunogenicity premarkete vaccine clinical trial typically phase initial phase clinical study conduct normal subject evaluate safety tolerability immunogenicity vaccine candidate phase study doserange study finally phase trial provide necessary datum effectiveness safety successful company submit regulatory filing appropriate regulatory agency united states fda review process begin complete nda bla submit receive accept review agency day receipt fda determine application sufficiently complete permit substantive review fda assess time application grant table content priority review standard review pursuant prescription drug user fee act pdufa fda review period target nda original bla month priority review month standard review time application deem sufficiently complete review timeline determine fda generally act application timeline major amendment submit company initiative fda request pende application occur fda extend review period allow review new information month extension review period communicate company fda act application issue approval letter issue complete response letter crl state application approve present form describe deficiency fda identify company wish pursue application receive crl resubmit application information address question issue identify fda order support approval resubmission subject review period target vary depend underlie submission type content resubmission fda program designation fast track breakthrough therapy accelerate approval priority review facilitate expedite development review new drug address unmet medical need treatment lifethreatening condition fast track designation provide pharmaceutical manufacturer opportunitie frequent interaction fda reviewer product development ability manufacturer roll submission ndabla rolling submission allow complete portion application submit review fda ongoing basis breakthrough therapy designation provide manufacturer feature fast track designation intensive guidance implement efficient development program product commitment fda involve senior manager experience staff review accelerate approval designation allow fda approve product base effect surrogate intermediate endpoint reasonably likely predict product clinical benefit generally require manufacturer conduct require postapproval confirmatory trial verify clinical benefit priority review designation mean fda goal action ndabla month compare month standard review addition generate antibiotic incentive act fda grant qualified infectious disease product qidp status antibacterial antifungal drug intend treat life threatening infection include cause antibiotic antifungal resistant pathogen novel emerge infectious pathogen qualify pathogen qidp designation offer certain incentive development qualify drug include priority review nda file eligibility fast track designation fiveyear extension applicable exclusivity provision food drug cosmetic act primary method company use obtain marketing authorization pharmaceutical product centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum marketing authorization application maa ema ema evaluate maa provide recommendation approve deny maa possible new chemical product obtain marketing authorization mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state outside united states company submit marketing application national regulatory authority examples pharmaceutical medical devices agency japan health canada agncia nacional vigilncia sanatria brazil korea food drug administration south korea therapeutic goods administration australia china food drug administration country separate independent review process timeline market approval time long regulatory authority require approval major market united states issuance certificate pharmaceutical product market initiate local review process table content research development update company currently candidate regulatory review united states keytruda fdaapprove antipd program death receptor therapy clinical development expand indication different cancer type keytruda currently approve treatment nsclc melanoma advanced melanoma head neck cancer february fda accept review supplemental blas sbla keytruda patient locally advanced metastatic urothelial cancer include bladder cancer application firstline use grant priority review treatment patient ineligible cisplatincontaine therapy application secondline use grant priority review patient disease progression platinum contain chemotherapy pdufa action date application june fda previously grant breakthrough therapy designation keytruda secondline treatment patient locally advanced metastatic urothelial cancer disease progression platinumcontaine chemotherapy january fda accept review sbla keytruda plus chemotherapy pemetrexed plus carboplatin firstline treatment patient metastatic advanced nonsquamous nsclc regardless pdl expression egfr alk genomic tumor aberration application regulatory approval keytruda combination treatment fda grant priority review pdufa action date sbla review fda accelerate approval program december fda accept review sbla keytruda treatment patient refractory classical hodgkin lymphoma patient relapse prior line therapy fda grant priority review pdufa action date march sbla review fdas accelerate approval program november fda accept review sbla keytruda treatment previously treat patient advance microsatellite instabilityhigh msih cancer fda grant priority review pdufa action date march sbla review fdas accelerate approval program fda recently grant breakthrough therapy designation keytruda unresectable metastatic msih noncolorectal cancer previously grant treatment patient unresectable metastatic msih colorectal cancer additionally keytruda receive breakthrough therapy designation fda treatment patient primary mediastinal bcell lymphoma refractory relapse prior line therapy keytruda clinical development program consist clinical trial include trial combine keytruda cancer treatment study encompass cancer type include bladder colorectal esophageal gastric head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma melanoma multiple myeloma nasopharyngeal nsclc ovarian prostate renal triplenegative breast currently phase clinical development trial plan cancer investigational followon biologic insulin glargine candidate treatment patient type type diabete review fda approve january develop collaboration partially fund samsung bioepis investigational pediatric hexavalent combination vaccine dtapipvhibhepb review fda develop approve commercialize partnership merck sanofi vaccine design help protect important disease diphtheria tetanus pertussis whooping cough polio poliovirus type invasive disease cause haemophilus influenzae type hib hepatitis november fda issue crl respect bla company review crl plan communication fda february grant marketing authorization prophylaxis diphtheria tetanus pertussis hepatitis poliomyelitis invasive disease cause hib infant toddler age week market vaxeli addition candidate regulatory review company drug candidate phase clinical development addition keytruda program discuss table content verubecestat investigational small molecule inhibitor betasite amyloid precursor protein cleave enzyme bace treatment alzheimer disease february merck announce external datum monitor committee edmc recommend termination phase epoch study verubecestat mildtomoderate alzheimer disease base low probability success study edmc recommend separate phase study apecs evaluate verubecestat amnestic mild cognitive impairment alzheimer disease know prodromal alzheimer disease continue plan estimate primary completion date apecs study fully enrol february anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp development raise hdlc reduce ldl anacetrapib evaluate patient eventdriven cardiovascular clinical outcome trial sponsor oxford university reveal randomize evaluation effect anacetrapib lipidmodification involve patient preexist vascular disease november merck announce datum monitor committee dmc reveal outcomes study complete planned review unblinde study datum recommend study continue change dmc review safety efficacy datum study include assessment futility merck remain blind actual result analysis reveal safety efficacy datum study patient visit occur january company anticipate receive topline result study midyear mka combination relebactam investigational betalactamase inhibitor imipenemcilastatin approve carbapenem antibiotic fda designate combination qidp designate fast track status treatment hospitalacquire bacterial pneumonia ventilatorassociate bacterial pneumonia complicated intraabdominal infection complicate urinary tract infection letermovir investigational oral oncedaily intravenous infusion antiviral candidate prevention clinicallysignificant cytomegalovirus cmv infection letermovir receive orphan drug status united states grant fast track designation october merck announce pivotal phase clinical study letermovir meet primary endpoint global multicenter randomize placebocontrolle study evaluate efficacy safety letermovir adult year old cmvseropositive recipient allogeneic hematopoietic stem cell transplant merck plan submit regulatory application approval letermovir united states ertugliflozin investigational oral sglt inhibitor evaluate treatment type diabete collaboration pfizer inc pfizer september merck pfizer announce phase study vertis sita ertugliflozin meet primary endpoint daily doses ertugliflozin show significantly great reduction average measure blood glucose past month add patient background sitagliptin metformin ertugliflozin study combination januvia sitagliptin metformin december merck submit nda fda ertugliflozin fixeddose combination mka ertugliflozin plus januvia mkb ertugliflozin plus metformin company anticipate response fda quarter ertugliflozin fixeddose combination currently review mkj investigational fixeddose combination sitagliptin ipragliflozin development commercialization japan collaboration astellas pharma inc astella ipragliflozin sglt inhibitor codevelope astellas kotobuki pharmaceutical ltd kotobuki approve use japan copromote merck kotobuki investigational rvsvzebov ebola vaccine candidate study large scale phase clinical trial november merck newlink genetic announce exclusive licensing collaboration agreement investigational ebola vaccine december merck announce application emergency use assessment list eual accept review world health organization accord eual process design expedite availability vaccine need public health emergency outbreak ebola decision grant eual status base datum quality safety efficacyeffectiveness riskbenefit analysis emergency use eual designation allow emergency use vaccine remain investigational license commercial distribution july merck announce fda grant breakthrough therapy designation ema grant vaccine candidate prime priority medicine status december end study result re vaccination trial report lancet support july interim assessment table content offer substantial protection ebola virus disease report case vaccinate individual day vaccination randomize nonrandomize cluster result ongoing study anticipate second half vericiguat investigational treatment heart failure study phase clinical trial patient suffer chronic heart failure development vericiguat worldwide strategic collaboration merck bayer inactivated varicella zoster virus vzv vaccine development prevention herpe zoster company complete phase trial autologous hematopoietic cell transplant patient conduct phase trial patient solid tumor malignancy undergo chemotherapy hematological malignancy study autologous hematopoietic cell transplant patient meet primary endpoint merck present result study american society blood marrow transplantation meeting february doravirine investigational nonnucleoside reverse transcriptase inhibitor develop merck treatment hiv infection february company receive positive result phase study show doravirine noninferior alternative regimen achieve maintain hiv suppression infect adult week treatment company divest discontinued certain drug candidate merck announce discontinuing development odanacatib investigational cathepsin inhibitor osteoporosis seek regulatory approval use merck previously report numeric imbalance adjudicate stroke event pivotal phase fracture outcomes study postmenopausal woman company decide discontinue development independent adjudication analysis major adverse cardiovascular event confirm increase risk stroke company determine business reason terminate north america partnership agreement alkabell include investigational allergy immunotherapy tablet house dust mite allergy merck give alkabell month notice terminate agreement compound return alkabell decision efficacy safety concern company decide business reason discontinue clinical development mkb refer generation ring investigational combination etonogestrel estradiol vaginal ring contraception treatment dysmenorrhea woman seek contraception decision efficacy safety concern merck announce business reason proceed submit marketing application omarigliptin investigational onceweekly dpp inhibitor united states europe decision result concern efficacy safety omarigliptin table content chart reflect company research pipeline february candidate show phase include specific product date candidate enter phase development candidate show phase include advanced compound specific mechanism list compound mechanism currently intend commercialization give therapeutic area small molecule biologic give mknumber designation vaccine candidate give vnumber designation note candidate phase additional indication therapeutic area respect keytruda additional claim line extension formulation inline product show phase phase phase entry date review asthma alzheimer disease new molecular entitiesvaccine verubecestat december allergy cancer atherosclerosis house dust mite keytruda anacetrapib diabete mellitus pmbcl primary mediastinal bacterial infection large bcell lymphoma mka relebactamimipenemcilastatin ertugliflozin advance solid tumor october mka ertugliflozinsitagliptin nasopharyngeal cancer mkb ertugliflozinmetformin ovarian keytruda pediatric hexavalent combination vaccine prostate bladder october breast october cough include cough ipf colorectal november certain supplemental filing esophageal december cancer diabete mellitus gastric keytruda head neck november previously treat microsatellite instabilityhigh cancer hepatitis hepatocellular relapse refractory classical hodgkin lymphoma mkb uprifosbuvirmk hodgkin lymphoma july combination chemotherapy firstline nonsquamous nonsmall grazoprevirmk ruzasvir multiple myeloma december cell lung cancer pneumoconjugate vaccine renal october line cisineligible bladder cancer cmv prophylaxis transplant patient second line metastatic bladder cancer letermovir june diabetes mellitus ertugliflozin november footnote develop collaboration mka ertugliflozinsitagliptin develop north america partnership september alkabell merck give alkabell month notice mkb ertugliflozinmetformin terminate agreement compound august return alkabell mkj sitagliptinipragliflozin october japan investigational pediatric hexavalent combination vaccine dtap ebola vaccine ipvhibhepb develop approve march commercialize partnership merck sanofi november heart failure fda issue crl respect company vericiguat september review crl plan communication fda herpe zoster inactivated vzv vaccine december hiv doravirine december employee december company approximately employee worldwide approximately employ united state include puerto rico approximately worldwide employee company represent collective bargaining group restructuring activity company incur substantial cost restructure program activity relate merck productivity cost reduction initiative connection integration certain acquire business company commence action global restructuring program design streamline cost structure action program include elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility company continue reduce global real estate footprint improve efficiency manufacture supply network nonfacility relate restructuring action program substantially complete remain activity primarily relate ongoing facility rationalization inception program december merck eliminate approximately position comprise table content employee separation elimination contractor vacant position company expect substantially complete remain action program end environmental matter company believe compliance issue associate applicable environmental law regulation material adverse effect company company remediate environmental contamination result past industrial activity certain site expenditure remediation environmental liability million estimate million aggregate year amount consider potential recovery party company take active role identify accrue cost management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure material adverse effect company financial position result operation liquidity capital resource year merck believe climate change present risk business potential impact climate change business include increase operating cost additional regulatory requirement physical risk company facility water limitation disruption supply chain potential risk integrate company business planning include investment reduce energy water use greenhouse gas emission company believe risk material business time geographic area information company operation outside united states conduct primarily subsidiarie sale worldwide subsidiary outside united states percentage total company sale sale sale sale company worldwide business subject risk currency fluctuation governmental action governmental proceeding abroad company regard risk deterrent expansion operation abroad company closely review method operation adopt strategy responsive change economic political condition merck operation country locate latin america middle east africa eastern europe asia pacific business develop area stable offer important opportunity growth time financial information geographic area company business provide item financial statement supplementary datum available information company internet website address wwwmerckcom company available free charge investor portion website annual report quarterly report form current report form amendment report file furnish pursuant section security exchange act amend soon reasonably practicable report electronically file furnish securities exchange commission sec addition company provide charge copy annual report include financial statement schedule write request shareholder merck shareholder services merck inc galloping hill road kenilworth usa companys corporate governance guideline charter board director stand committee available company website wwwmerckcomaboutleadership information available print stockholder request company table content item risk factor investor carefully consider information set forth include follow risk factor decide invest company security risk one company face additional risk currently know company company presently deem immaterial impair business operation company business financial condition result operation prospect materially adversely affect risk contain forwardlooke statement involve risk uncertainty company result materially differ anticipate forwardlooke statement result certain factor include risk face describe cautionary factor affect future result company dependent patent right patent right invalidate circumvent business adversely affect patent protection consider aggregate material importance company market human health product united states major foreign market patent cover product introduce normally provide market exclusivity important successful marketing sale product company seek patent cover product market intend sell product meaningful patent protection available company succeed obtain patent cover product party government authority challenge seek invalidate circumvent patent patent application important company business defend successfully patent right provide market exclusivity product company involve patent dispute relate challenge patent claim party infringement company company defend patent outside united state include file claim infringement party item financial statement supplementary datum note contingency environmental liability particular manufacturer generic pharmaceutical product time time file abbreviate nda fda seek market generic form company product prior expiration relevant patent own license company company normally respond defend patent include filing lawsuit allege patent infringement patent litigation challenge company patent costly unpredictable deprive company market exclusivity patent product case thirdparty patent prevent company marketing selling product particular geographic area additionally certain foreign government indicate compulsory license patent grant case national emergency circumstance diminish eliminate sale profit region negatively affect company result operation court decision relate company patent potential legislation relate patent regulatory initiative result general weaken intellectual property protection important product lose patent protection profitable market sale product likely decline significantly result generic version product available case certain product loss result material noncash impairment charge company result operation adversely affect lost sale company successfully launch commercially successful replacement product chart list patent protection certain company market product patent protection candidate review phase candidate set forth item business patent trademark license company product lose market exclusivity company generally experience significant rapid loss sale product company depend patent provide exclusive marketing right product period time loss patent protection company product typically lead significant rapid loss sale product lower price generic version drug available case product contribute significantly company sale loss market exclusivity material adverse effect company business cash flow result operation financial position prospect example pursuant table content agreement generic manufacturer manufacturer launch united states generic version zetia december addition company lose patent protection vytorin april company expect significant rapid loss sale zetia vytorin united states key product generate significant company profit cash flow event adversely affect market lead product material negative impact result operation cash flow company ability generate profit operate cash flow depend largely continue profitability company key product januvia janumet keytruda gardasilgardasil isentress zepati result company dependence key product event adversely affect product market product significant adverse impact result operation cash flow event include loss patent protection increase cost associate manufacturing generic overthecounter availability company product competitive product discovery previously unknown effect result postapproval trial increase competition introduction new effective treatment discontinuation removal market product reason event material adverse effect sale product company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequence company able replace sale successful product lose patent protection like major pharmaceutical company order remain competitive company continue launch new product year expect decline sale product loss market exclusivity mean company future success dependent pipeline new product include new product develop joint venture product able obtain license acquisition accomplish company commit substantial effort fund resource research development dedicate resource collaboration party high rate failure inherent research development process new drug result high risk fund invest company research program generate financial return risk profile compound fact research long investment cycle bring pharmaceutical compound discovery phase market decade failure occur point process include later process significant fund invest description research development process item business research development phase test highly regulate phase substantial risk company encounter obstacle achieve goal company abandon product invest substantial amount time resource risk encounter research development process include follow preclinical testing new compound yield disappointing result compete product manufacturer reach market clinical trial new drug successful new drug effective harmful effect new drug approve regulator intend use possible obtain patent new drug payer refuse cover reimburse new product sale new product disappointing company state certainty product development approve launch able develop license acquire compound product candidate product product launch commercially successful company maintain continuous flow successful new product successful new indication brand extension exist product sufficient cover substantial research development cost replace sale lose profitable product lose market exclusivity displace compete product therapie failure short term long term material adverse effect company business result operation cash flow financial position prospect table content company success dependent successful development marketing new product subject substantial risk product appear promise development fail reach market fail succeed numerous reason include follow finding ineffectiveness superior safety efficacy compete product harmful effect clinical preclinical testing failure receive necessary regulatory approval include delay approval new product new indication uncertainty time require obtain regulatory approval benefitrisk standard apply regulatory agency determine grant approval failure certain market obtain reimbursement commensurate level innovation clinical benefit present product lack economic feasibility manufacturing cost factor preclusion commercialization proprietary right future certain pipeline program cancel company believe commercial prospect reduce company recognize material noncash impairment charge program measure fair value capitalize connection acquisition failure successfully develop market new product short term long term material adverse effect company business result operations cash flow financial position prospect company product include product development market company obtain maintain regulatory approval company activity include research preclinical testing clinical trial manufacturing marketing product subject extensive regulation numerous federal state local governmental authority unite states include fda foreign regulatory authority include united states fda particular importance company administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time money necessary develop new product bring market united states regulation outside united states primarily focus drug safety effectiveness case cost reduction fda foreign regulatory authority substantial discretion require additional testing delay withhold registration marketing approval preclude distribution sale product company successful develop new product able market product obtain require regulatory approval jurisdiction propose market new product obtain company maintain approval long plan market new product jurisdiction approval require company failure obtain approval significant delay approval process failure maintain approval jurisdiction prevent sell new product jurisdiction approval obtain company able realize revenue new product jurisdiction approval development follow regulatory approval adversely affect sale company product product reach market certain development follow regulatory approval include result postapproval phase trial study decrease demand company product include follow rereview product market recall loss marketing approval product market table content change government standard public expectation safety efficacy labeling change great scrutiny advertising promotion past year clinical trial postmarkete surveillance certain market drug company competitor industry raise concern lead recall withdrawal adverse labeling market product clinical trial postmarkete surveillance certain market drug raise concern prescriber patient relate safety efficacy pharmaceutical product general negatively affect sale product addition increase scrutiny outcome clinical trial lead increase volatility market reaction matter attract litigation basis litigation groundless considerable resource need respond addition follow wake product withdrawal significant safety issue health authority fda ema japans pharmaceutical medical device agency increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication rereviewe select product market add uncertainty regulatory process great regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising previously unknown effect discover increase negative publicity know effect company product significantly reduce demand product require company action negatively affect sale include remove product market restrict distribution apply labeling change current environment pharmaceutical company operate company risk product liability consumer protection claim civil criminal governmental action relate product research andor marketing activity company face intense competition low costgeneric product general company face increase competition lowercost generic product patent right protect product vary strength duration addition country patent protection significantly weak united states united states political pressure reduce spending prescription drug lead legislation measure encourages use generic biosimilar product company policy actively protect patent right generic challenge company product arise time company patent prevent emergence generic competition product loss patent protection product typically follow promptly generic substitute reduce company sale product availability generic substitute company drug adversely affect result operation cash flow addition proposal emerge time time united states country legislation encourage early rapid approval generic drug proposal enact law worsen substantial negative effect company sale potentially business cash flow result operation financial position prospect company face intense competition competitor product addition factor certain circumstance lead noncash impairment charge company product face intense competition competitor product competition increase new product enter market event competitor product safer effective convenient use effectively market sell company product alternatively case generic competition include generic availability competitor brand product equally safe effective product sell substantially low price company product result company fail maintain competitive position material adverse effect business cash flow result operation financial position prospect addition product measure fair value capitalize connection acquisition experience difficulty market negatively impact product cash flow company recognize material non cash impairment charge respect value product table content company face pricing pressure respect product company face increase pricing pressure globally particularly mature market manage care organization government agency program negatively affect company sale profit margin united states include practice manage care group institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act aca iii state activity aim increase price transparency change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure addition large customer future ask receive high rebate drug certain highly competitive category company compete place formulary manage care organization exclusion product formulary lead reduce usage manage care organization order provide information company pricing practice company recently post website pricing action transparency report united states year report provide company average annual list price net price increase company portfolio date report show company average annual net price increase take sale deduction rebate discount return account human health portfolio low midsingle digit additionally weight average annual discount rate steadily increase time reflect competitive market brand medicine impact aca company gross sale reduce result rebate discount return outside united states numerous major market include japan pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine product consequently market company subject government decision make budgetary action respect product company expect pricing pressure increase future health care industry united states continue subject increase regulation political action company believe health care industry continue subject increase regulation political legal action future proposal reform health care system consider congress state legislature united states enact major health care reform legislation form aca insurance market reform advance state federal insurance exchange launch respect effect law pharmaceutical industry law increase mandate medicaid rebate expand rebate medicaid manage care utilization increase type entity eligible federal drug discount program law require pharmaceutical manufacturer pay point service discount medicare beneficiary medicare coverage gap socalle donut hole pharmaceutical manufacturer require pay annual nontax deductible health care reform fee total annual industry fee billion increase billion fee assess company proportion share prior year brand pharmaceutical sale certain government program medicare medicaid january centers medicare medicaid services cms issue medicaid rebate final rule implement provision aca effective april rule provide comprehensive guidance calculation average manufacturer price good price metric utilize determine rebate drug manufacturer require pay state medicaid programs impact change result issuance rule material merck time company await guidance cms aspect rule defer later implementation include definition constitute product line extension delay participation territory medicaid drug rebate program april company evaluate financial impact element effective table content company predict likelihood future change health care industry general pharmaceutical industry particular impact company result operation financial condition business change law regulation materially adversely affect company business aspect company business include research development manufacturing marketing pricing sale litigation intellectual property right subject extensive legislation regulation change applicable federal state law agency regulation material adverse effect company business particular significant uncertainty future aca healthcare law general united states company participate debate monitoring propose change affect business company unable predict likelihood change aca depend nature repeal replacement aca action material adverse effect company result operation financial condition business uncertainty global economic condition austerity measure take certain government negatively affect company operating result uncertainty global economic condition result slowdown global economy affect company business reduce price drug wholesaler retailer hospital government agency manage health care provider able willing pay company product reduce demand company product turn negatively impact company sale result material adverse effect company business cash flow result operation financial position prospect global effort health care cost containment continue exert pressure product pricing market access international market governmentmandate pricing action reduce price generic patent drug addition austerity measure negatively affect company revenue performance company anticipate pricing action austerity measure continue negatively affect revenue performance credit economic condition worsen result economic currency impact affect market globally material adverse effect company result company significant global operation expose additional risk adverse event material negative impact company result operation extent company operation outside united states significant risk inherent conduct global business include change medical reimbursement policy program price restriction key market multiple regulatory requirement restrict company ability manufacture sell product key market trade protection measure import export licensing requirement foreign exchange fluctuation diminish protection intellectual property country possible nationalization expropriation addition change company business political position instability disruption destruction significant geographic region regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease table content failure attract retain highly qualified personnel affect ability successfully develop commercialize product company success largely dependent continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical research development governmental regulation commercialization competition qualified personnel pharmaceutical industry intense company sure able attract retain quality personnel cost materially increase past company experience difficulty delay manufacture certain product merck past experienced difficulty manufacture certain vaccine product company future experience difficulty delay inherent manufacturing product failure company vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture construction delay relate construction new facility expansion exist facility include intended support future demand company product iii manufacture distribution problem include change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation impact continuous supply manufacturing difficulty result product shortage lead lose sale reputational harm company company able realize expect benefit investment emerge market company take step increase sale emerge market guarantee company effort expand sale market succeed country emerge market especially vulnerable period global financial instability limited resource spend health care order company successfully implement emerge market strategy attract retain qualified personnel company require increase reliance thirdparty agent develop market addition country currency fluctuate substantially currency devalue company offset devaluation company financial performance country adversely affect addition china commercial economic condition adversely affect company growth prospect market company continue believe china represent important growth opportunity event couple heighten scrutiny health care industry continue impact product pricing market access generally company anticipate report inquiry governmental authority involve multinational pharmaceutical company china continue reason sale emerge market carry significant risk failure maintain company presence emerge market material adverse effect business financial condition result company operation company expose market risk fluctuation currency exchange rate interest rate company operate multiple jurisdiction virtually sale denominate currency local jurisdiction additionally company enter enter acquisition licensing borrowing financial transaction rise currency interest rate exposure company certainty foresee mitigate adverse fluctuation fluctuation currency exchange rate interest rate negatively affect company result operation financial position cash flow occur respect venezuela order mitigate adverse impact market fluctuation company time time enter hedge agreement hedge agreement currency option forwards interest rate swap limit exposure exchange rate interest rate fluctuation attempt mitigate risk costly successful table content company subject evolve complex tax law result additional liability affect result operation company subject evolve complex tax law jurisdiction operate significant judgment require determine company tax liability company tax return periodically examine tax authority company believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority complexity tax contingency ultimate resolution tax matter result payment great amount accrue addition company affect change tax law include tax rate change change law relate remittance foreign earning deferral limitation impact tax treatment foreign earning new tax law revise tax law interpretation domestic foreign jurisdiction pharmaceutical product develop unexpected safety efficacy concern unexpected safety efficacy concern arise respect market product scientifically justified lead product recall withdrawal decline sale product liability consumer fraud andor claim include potential civil criminal governmental action reliance party relationship outsource arrangement adversely affect company business company depend party include supplier alliance pharmaceutical biotechnology company party service provider key aspect business include development manufacture commercialization product support information technology system failure party meet contractual regulatory obligation company development factor materially disrupt relationship company party material adverse effect company business company increasingly dependent sophisticated software application compute infrastructure company increasingly dependent sophisticated software application compute infrastructure conduct critical operation disruption degradation manipulation application system intentional accidental mean impact key business process cyberattack company application system result exposure confidential information modification critical datum andor failure critical operation misuse application system result disclosure sensitive personal information theft trade secret confidential business information company continue leverage new innovative technology enterprise improve efficacy efficiency business process use create new risk aggregate impact company operation financial condition material date company target event nature expect continue company monitor datum information technology personnel usage company system reduce risk continue ongoing basis current potential threat assurance company effort protect datum system prevent service interruption loss critical sensitive information company company party provider database system result financial legal business reputational harm company negative event animal health industry negative impact future result operation future sale key animal health product adversely affect number risk factor include certain risk specific animal health business example outbreak disease carry animal bovine spongiform encephalopathy mad cow disease lead widespread death precautionary destruction reduce consumption demand animal adversely impact company result operation outbreak highly contagious disease near company main production site require company immediately halt production vaccine site force company incur substantial expense procure raw material vaccine risk specific animal health include table content epidemic pandemic government procurement pricing practice weather global agribusiness economic event animal health segment company business significant impact event future result operation significant biologic carry unique risk uncertainty negative impact future result operation successful development testing manufacturing commercialization biologic particularly human animal health vaccine long expensive uncertain process unique risk uncertaintie biologic include limited access supply normal diseased tissue sample cell line pathogen bacteria viral strain biological material addition government regulation multiple jurisdiction united states result restrict access transport use material company lose access sufficient source material tight restriction impose use material company able conduct research activity plan incur additional development cost development manufacturing marketing biologic subject regulation fda ema regulatory body regulation complex extensive regulation applicable pharmaceutical product example united states bla include preclinical clinical trial datum extensive datum manufacturing procedure require human vaccine candidate fda approval require release manufacture commercial lot manufacture biologic especially large quantity complex require use innovative technology handle living micro organism lot approve biologic undergo thorough testing identity strength quality purity potency manufacturing biologic require facility specifically design validate purpose sophisticated quality assurance quality control procedure necessary slight deviation manufacturing process include fill labeling packaging storage shipping quality control testing result lot failure product recall spoilage change manufacturing process company require provide preclinical clinical datum show comparable identity strength quality purity potency product change biologic frequently costly manufacture production ingredient derive live animal plant material biologic synthetically particular keeping demand vaccine difficult complexity produce vaccine use biologically derive ingredient lead allegation harm include infection allergic reaction closure product facility possible contamination event result substantial cost product liability insurance product limit cost prohibitive unavailable result number factor product liability insurance available cost increase significantly respect product liability company selfinsure substantially risk availability commercial insurance restrictive company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance certain product liability effective august include liability legacy merck product sell date company continually assess efficient mean address risk guarantee insurance coverage obtained obtain sufficient fully cover product liability arise social medium platform present risk challenge inappropriate andor unauthorized use certain medium vehicle cause brand damage information leakage lead legal implication include improper collection andor dissemination personally identifiable information addition negative inaccurate post comment company table content social networking web site damage company reputation brand image goodwill disclosure nonpublic companysensitive information company workforce external medium channel lead information loss internal company social medium policy guide employee appropriate personal professional use social medium company process place completely secure protect information identify new point entry social medium continue expand present new challenge cautionary factor affect future result cautionary statement private security litigation reform act report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forward look statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement company caution place undue reliance forwardlooke statement possible predict identify factor include follow competition generic andor biosimilar product company product lose patent protection increase brand competition therapeutic area important company longterm business performance difficulty uncertaintie inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level pricing pressure unite states abroad include rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general change government law regulation include law govern intellectual property enforcement thereof affect company business efficacy safety concern respect market product scientifically justified lead product recall withdrawal decline sale significant change customer relationship change behavior spend pattern purchaser health care product service include delay medical procedure ration prescription medication reduce frequency physician visit forego health care insurance coverage legal factor include product liability claim antitrust litigation governmental investigation include tax dispute environmental concern patent dispute brand generic competitor preclude commercialization product negatively affect profitability exist product lose market opportunity result delay uncertaintie approval process fda foreign regulatory authority table content increase focus privacy issue country world include united states legislative regulatory landscape privacy datum protection continue evolve increase focus privacy datum protection issue potential affect directly company business include recently enact law majority state united states require security breach notification change tax law include change relate taxation foreign earning change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board sec adverse company economic factor company control include change inflation interest rate foreign currency exchange rate list consider exhaustive statement potential risk uncertainty risk factor item unresolved staff comment item property companys corporate headquarter locate kenilworth new jersey company commercial operation headquarter upper gwynedd pennsylvania company pharmaceutical business conduct divisional headquarters locate upper gwynedd pennsylvania kenilworth new jersey company vaccine business conduct divisional headquarters locate west point pennsylvania mercks animal health global headquarters locate madison new jersey principal research facility locate rahway kenilworth new jersey west point pennsylvania palo alto california boston massachusetts elkhorn nebraska animal health principal research facility outside united states locate switzerland china mercks manufacturing operation headquarter whitehouse station new jersey company production facility human health product location united states puerto rico outside united states subsidiary company own interest manufacturing plant property japan singapore south africa countries western europe central south america asia capital expenditure billion billion billion united states amount billion million million abroad expenditure amount million million million company subsidiarie principal facility manufacturing plant title consider satisfactory company believe property good operating condition machinery equipment maintain plant manufacture product suitable intend purpose capacity project capacity adequate current project need exist company product capacity plant convert need modification requirement newly introduce future product item legal proceeding information call item incorporate reference item financial statement supplementary datum note contingency environmental liability item safety disclosure applicable table content executive officer registrant age february officer list serve pleasure board director officer elect pursuant arrangement understand officer board age office business experience chairman president chief executive officer december president chief executive kenneth frazi officer january december president january adele ambrose senior vice president chief communication officer november executive vice president president merck manufacturing division march senior sanat chattopadhyay vice president operation merck manufacturing division november march executive vice president global services chief financial officer april executive vice president chief financial officer april april corporate vice president robert davis president medical products baxter international inc march richard deluca executive vice president president merck animal health september executive vice president chief patient officer strategic communication global public policy population health july executive vice president strategic communication global public policy population health january july president merck vaccines julie gerberde january january mirian graddickweir executive vice president human resource november executive vice president general counsel july executive vice president chief ethic compliance officer june july executive vice president general counsel michael holston board secretary hewlettpackard company december senior vice president finance global controller march assistant controller november rita karachun march executive vice president president merck research laboratory april executive roger perlmutter phd vice president research development amgen inc february adam schechter executive vice president president global human health table content item market registrant common equity relate stockholder matter issuer purchase equity security principal market trading company common stock new york stock exchange nyse symbol mrk common stock market price information set forth table base historical nyse market price follow table set forth calendar period indicate dividend share information cash dividend pay common share year common stock market price high low high low january approximately shareholder record issuer purchase equity security month end december follow issuer purchase equity security millions total number average price approximate dollar value share share pay purchase period purchase share plan programs october october november november december december total share purchase period plan approve board director march purchase billion merck share share approximate table content performance graph follow graph assume investment december reinvestment dividend companys common share index composite peer group major usbased pharmaceutical company abbvie inc bristolmyers squibb company johnson johnson eli lilly company pfizer inc comparison fiveyear cumulative total return merck inc composite peer group index end period value cagr merck peer grp merck peer grp compound annual growth rate peer group average calculate market cap weight basis addition abbvie inc replace abbott laboratories peer group begin follow spin abbott laboratories performance graph deem incorporate reference file security act securities exchange act extent company specifically incorporate reference addition performance graph deem soliciting material file sec subject regulation provide regulation liabilities section securities exchange act extent company specifically request information treat soliciting material specifically incorporate reference filing security act exchange act table content item select financial datum follow select financial datum read conjunction item management discussion analysis financial condition result operation consolidate financial statement note thereto contain item financial statement supplementary datum report merck inc subsidiarie million share amount result year sale material production marketing administrative research development restructuring cost income expense net income taxis tax income net income net income attributable noncontrolle interest net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder cash dividend declare cash dividend declare common share capital expenditure depreciation average common share outstanding million average common share outstanding assume dilution million yearend position work capital property plant equipment net total asset longterm debt total equity yearend statistic number stockholder record number employee amount include charge relate settlement worldwide patent litigation relate keytruda amount include net charge relate settlement vioxx shareholder class action litigation foreign exchange loss relate venezuela gain disposition business asset favorable benefit certain tax item amount reflect divestiture merck consumer care business october include gain sale gain recognize option exercise astrazeneca gain disposition business asset loss extinguishment debt amount include net charge record connection settlement certain shareholder litigation amount restate effect adoption accounting guidance issue financial accounting standard board note item financial statement table content item management discussion analysis financial condition result operation description merck business merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product company operation principally manage product basis include operating segment pharmaceutical animal health healthcare service alliance segment pharmaceutical segment reportable segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity sale vaccine major european market market company sanofi pasteur msd spmsd joint venture termination december begin merck record vaccine sale european market previously joint venture company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer companys healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient merck alliance segment primarily include result company relationship astrazeneca termination relationship june october company divest consumer care segment develop manufacture market overthecounter foot care sun care product overview merck continue execute innovation strategy company sustain investment research yield number recent approval regulatory milestone therapeutic area company receive approval include expand indication keytruda company antipd program death receptor therapy approve food drug administration fda firstline treatment metastatic nonsmallcell lung cancer nsclc treatment head neck cancer additionally fda european commission approve zepati oncedaily single tablet combination therapy treatment chronic hepatitis virus hcv genotype infection ribavirin certain patient population worldwide sale billion increase compare include unfavorable effect foreign exchange sale growth drive oncology hcv vaccine hospital acute care product reflect ongoing launch keytruda zepatier bridion positive performance merck animal health business growth area largely offset effect generic biosimilar competition result decline product remicade nasonex business development remain important component company overall strategy merck seeks identify good external innovation augment portfolio pipeline particular focus earlytomidstage pipeline asset merck look growth opportunity meet company strategic criterion look good scientific opportunity merck remain financially discipline pursue business opportunity company believe contribute longterm growth sustainable value shareholder january merck acquire iomet pharma ltd iomet drug discovery company focus development innovative medicine treatment cancer particular emphasis field cancer immunotherapy cancer metabolism july merck acquire afferent pharmaceutical afferent privately hold pharmaceutical company focus development therapeutic candidate target receptor treatment common poorlymanage neurogenic condition chronic cough addition merck enter strategic collaboration license agreement moderna therapeutic moderna develop commercialize novel messenger rna mrnabase personalize cancer vaccine table content merck continue support inline portfolio ongoing upcoming product launch keytruda launch world multiple indication merck achieve multiple additional regulatory milestone keytruda include approval fda firstline treatment patient nsclc tumor high pdl expression tumor proportion score tps determine fdaapproved test egfr alk genomic tumor aberration treatment patient recurrent metastatic head neck squamous cell carcinoma disease progression platinumcontaine chemotherapy additionally approve keytruda treatment locally advanced metastatic nsclc patient tumor express pdl receive prior chemotherapy regiman january approve keytruda firstline treatment metastatic nsclc adult tumor high pdl expression tps egfr alk positive tumor mutation additionally company continue launch zepatier united states emerge market launch european union japan merck focus research effort therapeutic area believe impact human health oncology diabetes cardiometabolic disease resistant microbial infection alzheimer disease addition recent regulatory approval discuss company continue advance program latestage pipeline regulatory submission merck supplemental biologic license application sbla priority review fda keytruda include use combination chemotherapy firstline treatment patient metastatic advanced nonsquamous nsclc regardless pdl expression egfr alk genomic tumor aberration treatment patient classical hodgkin lymphoma treatment previously treat patient advance microsatellite instabilityhigh cancer firstline treatment patient locally advanced metastatic urothelial cancer include bladder cancer secondline treatment patient locally advanced metastatic urothelial cancer disease progression platinumcontaine chemotherapy merck drive broad immunooncology development program invest longterm potential keytruda foundational treatment range cancer keytruda clinical development program include clinical trial tumor type trial combine keytruda cancer treatment insulin glargine candidate treatment patient type type diabete develop collaboration review fda addition phase program keytruda therapeutic area breast colorectal esophageal gastric hepatocellular multiple myeloma renal cancer company candidate phase clinical development therapeutic area research development past year company continue focus productivity improvement look opportunity reallocate resource portfolio grow strong brand support promise asset pipeline marketing administrative expense decline compare reflect continue focus company prioritize resource high growth area research development expense reflect increase clinical development spending company continue invest pipeline november mercks board director raise company quarterly dividend share share company return billion shareholder dividend share repurchase january merck enter settlement license agreement resolve worldwide patent infringement litigation relate keytruda connection settlement merck record pretax charge million fourth quarter note consolidated financial statement earning common share assume dilution attributable common shareholder ep compare eps year reflect impact acquisition divestiturerelate cost include charge relate uprifosbuvir clinical development program restructuring cost certain item nongaap eps exclude item nongaap income non gaap eps table content operate result sale worldwide sale billion increase compare foreign exchange unfavorably affect global sale performance include low benefit revenue hedging activity compare revenue growth primarily reflect high sale oncology franchise largely keytruda launch hcv treatment zepati growth vaccine product include gardasilgardasil varivax pneumovax contribute sale growth high sale hospital acute care product include bridion noxafil growth diabetes franchise januvia janumet high sale animal health product particularly bravecto increase partially offset sale decline attributable ongoing effect generic biosimilar competition certain product include remicade nasonex product diversify brand decline isentress pegintron dulera inhalation aerosol partially offset revenue growth sale performance reflects decline approximately million reduce operation company venezuela result evolve economic condition volatility country sales united states billion increase compare billion pharmaceutical segment sale united states grew drive primarily launch zepati bridion high sale keytruda gardasilgardasil partially offset low sale nasonex cubicin dulera inhalation aerosol isentress international sale billion decline compare billion foreign exchange unfavorably affect international sale performance international sale pharmaceutical segment decline include unfavorable effect foreign exchange largely reflect decline certain emerge market offset increase japan sale emerge market billion decline include unfavorable effect foreign exchange drive primarily reduce operation venezuela partially offset growth market sale japan grow billion include favorable effect foreign exchange exclude favorable effect foreign exchange sale decline japan largely drive loss market exclusivity singulair combine ongoing generic erosion product diversified brand partially offset high sale belsomra sale europe billion essentially flat compare include unfavorable effect foreign exchange exclude unfavorable effect foreign exchange sale performance europe primarily reflect volume growth keytruda cubicin simponi adempas liptruzet januvia franchise partially offset ongoing biosimilar competition generic erosion certain product particularly remicade pricing pressure region total international sale represent total sale respectively global effort health care cost containment continue exert pressure product pricing market access worldwide united states health care reform contribute increase number patient medicaid program sale pharmaceutical product subject substantial rebate international market governmentmandate pricing action reduce price generic patent drug addition austerity measure negatively affect company revenue performance company anticipate pricing action austerity measure continue negatively affect revenue performance table content worldwide sale billion decline compare include unfavorable effect foreign exchange acquisition cubist pharmaceuticals inc cubist divestiture merck consumer care mcc business product divestiture termination company relationship astrazeneca azlp discuss net unfavorable impact sale approximately addition sale performance reflect decline pegintron victrelis remicade pneumovax nasonex vytorin decline partially offset volume growth keytruda januvia janumet gardasilgardasil noxafil simponi implanonnexplanon invanz dulera inhalation aerosol bridion volume growth animal health product high thirdparty manufacturing sale january company acquire cubist contribute sale billion merck revenue company divest certain ophthalmic product international market close july addition october company divest mcc business include prescription right claritin afrin sale decline attributable divestiture approximately billion billion related consumer care segment million relate pharmaceutical segment company sell marketing right saphris antipsychotic indicate treatment schizophrenia bipolar disorder adult result revenue million additionally company relationship azlp terminate june effective july company long record supply sale azlp supply sale million termination date reflect alliance segment table content sale company product follow million primary care women health cardiovascular zetia vytorin diabete januvia janumet general medicine women health nuvare implanonnexplanon dulera follistim hospital specialty hepatitis zepati hiv isentress hospital acute care cubicin noxafil invanz cancidas bridion primaxin immunology remicade simponi oncology keytruda emend temodar diversify brand respiratory singulair nasonex cozaarhyzaar arcoxia fosamax zocor vaccine gardasilgardasil proquadmmr iivarivax zostavax rotateq pneumovax pharmaceutical total pharmaceutical segment sale segment sale total segment sale sale cubicin represent sale subsequent cubist acquisition date sale cubicin reflect sale japan pursuant previously exist licensing agreement amount reflect sale vaccine sell major european market company joint venture spmsd result reflect equity income affiliate include income expense net amount reflect supply sale spmsd december merck sanofi pasteur terminate spmsd joint venture note consolidated financial statement pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately represent nonreportable segment animal health healthcare service alliance consumer care divestiture october alliance segment include revenue company relationship azlp termination june primarily comprise miscellaneous corporate revenue include revenue hedging activity thirdparty manufacture sale include approximately million million respectively connection sale marketing right certain productstable content pharmaceutical segment primary care women health cardiovascular combine global sale zetia market country outside united states ezetrol vytorin market outside united states inegy medicine lower ldl cholesterol billion decline compare include unfavorable effect foreign exchange addition company record sale million atozet medicine lower ldl cholesterol company market certain country outside united states global sale ezetimibe family include atozet billion growth compare reflect volume growth europe high pricing united states largely offset low sale venezuela reduce operation country low volume united states reflect generic competition zetia agreement generic manufacturer launch generic version zetia united states december company experience rapid decline zetia sale company anticipate decline accelerate future period patent exclusivity period zetia vytorin expire april company anticipate decline zetia vytorin sale sale zetia vytorin billion million respectively company market exclusivity major european market ezetrol april inegy april combine worldwide sale ezetimibe family billion decline compare include unfavorable effect foreign exchange sale decline drive primarily low volume ezetrol canada lose market exclusivity september low volume united states partially offset high pricing united states pursuant collaboration merck bayer bayer note consolidated financial statement merck lead commercial right adempas novel cardiovascular drug treatment pulmonary arterial hypertension country outside america bayer lead right america include united states merck begin promote distribute adempas europe transition merck territory continue merck record sale adempas million include sale merck marketing territory merck share profit sale adempas bayer marketing territory september merck sell marketing right zontivity united states canada aralez pharmaceuticals inc million upfront payment royalty graduate rate plus potential future consideration dependent achievement certain aggregate annual salesbase milestone previously march follow business decision reduce sale expectation zontivity united states europe company lower cash flow projection zontivity company utilize market participant assumption consider different scenario determine fair value intangible asset relate zontivity compare related carrying value result impairment charge million record material production cost diabete worldwide combine sale januvia janumet medicine help lower blood sugar level adult type diabete billion increase compare sale growth drive primarily high volume united states europe canada partially offset pricing pressure united states europe low sale venezuela company reduce operation country combine global sale januvia janumet billion essentially flat compare include unfavorable effect foreign exchange sale performance reflect high volume pricing united states volume growth emerge market europe volume decline comarkete sitagliptin japan time sale licensee partially offset growth general medicine women health worldwide sale nuvare vaginal contraceptive product million increase compare million increase compare foreign exchange unfavorably affect global sale performance respectively sale growth year largely reflect high pricing united states volume decline europe partially offset revenue growth august district court rule company delivery system patent nuvare invalid company appeal verdict court appeal federal circuit give district court decision generic entrant market advance april patent table content expiration occur company anticipate significant decline nuvare sale sale nuvare million result unfavorable district court decision company evaluate intangible asset relate nuvaring impairment conclude impaired intangible asset value nuvare million december worldwide sale implanonnexplanon singlerod subdermal contraceptive implant grow million increase compare include unfavorable effect foreign exchange sale growth reflect high demand united states partially offset decline certain emerge market particularly venezuela implanonnexplanon sale rise million increase compare include unfavorable effect foreign exchange increase drive primarily high demand united states emerge market global sale dulera inhalation aerosol combination medicine treatment asthma million decline compare include unfavorable effect foreign exchange decline drive low sale united sale reflect competitive pricing pressure partially offset high demand worldwide sale dulera inhalation aerosol grow million drive primarily high demand united states global sale follistim market country outside united states puregon fertility treatment million decline compare include unfavorable effect foreign exchange sale decline primarily reflect low volume europe supply issue low demand certain emerge market worldwide sale follistim million decline compare reflect unfavorable effect foreign exchange offset high pricing united states company determine business reason terminate north america partnership agreement alkabell include grastek ragwitek allergy immunotherapy tablet sublingual use decision efficacy safety concern tablet merck provide alkabell month notice terminate agreement compound return alkabell connection decision company wroteoff million intangible asset relate product note consolidated financial statement hospital specialty hepatitis global sale zepatier million zepatier approve fda january treatment adult patient chronic hcv infection ribavirin certain patient population zepatier approve july available european market late november launch expect continue company launch zepati japan emerge market worldwide sale pegintron treatment chronic hcv decline million decrease million decline drive low volume nearly region availability new therapeutic option result continued loss market share global sale victrelis oral medicine treatment chronic hcv million decline compare sale million drive low volume europe emerge market availability new therapeutic option result continued loss market share sale victrelis minimis hiv worldwide sale isentress hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection billion decline compare include unfavorable effect foreign exchange sale decline drive primarily low volume united states low demand pricing europe competitive pressure partially offset favorable adjustment discount reserve united states high demand certain emerge market global sale isentress billion decline compare include unfavorable effect foreign exchange decline drive primarily low volume united states low demand table content price europe competitive pressure partially offset high volume latin america high pricing united states hospital acute care global sale cubicin antibiotic complicated skin skin structure infection bacteremia cause designate susceptible organism billion decline compare composition patent cubicin expire june company experience significant decline cubicin sale expect decline continue sale decline united states partially offset sale cubicin certain international market company acquire marketing right fourth quarter include europe latin america australia new zealand china south africa certain asia pacific country company anticipate lose market exclusivity cubicin europe worldwide sales noxafil prevention invasive fungal infection grow million drive primarily high pricing united states volume growth europe reflect ongoing positive impact approval new formulation high demand emerge market global sale noxafil rise million drive pricing high demand united states volume growth europe reflect positive impact approval new formulation foreign exchange unfavorably affect global sale performance global sale invanz treatment certain infection million decline compare include unfavorable effect foreign exchange sale performance reflect volume growth certain emerge market high pricing united states largely offset decline venezuela worldwide sale invanz million increase compare reflect high sale united states volume growth emerge market partially offset unfavorable effect foreign exchange company lose patent protection invanz november company anticipate significant decline invanz sale sale invanz million global sale cancidas antifungal product sell primarily outside united states million decline compare reflect unfavorable effect foreign exchange pricing decline europe offset high volume certain emerge market particularly china worldwide sale cancida million decrease compare reflect unfavorable effect foreign exchange volume decline certain emerge market compound patent cancida expire april company anticipate decline cancidas sale european market sale cancida europe million global sale bridion reversal type neuromuscular block agent surgery million growth compare include favorable effect foreign exchange sale growth reflect volume growth market include united states approve fda december partially offset decline venezuela reduce operation company country sale bridion increase million drive volume growth international market foreign exchange unfavorably affect global sale performance october merck announce fda approve zinplava injection mgml zinplava indicate reduce recurrence clostridium difficile infection cdi patient year age old receive antibacterial drug treatment cdi high risk cdi recurrence zinplava available united states february zinplava approve january company anticipate zinplava available march immunology sale remicade treatment inflammatory disease market company europe russia turkey billion decline compare billion decline compare foreign exchange unfavorably affect sale performance february company lose market exclusivity remicade major european market long market exclusivity marketing territory company experience pricing volume decline market result biosimilar competition expect decline continue table content sale simponi oncemonthly subcutaneous treatment certain inflammatory disease market company europe russia turkey million increase compare include unfavorable effect foreign exchange sale growth drive primarily high volume europe reflect ongoing positive impact ulcerative colitis indication sale simponi million essentially flat compare drive high demand europe reflect ongoing positive impact ulcerative colitis indication offset unfavorable effect foreign exchange oncology sale keytruda antipd therapy billion million million yearoveryear increase primarily reflect high sale united states europe emerge market company continue launch keytruda october merck announce fda approve keytruda firstline treatment patient nsclc tumor high pdl expression tps determine fdaapprove test egfr alk genomic tumor aberration new indication keytruda antipd therapy approve firstline treatment set patient addition fda approve labeling update include datum keynote secondline great treatment set patient metastatic nsclc tumor express pdl tps determine fdaapprove test disease progression platinumcontaine chemotherapy patient egfr alk genomic tumor aberration disease progression fdaapprove therapy aberration prior receive keytruda december keytruda approve japan treatment certain patient pdlpositive unresectable advancedrecurrent nsclc secondline treatment setting additionally january approve keytruda firstline treatment metastatic nsclc adult tumor high pdl expression tps egfr alk positive tumor mutation august merck announce fda approve keytruda treatment patient recurrent metastatic head neck squamous cell carcinoma hnscc disease progression platinumcontaine chemotherapy keytruda approve united states treatment previously untreated metastatic nsclc patient tumor express high level pdl previously treat metastatic nsclc patient tumor express pdl treatment advanced melanoma keytruda approve united states previously treat recurrent metastatic hnscc company launch keytruda market globally merck sbla priority review fda keytruda include use combination chemotherapy firstline treatment patient metastatic advanced nonsquamous nsclc regardless pdl expression egfr alk genomic tumor aberration treatment patient classical hodgkin lymphoma treatment previously treat patient advance microsatellite instabilityhigh cancer firstline treatment patient locally advanced metastatic urothelial cancer include bladder cancer secondline treatment patient locally advanced metastatic urothelial cancer disease progression platinumcontaine chemotherapy company plan additional regulatory filing united states countries keytruda clinical development program include study broad range cancer type research development january merck enter settlement license agreement resolve worldwide patent infringement litigation relate keytruda note consolidated financial statement global sale emend prevention chemotherapyinduce postoperative nausea vomit million increase compare include unfavorable effect foreign exchange largely reflect high pricing united states partially offset volume decline japan february merck announce fda approve supplemental new drug application singledose emend injection prevention delay nausea vomit adult receive initial repeat course moderately emetogenic chemotherapy worldwide sale emend million decline reflect unfavorable effect foreign exchange partially offset high pricing united states volume growth europe table content diversify brand mercks diversify brand include human health pharmaceutical product approach expiration marketing exclusivity long protect patent develop market continue core company offer market world respiratory worldwide sale singulair onceaday oral medicine chronic treatment asthma relief symptom allergic rhinitis million decrease compare include favorable effect foreign exchange sale performance primarily reflect low volume japan patent provide market exclusivity singulair japan expire february october result company experience singulair volume decline japan expect decline continue singulair sale japan million year prior company lose market exclusivity singulair united states major international market exception japan company long market exclusivity singulair major market global sale singulair million decline compare include unfavorable effect foreign exchange sale decline drive primarily low volume japan low demand europe result generic competition global sale nasonex inhale nasal corticosteroid treatment nasal allergy symptom million decline compare drive primarily low volume united states result generic competition march apotex launch generic version nasonex united states pursuant june district court district new jersey ruling uphold appeal court appeal federal circuit hold apotexs generic version nasonex infringe company formulation patent accordingly company experience substantial decline nasonex sale expect decline continue decline global nasonex sale drive low volume price europe ongoing generic erosion low sale venezuela reduce operation company country worldwide sale nasonex million decline compare include unfavorable effect foreign exchange decline drive primarily low volume united states reflect competition alternative generic treatment option supply constraint addition low volume price europe ongoing generic erosion contribute nasonex sale decline global sale cozaar companion agent hyzaar combination cozaar hydrochlorothiazide treatment hypertension decline million decrease million foreign exchange unfavorably affect global sale performance respectively patent provide market exclusivity cozaar hyzaar united states major international market expire accordingly company experience decline cozaar hyzaar sale expect decline continue vaccine follow discussion vaccine include sale vaccine sell major european market spmsd company joint venture sanofi pasteur sanofi result reflect equity income affiliate include income expense net select joint venture affiliate information supply sale spmsd include december merck sanofi terminate spmsd end joint vaccine operation europe note consolidated financial statement begin merck record vaccine sale european market previously spmsd joint venture merck sale gardasilgardasil vaccine help prevent certain cancer disease cause certain type hpv billion growth compare sale growth drive primarily high volume pricing united states high demand certain emerge market partially offset decline government tender brazil october fda approve dose vaccination regimen gardasil use girl boy year age center disease control prevention advisory committee immunization practice vote recommend dose vaccination regimen certain year old company anticipate dose vaccination regiman unfavorable effect sale gardasil period transition merck sale gardasilgardasil billion increase compare include unfavorable effect foreign exchange sale growth table content drive primarily high sale united states result high pricing increase volume reflect time public sector purchase increase government tender asia pacific region partially offset decline latin america price volume gardasil merck valent hpv vaccine approve fda december use female year age male year age gardasil include great number hpv type available hpv vaccine december fda approve expand age indication gardasil include use male year age prevention anal cancer precancerous dysplastic lesion genital wart cause certain hpv type company party certain thirdparty license agreement respect gardasilgardasil include crosslicense settlement agreement glaxosmithkline result agreement company pay royalty worldwide gardasilgardasil sale vary country include material production cost merck sale proquad pediatric combination vaccine help protect measle mump rubella varicella million million million sale growth compare drive primarily high demand pricing united states sale growth compare primarily reflect high sale united states reflect increase volume drive measle outbreak united states high pricing merck sale mmr vaccine help protect measle mump rubella million million million sale performance compare drive high demand result measle outbreak united states merck sale varivax vaccine help prevent chickenpox varicella million million million sale growth compare drive primarily high sale united states reflect effect public sector purchase high pricing partially offset low demand volume growth certain emerge market reflect time government tender contribute sale increase compare sale growth compare reflect high volume certain emerge market high pricing united states partially offset low volume united states mercks sale zostavax vaccine help prevent shingles herpe zoster adult year age old million decline compare include unfavorable effect foreign exchange decline drive primarily low volume united states partially offset high pricing united states high demand certain emerge market merck sale zostavax million decline compare include unfavorable effect foreign exchange sale performance compare reflect low volume united states partially offset high demand canada high pricing united states company continue educate customer broad manage care coverage zostavax process obtain reimbursement merck continue launch zostavax outside united states mercks sale rotateq vaccine help protect rotavirus gastroenteritis infant child million increase compare million decline compare include unfavorable effect foreign exchange sale performance period drive primarily effect public sector purchasing united states volume growth certain emerge market contribute sale growth merck sale pneumovax vaccine help prevent pneumococcal disease million increase compare drive primarily high volume pricing united states high demand certain emerge market merck sale pneumovax million decrease compare drive primarily low demand united states sale decline emerge market foreign exchange favorably affect sale performance unfavorably affect sale performance segment company segment animal health healthcare service alliance segment material separate reporting alliance segment include revenue azlp termination company relationship azlp june select joint venture affiliate information table content prior disposition october company consumer care segment sale billion animal health animal health include pharmaceutical vaccine product prevention treatment control disease major farm companion animal species animal health sale affect competition frequent introduction generic product worldwide sale animal health product billion billion billion global sale animal health product increase compare include unfavorable effect foreign exchange sale growth primarily reflect volume growth species area particularly product companion animal drive primarily high sale bravecto poultry swine product worldwide sale animal health product decline compare include unfavorable effect foreign exchange sale performance reflect volume growth companion animal product drive primarily high sale bravecto begin launch europe united states volume growth swine aqua product company receive marketing approval european medicine agency ema bravecto spoton solution cat dog july company receive approval united states market product tradename bravecto topical july merck announce execute agreement acquire control interest valle lead privately hold producer animal health product brazil note consolidated financial statement cost expense million change change material production marketing administrative research development restructuring cost income expense net great material production material production cost billion billion billion cost include expense amortization intangible asset record connection business acquisition total billion billion billion cost include intangible asset impairment charge million million billion respectively relate marketed product intangible note consolidated financial statement company recognize additional noncash impairment charge future relate intangible asset measure fair value capitalize connection business acquisition charge material addition expense include million amortization purchase accounting adjustment cubist inventory include material production cost expense associate restructuring activity amount million million million respectively include accelerate depreciation asset writeoff relate plan sale closure manufacturing facility separation cost associate manufacturingrelate headcount reduction incur reflect restructure cost discuss gross margin compare improvement gross margin compare drive primarily low net impact amortization intangible asset purchase accounting adjustment inventory intangible asset impairment charge restructure cost note reduce gross margin percentage point compare percentage point low inventory writeoff favorable effect foreign exchange contribute gross margin improvement compare gross margin improvement compare drive primarily favorable effect foreign exchange low inventory writeoff table content net impact acquisition divestiture amortization intangible asset purchase accounting adjustment inventory restructure intangible asset impairment charge note reduce gross margin percentage point market administrative marketing administrative expense billion decline compare drive largely low acquisition divestiturerelated cost favorable effect foreign exchange low administrative expense legal defense cost low selling cost high promotional spending largely relate product launch high restructuring cost partially offset decline expense billion decline compare largely reflect favorable effect foreign exchange divestiture mcc additional expense relate health care reform fee discuss low restructuring cost low selling cost partially offset high promotional spending largely relate product launch high cost relate january acquisition cubist high acquisition divestiturerelated cost expense include acquisition divestiturerelated cost million million million respectively consist integration transaction certain cost relate business acquisition include severance cost company formal restructuring program transaction certain cost relate divestiture business acquisition divestiturerelated cost include cost relate acquisition cubist note consolidated financial statement expense include restructure cost million million million respectively relate primarily accelerate depreciation facility close divest separation cost associate sale force reduction incur reflect restructure cost discuss july internal revenue service irs issue final regulation annual nontax deductible health care reform fee impose patient protection affordable care act base allocation company market share prior year brand pharmaceutical sale certain government program final irs regulation accelerate recognition criterion fee obligation year year underlie sale allocate fee occur year fee pay result change merck record additional year expense million research development research development expense billion compare billion increase drive primarily higher acquire inprocess research development iprd impairment charge increase clinical development spend high restructuring licensing cost partially offset reduction expense associate decrease estimate fair value measurement liability contingent consideration favorable effect foreign exchange expense billion decline compare drive primarily favorable effect foreign exchange expense recognize increase estimate fair value liability contingent consideration low restructuring cost charge relate collaboration bayer bayer divestiture mcc partially offset acquisition cubist high licensing cost high clinical development spending expense comprise cost directly incur merck research laboratory mrl company research development division focus human healthrelated activity approximately billion billion billion include expense cost incur division support activity include depreciation production general administrative licensing activity certain cost operate segment include pharmaceutical animal health segment aggregate billion billion billion respectively expense include iprd impairment charge billion million million respectively research development company recognize additional noncash impairment charge future relate cancellation delay pipeline program measure fair value capitalize connection business acquisition charge material addition expense include expense income relate change estimate fair value measurement liability contingent consideration record connection acquisition company record reduction expense million million respectively decrease estimate fair value liability contingent consideration relate discontinuation delay certain program note consolidated financial statement company record charge million table content increase estimate fair value liability contingent consideration expense reflect million million million respectively accelerate depreciation asset abandonment cost associate restructuring activity restructuring cost company incur substantial cost restructure program activity relate merck productivity cost reduction initiative connection integration certain acquire business company commence action global restructuring program design streamline cost structure action program include elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility company continue reduce global real estate footprint improve efficiency manufacture supply network nonfacility relate restructuring action program substantially complete remain activity primarily relate ongoing facility rationalization restructuring cost primarily represent separation relate cost associate restructuring activity million million billion respectively separation cost million million million respectively incur associate actual headcount reduction estimate expense exist severance program headcount reduction probable reasonably estimate merck eliminate approximately position position position relate restructuring activity position elimination comprise actual headcount reduction elimination contractor vacant position include restructuring cost asset abandonment shutdown relate cost employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation plan cost segment report restructuring cost unallocated expense additional cost associate company restructuring activity include material production marketing administrative research development discuss company record aggregate pretax cost billion billion billion related restructuring program activity note consolidated financial statement company expect substantially complete remain action program end incur approximately million additional pretax cost income expense net income expense net million expense billion expense billion income detail component income expense net note consolidated financial statement segment profit million pharmaceutical segment profit nonreportable segment profit income income taxis segment profit comprise segment sale standard cost certain operating expense directly incur segment component equity income loss affiliate certain depreciation amortization expense internal management reporting present chief operating decision maker merck allocate material production cost standard cost majority research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit exclude determination segment profit acquisition divestiturerelated cost include amortization purchase accounting adjustment intangible asset impairment charge restructure cost taxis pay joint venture level portion equity income additionally segment profit reflect expense corporate manufacturing cost center table content miscellaneous income expense unallocated item include charge relate settlement worldwide keytruda patent litigation gain divestitures net charge relate settlement vioxx shareholder class action litigation gain astrazenecas option exercise foreign exchange loss relate devaluation company net monetary asset venezuela loss extinguishment debt additional year expense relate health care reform fee reflect table include miscellaneous corporate profit loss operate profit loss relate thirdparty manufacture sale pharmaceutical segment profit grew compare primarily reflect high sale pharmaceutical segment profit decline compare primarily reflect unfavorable effect foreign exchange taxis income effective income tax rate reflect impact acquisition divestiturerelated cost include billion iprd impairment charge restructure cost beneficial impact foreign earning effective income tax rate reflect favorable impact net benefit million relate settlement certain federal income tax issue impact net charge relate settlement vioxx shareholder class action litigation fully deductible combine federal state tax rate favorable impact tax legislation enact fourth quarter unfavorable effect nontax deductible foreign exchange loss relate venezuela note consolidated financial statement effective income tax rate reflect impact gain divestiture mcc tax combine federal state tax rate addition effective income tax rate include net tax benefit million record connection astrazenecas option exercise note consolidated financial statement benefit approximately million associate capital loss generate connection sale sirna note consolidated financial statement effective income tax rate include unfavorable impact additional year expense nontax deductible health care reform fee company record accordance final regulation issue irs company examination numerous tax authority jurisdiction globally ultimate finalization company examination relevant tax authority include formal administrative legal proceeding significant impact time reversal unrecognized tax benefit company believe reserve uncertain tax position adequate cover exist risk exposure item currently discussion irs relate examination company conclude position sustain audit item result unfavorable outcome settlement material adverse impact company financial position liquidity result operation net income earning common share net income attributable merck inc billion billion billion eps nongaap income nongaap ep nongaap income nongaap eps alternative view company performance merck provide management believe information enhance investor understand company result permit investor understand management assess performance nongaap income nongaap eps exclude certain item nature item impact analysis underlie business performance trend exclude item consider nonrecurre consist acquisition divestiturerelate cost restructure cost certain item exclude item significant component understand assess financial performance nongaap income nongaap ep important internal measure company senior management receive monthly analysis operating result include nongaap eps management use measure internally plan forecasting purpose measure performance company metric senior management annual compensation derive nongaap income nongaap eps nongaap income nongaap ep measure determine accordance gaap standardize mean prescribed gaap comparable calculation table content similar measure company information nongaap income nongaap eps consider addition substitute superior net income ep prepared accordance generally accept accounting principle united states gaap reconciliation gaap financial measure nongaap financial measure follow million share amount pretax income report gaap increase decrease exclude item acquisition divestiturerelated cost restructure cost item charge relate settlement worldwide keytruda patent litigation foreign currency devaluation relate venezuela net charge relate settlement vioxx shareholder class action litigation gain sale certain migraine clinical development program gain divestiture certain ophthalmic product gain divestiture merck consumer care gain astrazeneca option exercise loss extinguishment debt additional year expense health care reform fee taxis income report gaap estimate tax benefit provision exclude item net tax benefit settlement federal income tax issue tax benefit relate sale sirna therapeutics inc subsidiary nongaap net income net income attributable noncontrolle interest report gaap acquisition divestiturerelate cost attributable noncontrolle interest nongaap net income attributable merck inc eps assume dilution report gaap ep difference nongaap ep assume dilution estimate tax impact exclude item determine apply statutory rate originate territory nongaap adjustment include net benefit million record connection astrazeneca option exercise represent difference calculate gaap ep calculate nongaap eps different calculate dividing impact exclude item weightedaverage share applicable year acquisition divestiturerelate cost nongaap income nongaap eps exclude impact certain amount record connection business acquisition divestiture amount include amortization intangible asset amortization purchase accounting adjustment inventory intangible asset impairment charge expense income relate change estimate fair value measurement contingent consideration exclude integration transaction certain cost associate business acquisition include severance cost table content company formal restructuring program transaction certain cost associate divestiture business restructure cost nongaap income nongaap eps exclude cost relate restructuring action note consolidated financial statement amount include employee separation cost accelerate depreciation associate facility close divested accelerated depreciation cost represent difference depreciation expense recognize revise useful life asset base anticipate date site close divest equipment dispose depreciation expense determine utilize useful life prior restructure action restructure cost include asset abandonment shutdown relate cost employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation cost certain item nongaap income nongaap eps exclude certain item item adjusted evaluate individual basis consider quantitative qualitative aspect typically consist item unusual nature significant result particular period indicative future operating result exclude nongaap income nongaap eps charge settle worldwide patent litigation relate keytruda note consolidated financial statement exclude nongaap income nongaap eps foreign exchange loss relate devaluation company net monetary asset venezuela note consolidated financial statement net charge relate settlement vioxx shareholder class action litigation note consolidated financial statement gain sale certain migraine clinical development program note consolidated financial statement gain divestiture company remain ophthalmic business international market note consolidated financial statement net tax benefit relate settlement certain federal income tax issue note consolidated financial statement exclude nongaap income nongaap ep certain gain include gain divestiture mcc note consolidated financial statement gain recognize conjunction astrazeneca option exercise include related net tax benefit transaction note consolidated financial statement gain divestiture certain ophthalmic product international market note consolidated financial statement loss extinguishment debt note consolidated financial statement additional year expense relate health care reform fee discuss tax benefit sale company sirna therapeutics inc sirna subsidiary note consolidated financial statement research development chart reflect company current research pipeline february set forth item business research development research development update company currently candidate regulatory review united states keytruda fdaapprove antipd therapy clinical development expand indication different cancer type keytruda currently approve treatment nsclc melanoma advanced melanoma head neck cancer pharmaceutical segment february fda accept review sbla keytruda patient locally advanced metastatic urothelial cancer include bladder cancer application firstline use grant priority review treatment patient ineligible cisplatincontaine therapy application secondline use grant priority review patient disease progression platinumcontaine chemotherapy prescription drug user fee act pdufa action date application june fda previously grant breakthrough therapy designation keytruda secondline treatment patient locally advanced metastatic urothelial cancer disease progression platinumcontaine chemotherapy january fda accept review sbla keytruda plus chemotherapy pemetrexed plus carboplatin firstline treatment patient metastatic advanced nonsquamous nsclc regardless table content pdl expression egfr alk genomic tumor aberration application regulatory approval keytruda combination treatment fda grant priority review pdufa action date sbla review fda accelerate approval program december fda accept review sbla keytruda treatment patient refractory classical hodgkin lymphoma patient relapse prior line therapy fda grant priority review pdufa action date march sbla review fdas accelerate approval program november fda accept review sbla keytruda treatment previously treat patient advance microsatellite instabilityhigh msih cancer fda grant priority review pdufa action date march sbla review fdas accelerate approval program fda recently grant breakthrough therapy designation keytruda unresectable metastatic msih noncolorectal cancer previously grant treatment patient unresectable metastatic msih colorectal cancer additionally keytruda receive breakthrough therapy designation fda treatment patient primary mediastinal bcell lymphoma refractory relapse prior line therapy fda breakthrough therapy designation intend expedite development review candidate plan use combination treat lifethreatening disease condition preliminary clinical evidence indicate drug demonstrate substantial improvement exist therapy clinically significant endpoint keytruda clinical development program consist clinical trial include trial combine keytruda cancer treatment study encompass cancer type include bladder colorectal esophageal gastric head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma melanoma multiple myeloma nasopharyngeal nsclc ovarian prostate renal triplenegative breast currently phase clinical development trial plan cancer investigational followon biologic insulin glargine candidate treatment patient type type diabete review fda approve january develop collaboration partially fund samsung bioepis investigational pediatric hexavalent combination vaccine dtapipvhibhepb review fda develop approve commercialize partnership merck sanofi vaccine design help protect important disease diphtheria tetanus pertussis whooping cough polio poliovirus type invasive disease cause haemophilus influenzae type hib hepatitis november fda issue complete response letter crl respect biologic license application company review crl plan communication fda february grant marketing authorization prophylaxis diphtheria tetanus pertussis hepatitis poliomyelitis invasive disease cause hib infant toddler age week market vaxeli addition candidate regulatory review company drug candidate phase clinical development addition keytruda program discuss verubecestat investigational small molecule inhibitor betasite amyloid precursor protein cleave enzyme bace treatment alzheimer disease february merck announce external datum monitor committee edmc recommend termination phase epoch study verubecestat mildtomoderate alzheimer disease base low probability success study edmc recommend separate phase study apecs evaluate verubecestat amnestic mild cognitive impairment alzheimer disease know prodromal alzheimer disease continue plan estimate primary completion date apecs study fully enrol february anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp development raise hdlc reduce ldl anacetrapib evaluate patient eventdriven cardiovascular clinical outcome trial sponsor oxford university reveal randomize evaluation effect anacetrapib lipidmodification involve patient preexist vascular disease november table content merck announce datum monitor committee dmc reveal outcomes study complete planned review unblinde study datum recommend study continue change dmc review safety efficacy datum study include assessment futility merck remain blind actual result analysis reveal safety efficacy datum study patient visit occur january company anticipate receive topline result study midyear mka combination relebactam investigational betalactamase inhibitor imipenemcilastatin approve carbapenem antibiotic fda designate combination qualified infectious disease product designate fast track status treatment hospitalacquire bacterial pneumonia ventilatorassociate bacterial pneumonia complicated intraabdominal infection complicate urinary tract infection letermovir investigational oral oncedaily intravenous infusion antiviral candidate prevention clinicallysignificant cytomegalovirus cmv infection letermovir receive orphan drug status united states grant fast track designation october merck announce pivotal phase clinical study letermovir meet primary endpoint global multicenter randomize placebocontrolle study evaluate efficacy safety letermovir adult year old cmvseropositive recipient allogeneic hematopoietic stem cell transplant merck plan submit regulatory application approval letermovir united states ertugliflozin investigational oral sglt inhibitor evaluate treatment type diabete collaboration pfizer inc pfizer september merck pfizer announce phase study vertis sita ertugliflozin meet primary endpoint daily doses ertugliflozin show significantly great reduction average measure blood glucose past month add patient background sitagliptin metformin ertugliflozin study combination januvia sitagliptin metformin december merck submit new drug application fda ertugliflozin fixeddose combination mka ertugliflozin plus januvia mkb ertugliflozin plus metformin company anticipate response fda quarter ertugliflozin fixeddose combination currently review term collaboration agreement pfizer merck million milestone payment pfizer mkj investigational fixeddose combination sitagliptin ipragliflozin development commercialization japan collaboration astellas pharma inc astella ipragliflozin sglt inhibitor codevelope astellas kotobuki pharmaceutical ltd kotobuki approve use japan copromote merck kotobuki investigational rvsvzebov ebola vaccine candidate study large scale phase clinical trial november merck newlink genetic announce exclusive licensing collaboration agreement investigational ebola vaccine december merck announce application emergency use assessment list eual accept review world health organization accord eual process design expedite availability vaccine need public health emergency outbreak ebola decision grant eual status base datum quality safety efficacyeffectiveness riskbenefit analysis emergency use eual designation allow emergency use vaccine remain investigational license commercial distribution july merck announce fda grant breakthrough therapy designation ema grant vaccine candidate prime priority medicine status december end study result re vaccination trial report lancet support july interim assessment offer substantial protection ebola virus disease report case vaccinate individual day vaccination randomize nonrandomize cluster result ongoing study anticipate second half vericiguat investigational treatment heart failure study phase clinical trial patient suffer chronic heart failure development vericiguat worldwide strategic collaboration merck bayer note consolidated financial statement inactivated varicella zoster virus vaccine development prevention herpe zoster company complete phase trial autologous hematopoietic cell transplant patient conduct phase trial patient solid tumor malignancy undergo chemotherapy hematological malignancy table content study autologous hematopoietic cell transplant patient meet primary endpoint merck present result study american society blood marrow transplantation meeting february doravirine investigational nonnucleoside reverse transcriptase inhibitor develop merck treatment hiv infection february company receive positive result phase study show doravirine noninferior alternative regimen achieve maintain hiv suppression infect adult week treatment company divest discontinued certain drug candidate merck announce discontinuing development odanacatib investigational cathepsin inhibitor osteoporosis seek regulatory approval use merck previously report numeric imbalance adjudicate stroke event pivotal phase fracture outcomes study postmenopausal woman company decide discontinue development independent adjudication analysis major adverse cardiovascular event confirm increase risk stroke company determine business reason terminate north america partnership agreement alkabell include investigational allergy immunotherapy tablet house dust mite allergy merck give alkabell month notice terminate agreement compound return alkabell decision efficacy safety concern connection decision company record iprd impairment charge note consolidated financial statement company decide business reason discontinue clinical development mkb refer generation ring investigational combination etonogestrel estradiol vaginal ring contraception treatment dysmenorrhea woman seek contraception decision efficacy safety concern result decision company record iprd impairment charge note consolidated financial statement merck announce business reason proceed submit marketing application omarigliptin investigational onceweekly dpp inhibitor united states europe decision result concern efficacy safety omarigliptin company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource candidate company believe capable provide unambiguous promotable advantage patient payer deliver maximum value approve medicine vaccine new indication new formulation merck pursue emerge product opportunity independent therapeutic area modality small molecule biologic vaccine build biologic capability company commit make externally source program great component pipeline strategy focus supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound access new technology company review pipeline examine candidate provide value outlicense company continue evaluate certain latestage clinical development platform technology asset determine outlicense sale potential company clinical pipeline include candidate multiple disease area include atherosclerosis cancer cardiovascular disease diabete infectious disease inflammatoryautoimmune disease neurodegenerative disease respiratory disease acquire inprocess research development connection business acquisition company record fair value inprocess research project time acquisition reach technological feasibility december balance iprd billion company record iprd project obtain connection acquisition afferent iomet discuss table content million million million respectively iprd project receive marketing approval major market company begin amortize asset base estimate useful life iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate time period receive approval fda regulatory agency subject uncertainty significant delay approval process company failure obtain approval delay prevent company realize revenue product additionally certain iprd program fail abandon development company realize future cash flow estimate record iprd acquisition date company recover research development expenditure acquisition develop program circumstance occur company future operating result adversely affect company recognize impairment charge charge material company record billion iprd impairment charge research development expense billion relate clinical development program uprifosbuvir nucleotide prodrug clinical development evaluate treatment hcv company determine recent change product profile change merck expectation pricing market opportunity take constitute trigger event require company evaluate uprifosbuvir intangible asset impairment utilize market participant assumption consider different scenario company conclude good estimate current fair value intangible asset relate uprifosbuvir million result recognition pretax impairment charge note iprd impairment charge include charge million million relate discontinuation program obtain connection acquisition ccam biotherapeutics ltd oncoethix respectively result unfavorable efficacy datum additional million relate program obtain connection smartcell acquisition follow decision terminate lead compound lack efficacy pursue backup compound reduce project future cash flow iprd impairment charge include million relate inlicense program house dust mite allergy business reason return licensor remain iprd impairment charge primarily relate deprioritize pipeline program deem alternative use period include million impairment charge investigational candidate contraception discontinuation delay certain clinical development program result reduction relate liability contingent consideration note consolidated financial statement company record million iprd impairment charge million relate surotomycin clinical development program company receive unfavorable efficacy datum clinical trial surotomycin evaluation datum combine assessment commercial opportunity surotomycin result discontinuation program iprd impairment charge note company record million iprd impairment charge primarily result change cash flow assumption certain compound obtain connection company joint venture supera farma laboratorio discontinuation certain animal health program additional research development require remain program reach technological feasibility cost complete research project depend project bring final stage development ultimately submit fda regulatory agency approval december estimate cost complete project acquire connection acquisition phase development human health approximately million acquisition research collaboration license agreement merck continue remain focused pursue opportunity potential drive near longterm growth certain recent significant transaction describe merck actively monitor landscape growth opportunity meet company strategic criterion july merck acquire afferent privately hold pharmaceutical company focus development therapeutic candidate target receptor treatment common poorlymanage neurogenic table content condition afferent lead investigational candidate selective nonnarcotic orallyadministere antagonist evaluate phase clinical trial treatment refractory chronic cough phase clinical trial idiopathic pulmonary fibrosis cough total consideration transfer million include cash pay outstanding afferent share million sharebase compensation payment settle equity award attributable precombination service cash pay transaction cost behalf afferent addition afferent shareholder eligible receive total additional million contingent attainment certain clinical development commercial milestone multiple indication candidate include transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value acquisition date company determine fair value contingent consideration million acquisition date utilize probabilityweighte estimate cash flow stream adjust expect timing payment appropriate discount rate dependent nature time milestone payment merck recognize intangible asset iprd million net defer tax liability million net asset million primarily consist cash acquire excess consideration transfer fair value net asset acquire million record goodwill allocate pharmaceutical segment deductible tax purpose fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probability adjust future net cash flow reflect stage development project associate probability successful completion net cash flow discount present value discount rate actual cash flow likely different assume june merck moderna enter strategic collaboration license agreement develop commercialize novel mrnabase personalize cancer vaccine development program entail multiple study type cancer include evaluation mrnabase personalize cancer vaccine combination merck keytruda pursuant term agreement merck upfront cash payment moderna million record research development expense follow human proof concept study merck right elect additional payment moderna merck exercise right company equally share cost profit worldwide collaboration development personalize cancer vaccine moderna right elect copromote personalize cancer vaccine united states agreement entail exclusivity combination keytruda moderna merck ability combine mrnabase personalize cancer vaccine nonpd agents january merck acquire iomet privately hold ukbased drug discovery company focus development innovative medicine treatment cancer particular emphasis field cancer immunotherapy cancer metabolism acquisition provide merck iomet preclinical pipeline ido indoleaminedioxygenase tdo tryptophandioxygenase dualacte idotdo inhibitors transaction account acquisition business total purchase consideration transaction include cash payment million future additional milestone payment million contingent certain clinical regulatory milestone achieve company determine fair value contingent consideration million acquisition date utilize probabilityweighte estimate cash flow stream adjust expect timing payment utilize discount rate merck recognize intangible asset iprd million net defer tax asset million excess consideration transfer fair value net asset acquire million record goodwill allocate pharmaceutical segment deductible tax purpose fair value identifiable intangible asset relate iprd determine income approach asset probabilityadjuste future net cash flow discount present value discount rate actual cash flow likely different assume select joint venture affiliate information sanofi pasteur msd december merck sanofi terminate equallyowne joint venture form develop market vaccine europe note consolidated financial statement table content sale joint venture product prior termination follow millions gardasilgardasil influenza vaccine viral vaccine rotateq zostavax hepatitis vaccine vaccine astrazeneca june astrazeneca exercise option result redemption merck remain interest astrazeneca azlp partnership merck astrazeneca million cash note consolidated financial statement million reflect estimate fair value merck interest nexium prilosec product sell azlp portion exercise price subject trueup base actual sale closing june defer recognize income million million million respectively income expense net contingency eliminate sale occur defer income fully amortize quarter company begin recognize income correspond receivable amount merck astrazeneca base sale performance nexium prilosec subject trueup june company recognize million income include income expense net remain exercise price million primarily represent multiple time merck average annual profit allocation partnership year prior exercise merck recognize million gain income expense net company recognize noncash gain approximately million income expense net result retirement billion preferred stock elimination company billion investment azlp million reduction goodwill transaction result net tax benefit million primarily reflect reversal defer taxis azlp investment balance prior termination merck record revenue azlp million earn partnership return million record equity income affiliate include income expense net capital expenditure capital expenditure billion billion billion expenditure united states billion million million depreciation expense billion billion billion billion billion billion respectively apply location united states total depreciation expense include accelerate depreciation million million million respectively associate restructuring activity note consolidated financial statement analysis liquidity capital resource merck strong financial profile enable fund research development focus external alliance support inline product maximize upcoming launch provide significant cash return shareholder select datum millions work capital total debt total liability equity cash provide operation total debt cash provide operating activity billion billion billion cash provide operating activity reflect net payment approximately million fund table content vioxx shareholder class action litigation settlement cover insurance proceed note consolidated financial statement cash provide operating activity reflect approximately billion taxis pay divestiture mcc cash provide operating activity continue company primary source fund finance operating need capital expenditure portion treasury stock purchase dividend pay shareholder cash investing activity billion compare billion low use cash drive primarily cash acquisition cubist low purchase security investment partially offset low proceed sale security investment use cash acquisition afferent staywell cash investing activity billion compare million primarily reflect cash receive divestiture mcc high cash receive disposition business connection astrazeneca option exercise cash acquisition cubist partially offset low purchase security investment high proceed sale security investment cash acquisition idenix cash payment formation collaboration bayer cash financing activity billion compare billion drive primarily low proceed issuance debt partially offset decrease shortterm borrowing prior year low payment debt low purchase treasury stock high proceed exercise stock option cash financing activity billion compare billion drive primarily high proceed issuance debt low payment debt low purchase treasury stock partially offset low proceed exercise stock option decrease shortterm borrowing company record charge million relate devaluation net monetary asset venezuela large majority cash note consolidated financial statement december total worldwide cash investment billion include billion cash cash equivalent shortterm investment billion longterm investment generally cash investment hold foreign subsidiary subject significant tax payment cash investment repatriate form dividend company record defer tax liability certain unremitte earning amount earn overseas expect indefinitely reinveste outside united states accrual taxis provide cash investment hold foreign subsidiary fluctuate variety factor include time receipt payment normal course business cash provide operating activity united states continue company primary source fund finance domestic operating need capital expenditure portion treasury stock purchase dividend pay shareholder company contractual obligation december follow payment period million total purchase obligation loan payable current portion longterm debt longterm debt interest relate debt obligation keytruda patent litigation settlement unrecognized tax benefit operating lease include future inventory purchase company commit connection certain divestiture february million float rate note mature repay december company consolidated balance sheet reflect liability unrecognize tax benefit interest penalty billion include billion reflect current liability high degree uncertainty time future cash outflow liability unrecognize tax benefit year reasonable estimate period cash settlement year table content purchase obligation enforceable legally bind obligation purchase good service include minimum inventory contract research development advertising amount reflect research development obligation include contingent milestone payment company million milestone payment connection clinical program develop collaboration research development exclude research development obligation potential future funding commitment approximately million investment research venture capital fund loan payable current portion longterm debt reflect million longdate note subject repayment option holder require funding obligation relate company pension postretirement benefit plan expect material company currently anticipate contribute approximately million pension plan million international pension plan million postretirement benefit plan november company issue billion principal senior unsecured note consist million principal note million principal note company intend use net proceed offer billion general corporate purpose include limitation repayment outstanding commercial paper borrowing indebtedness upcoming maturity june company terminate exist credit facility enter new billion fiveyear credit facility mature june facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility december company file security registration statement securities exchange commission sec automatic shelf registration process available wellknown seasoned issuer effective year february merck issue billion aggregate principal senior unsecured note company portion net proceed offer billion repay commercial paper issue substantially finance company acquisition cubist remain net proceed general corporate purpose include repurchase company common stock repayment outstanding commercial paper borrowing debt maturity february company redeem billion legacy cubist debt acquire acquisition note consolidated financial statement october company issue billion principal senior unsecured note net proceed offer billion repay debt validly tender connection tender offer launch company certain outstanding note debenture company pay billion aggregate consideration applicable purchase price accrue interest redeem billion principal debt november merck redeem additional billion principal senior unsecured note effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date company continue maintain conservative financial profile company place cash investment instrument meet high credit quality standard specify investment policy guideline guideline limit credit exposure issuer company participate offbalance sheet arrangement involve unconsolidated subsidiary provide financing potentially expose company unrecorde financial obligation november board director declare quarterly dividend share company common stock payable january march mercks board director authorize additional purchase billion merck common stock treasury treasury stock purchase authorization time limit time table content openmarket transaction block transaction exchange privately negotiate transaction company purchase billion common stock million share treasury company approximately billion remain march share repurchase program company purchase billion billion common stock respectively previously authorize share repurchase program financial instrument market risk disclosure company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce variability cause change foreign exchange rate affect dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale forecast sale expect occur planning cycle typically year future company layer hedge time increase portion forecast sale hedge get close expect date forecast foreign currency denominate sale portion forecast sale hedge base assessment cost benefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument company manage anticipate transaction exposure principally purchase local currency option forward contract purchase collar option merck principally sell foreign currency revenue hedging program uniform weaken dollar yield large overall potential loss market value hedge instrument market value merck hedge decline estimate million million december respectively uniform weaken dollar market value determine foreign exchange option pricing model hold factor exchange rate constant predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow company manage operating activity net asset position local level order mitigate effect exchange monetary asset liability company use balance sheet risk management program mitigate exposure net monetary asset denominate currency subsidiary functional currency effect volatility foreign exchange instance merck principally utilize forward exchange contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument cash flow contract report operating activity consolidate statement cash flow sensitivity analysis change value dollar foreign currency denominate derivative investment monetary asset liability indicate dollar uniformly weaken currency exposure company december income taxis decline approximately million company net short payable position relative major foreign currency consideration forward contract uniform weaken dollar yield large overall potential net loss earning exchange december company net long receivable table content position relative major foreign currency consideration forward contract uniform strengthen dollar reduce income taxis approximately million measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow january venezuela designate hyperinflationary result local foreign operation remeasure dollar impact record result operation venezuelan government identify multiple exchange rate include cencoex rate vef dollar simadi rate venezuelan government indicate essential good include food medicine remain cencoex rate second quarter evaluation evolve economic condition venezuela volatility country combine decline transaction settle cencoex rate company determine unlikely outstanding net monetary asset settle cencoex rate accordingly second quarter company record charge million income expense net devalue net monetary asset venezuela represent company estimate dollar ultimately collect quarter company record additional exchange loss million aggregate reflect ongoing effect translate transaction net monetary asset consistent second quarter result deterioration economic condition venezuela continue decline transaction settle cencoex rate subsequently replace dipro rate fourth quarter company begin simadi rate vef december report venezuelan operation company revalue remain net monetary asset simadi rate subsequently replace dicom rate result additional charge fourth quarter million company use forward exchange contract hedge net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation company hedge portion net investment certain foreign operation measure ineffectiveness base change spot foreign exchange rate record income expense net effective portion unrealize gain loss contract record foreign currency translation adjustment comprehensive income oci remain accumulated comprehensive income aoci sale complete substantially complete liquidation subsidiary cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk interest rate swap notional amount million mature swap effectively convert company billion fixedrate note variable rate debt december company party payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note detailed table table content million number interest rate total swap notional debt instrument par value debt swap hold note note note note note note interest rate swap contract designate hedge fair value change note attributable change benchmark london interbank offer rate libor swap rate fair value change note attributable change libor swap rate record interest expense offset fair value change swap contract cash flow contract report operating activity consolidate statement cash flow company investment portfolio include cash equivalent shortterm investment market value significantly affect change interest rate market value company medium longterm fixedrate investment modestly affect change interest rate change medium longterm interest rate significant impact market value company fixedrate borrowing generally long maturity sensitivity analysis measure potential change market value merck investment debt change interest rate indicate percentage point increase interest rate december positively affect net aggregate market value instrument billion billion respectively percentage point decrease december negatively affect net aggregate market value billion billion respectively fair value merck debt determine pricing model reflect percentage point shift appropriate yield curve fair value merck investment determine combination pricing duration model critical accounting policy company consolidated financial statement prepare conformity gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection acquisition include initial fair value determination asset liability primarily iprd intangible asset contingent consideration subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate application follow accounting policy result accounting estimate potential significant impact financial statement acquisition determine acquisition qualify business combination asset acquisition company make certain judgment include assessment input process output associate acquire set activity october company adopt new accounting guidance intend clarify transaction account acquisition disposal asset business company determine substantially fair value gross asset include transaction concentrate single asset group similar asset asset represent business consider business asset transaction need include input substantive process significantly contribute ability create output prior adoption new guidance company consider acquisition disposition business input process apply input ability create output business combination acquisition method accounting require asset acquire liability assume record date acquisition respective fair value limited exception table content asset acquire liability assume business combination arise contingency recognize fair value fair value reasonably estimate acquisition date fair value asset acquire liability assume arise contingency determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date acquisition fair value intangible asset include acquire iprd determine utilize information available near acquisition date base expectation assumption deem reasonable management give considerable judgment involve determine fair value company typically obtain assistance thirdparty valuation specialist significant item amount allocate acquire iprd capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project merck separate determination useful life asset generally determine period substantial majority cash flow expect generate begin amortization certain company business acquisition involve potential future payment consideration contingent achievement performance milestone include product development milestone royalty payment future product sale fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probabilityweighte cash flow subsequent acquisition date report period contingent consideration liability remeasure current fair value change expense income record earning change input result significantly different fair value adjustment judgment determine estimate fair value assign asset acquire liability assume business combination asset life materially affect company result operation company determine transaction account acquisition business transaction account acquisition asset business combination goodwill record asset acquisition acquire iprd alternative future use charge expense acquisition date fair value identifiable intangible asset relate currently market product product right primarily determined income approach fair value estimate base asset discount project net cash flow company estimate market participant net cash flow consider historical project pricing margin expense level performance compete product applicable relevant industry therapeutic area growth driver factor current expect trend technology product life cycle time investment require develop product technology ability obtain market regulatory approval ability manufacture commercialize product extent time potential new product introduction company competitor life asset underlie patent net cash flow probabilityadjuste appropriate consider uncertainty associate underlie assumption risk profile net cash flow utilize valuation probabilityadjuste future net cash flow product discount present value utilize appropriate discount rate fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probabilityadjuste future net cash flow reflect different stage development product associate probability successful completion net cash flow discount present value appropriate discount rate revenue recognition revenue sale product recognize title risk loss pass customer typically time delivery recognition revenue require reasonable assurance collection sale proceed table content completion performance obligation domestically sale discount issue customer direct discount pointofsale indirectly intermediary wholesaler know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition revenue record net time value money discount customer collection account receivable expect excess year provision aggregate indirect customer discount cover chargeback rebate chargeback discount occur contract customer purchase directly intermediary wholesaler contract customer generally purchase product contract price plus markup wholesaler wholesaler turn charge company difference price initially pay wholesaler contract price pay wholesaler customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product pharmacy benefit plan participant provision base expect payment drive patient usage contract performance benefit provider customer company use historical customer segment mix adjust know event order estimate expect provision amount accrue aggregate indirect customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager customer amount accrue adjustment record trend significant event indicate change estimate provision appropriate company continually monitor provision aggregate indirect customer discount material adjustment estimate associate aggregate indirect customer discount provision summarize information change aggregate indirect customer discount accrual relate sale follow million balance january current provision adjustment prior year payment balance december accrual chargeback reflect direct reduction account receivable accrual rebate current liability accrue balance relative provision include account receivable accrue current liability million billion respectively december million billion respectively december company maintain return policy allow pharmaceutical customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market additional generic competition change formulary launch overthecounter product product return provision pharmaceutical sale percentage net pharmaceutical sale distribution program wholesaler company encourage wholesaler align purchase underlie demand maintain inventory specify level term program allow wholesaler earn fee provide visibility inventory level achieve certain performance parameter inventory management customer service level reduce shortage claim reduce product return information provide wholesaler distribution program include item sale trend inventory onhand onorder quantity product return table content wholesaler generally provide mention datum company regulatory requirement report lot level information manufacturer level information need determine remain shelf life original sale date inventory give current wholesaler inventory level generally month company believe collection order lot information wholesale customer limited use estimate sale discount return inventory produce preparation product launch company capitalize inventory produce preparation product launch sufficient support estimate initial market demand typically capitalization inventory begin relate product candidate phase clinical trial consider high probability regulatory approval company monitor status respective product regulatory approval process company generally disclose specific timing regulatory approval company aware specific risk contingency normal regulatory approval process specific issue identify research process relate safety efficacy manufacturing marketing label relate inventory generally capitalize expiry date inventory affect stage completion company manage level inventory stage optimize shelf life inventory relation anticipate market demand order avoid product expiry issue inventory capitalize anticipated future sale shelf live support realization inventory value inventory shelf life sufficient meet initial product launch requirement inventory produce preparation product launch capitalize december million million respectively contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation certain additional matter note consolidated financial statement company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust site investigation feasibility study relate cost assessment remedial technique complete extent potentially responsible party jointly severally liable expect contribute determine company remediate environmental contamination result past industrial activity certain site take active role identify accrue cost past merck perform worldwide survey assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate table content definitive information available course investigation andor remedial effort site estimate refined accrual establish adjust accordingly estimate related accrual continue refine annually company believe compliance issue associate applicable environmental law regulation material adverse effect company expenditure remediation environmental liability million estimate million aggregate year management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year sharebase compensation company expense sharebase payment award employee include grant stock option requisite service period base grant date fair value award company determine fair value certain sharebased award blackschole optionprice model use historical current market datum estimate fair value method incorporate assumption riskfree interest rate expect volatility expect dividend yield expect life option total pretax sharebase compensation expense million million million december million total pretax unrecognized compensation expense relate nonveste stock option restrict stock unit performance share unit award recognize weighted average period year segment report sharebased compensation cost unallocated expense pension postretirement benefit plan net periodic benefit cost pension postretirement benefit plan total million million million pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption include discount rate plan benefit obligation expect rate return plan asset change net periodic benefit cost year year pension plan largely attributable change discount rate affect net amortization decrease net periodic benefit cost postretirement benefit plan compare largely attributable change retiree medical benefit approve company december company reassesse benefit plan assumption regular basis pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come discount rate company pension postretirement benefit plan range december compare range december expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company consider longterm compound annualize return historical market datum actual return company plan asset reference information company develop forward look return expectation asset category weightedaverage expect longterm rate return target portfolio allocate investment category expect portfolio performance reflect contribution active management appropriate expect rate return company pension postretirement benefit plan range compare range company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension table content postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest nonus pension plan target investment portfolio vary base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline actuarial assumption base management good estimate judgment reasonably possible change plus minus basis point discount rate assumption assumption hold constant estimate million favorable unfavorable impact company current year net periodic benefit cost reasonably possible change plus minus basis point expect rate return assumption assumption hold constant estimate million favorable unfavorable impact merck current year net periodic benefit cost require funding obligation relate company pension postretirement benefit plan expect material precede hypothetical change discount rate expect rate return assumption impact company funding requirement net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption record component aoci expect return pension plan base calculate marketrelated value asset methodology asset gainslosse result actual return differ company expect return recognize market relate value asset ratably fiveyear period net loss amount aoci excess certain threshold amortize net periodic benefit cost average remain service life employee restructure cost restructure cost record connection restructuring program design streamline company cost structure result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place accrue cost company recognize range cost good estimate range range well estimate company recognize minimum range connection action management assess recoverability longlive asset employ business certain instance asset life shorten base change expect useful life affect asset severance relate cost reflect restructuring cost assetrelate charge reflect material production cost market administrative expense research development expense depend nature asset impairment longlive asset company assess change economic regulatory legal condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset company periodically evaluate current fact circumstance indicate carry value longlive asset hold recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow approach goodwill represent excess consideration transfer fair value net asset business acquire assign reporting unit company test goodwill impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying factor consider assessment include general macroeconomic condition condition specific industry market cost factor significant effect earning cash flow overall financial performance report unit sustained decline company share price additionally company evaluate table content extent fair value exceed carry value reporting unit date valuation perform company conclude likely fair value report unit carrying quantitative fair value test perform acquire intangible asset exclude iprd record fair value assign estimate useful life amortize primarily straight line basis estimate useful life event circumstance warrant review company assess recoverability future operation pretax undiscounte cash flow derive low appropriate asset grouping impairment recognize operating result extent carry value intangible asset exceed fair value determine base net present value estimate future cash flow iprd company acquire business combination represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project company test iprd impairment annually frequently impairment indicator exist assess qualitative factor determine likely fair value iprd intangible asset carrying company conclude likely fair value carrying quantitative test compare fair value iprd intangible asset carrying value perform impairment testing purpose company combine separately record iprd intangible asset unit account base relevant fact circumstance generally company combine iprd intangible asset testing purpose operate single asset essentially inseparable fair value carrying impairment loss recognize company operating result judgment evaluate impairment longlive intangible materially affect company result operation impairment investment company review investment impairment base determination decline market value investment carrying value otherthantemporary company consider available evidence evaluate potential impairment investment include duration extent fair value cost equity security company ability intent hold investment debt security otherthan temporary impairment occur company expect recover entire amortize cost basis debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning limited portion attribute credit loss remain portion otherthantemporary impairment relate factor recognize oci taxis income company effective tax rate base pretax income statutory tax rate tax planning opportunity available jurisdiction company operate estimate effective tax rate year apply company quarterly operating result event significant unusual onetime item recognize expect recognize company quarterly operating result tax attributable item separately calculate record time unusual onetime item company consider resolution prior year tax matter item significant judgment require determine company tax provision evaluate tax position recognition measurement tax position base management good judgment give fact circumstance information available reporting date company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement likely threshold meet period tax position take company subsequently recognize benefit tax position tax matter effectively settle statute limitation expire likely threshold meet subsequent period note consolidated financial statement table content tax regulation require item include tax return different time item reflect financial statement time difference create defer tax asset liability defer tax asset generally represent item tax deduction credit tax return future year company record tax benefit financial statement company establish valuation allowance defer tax asset expect future taxable income likely support use deduction credit defer tax liability generally represent tax expense recognize financial statement payment defer expense company take deduction tax return recognize expense financial statement december foreign earning billion retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability recently issue accounting standard financial accounting standard board fasb issue amend accounting guidance revenue recognition apply contract customer objective new guidance improve comparability revenue recognition practice entity provide useful information user financial statement improve disclosure requirement august fasb approve oneyear deferral effective date make guidance effective interim annual period begin new standard permit method adoption retrospectively prior reporting period present retrospective method retrospectively cumulative effect adopt guidance recognize date initial application modify retrospective method company adopt new standard january currently plan use modify retrospective method majority company business ship bill primary revenue stream merck expect significant difference company analysis preliminary subject change merck complete assessment multiple element arrangement certain discount trade promotion program january fasb issue revise guidance accounting report financial instrument new guidance require equity investment readily determinable fair value currently classify available sale measure fair value change fair value recognize net income new guidance simplify impairment testing equity investment readily determinable fair value change certain disclosure requirement guidance effective interim annual period begin early adoption permit company currently assess impact adoption consolidate financial statement february fasb issue new accounting guidance accounting reporting lease new guidance require lessee recognize rightofuse asset lease liability record balance sheet lease lease meet definition shortterm lease lease classify operating finance operating lease result straightline expense income statement similar current operating lease finance lease result expense recognize early year lease term similar current capital lease new guidance effective interim annual period begin early adoption permit company currently evaluate impact adoption consolidate financial statement june fasb issue amend guidance accounting credit loss financial instrument scope guidance introduce expect loss model estimate credit loss replace incur loss model new guidance change impairment model availableforsale debt security require use allowance record estimate credit loss subsequent recovery new guidance effective interim annual period begin early application permit company currently evaluate impact adoption consolidate financial statement august fasb issue guidance classification certain cash receipt payment statement cash flow intend reduce diversity practice guidance effective interim annual period begin early adoption permit guidance apply retrospectively period present apply prospectively retrospective application impracticable company currently evaluate effect standard consolidate statement cash flow table content october fasb issue guidance accounting income tax consequence intraentity transfer asset inventory exist guidance recognition current defer income taxis intraentity asset transfer prohibit asset sell party new guidance require recognition income tax consequence intraentity transfer asset exception inventory intraentity transfer occur guidance effective interim annual period begin early adoption permit new guidance apply modify retrospective basis cumulativeeffect adjustment directly retain earning begin period adoption company anticipate adoption new guidance material effect consolidated financial statement november fasb issue guidance require amount generally describe restrict cash restrict cash equivalent include cash cash equivalent reconcile beginningofperiod endofperiod total amount show statement cash flow guidance effective interim annual period beginning apply retrospective transition method period present early adoption permit company currently evaluate effect standard consolidate statement cash flow january fasb issue guidance provide elimination step goodwill impairment test impairment charge recognize record carry exceed reporting unit fair value certain limitation new guidance effective interim annual period company anticipate adoption new guidance material effect consolidated financial statement cautionary factor affect future result report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forward look statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement carefully evaluate statement light factor include risk factor describe company filing securities exchange commission especially form item risk factor annual report company discuss detail important risk factor cause actual result differ expect historic result company note factor investor permit private security litigation reform act understand possible predict identify factor consequently reader consider list complete statement potential risk uncertaintie item quantitative qualitative disclosure market risk information require item incorporate reference discussion financial instrument market risk disclosure item management discussion analysis financial condition result operation table content item financial statement supplementary datum financial statement consolidate balance sheet merck inc subsidiary december relate consolidated statement income comprehensive income equity cash flow year period end december note consolidated financial statement report date february pricewaterhousecooper llp independent register public accounting firm follow consolidated statement income merck inc subsidiary year end december millions share amount sale cost expense material production marketing administrative research development restructuring cost income expense net income taxis tax income net income net income attributable noncontrolle interest net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder consolidate statement comprehensive income merck inc subsidiary year end december million net income attributable merck inc comprehensive income loss net taxis net unrealized loss gain derivative net reclassification net unrealized loss gain investment net reclassification benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment comprehensive income attributable merck inc accompany note integral consolidated financial statement table content consolidate balance sheet merck inc subsidiary december millions share amount asset current asset cash cash equivalent shortterm investment account receivable net allowance doubtful account exclude account receivable classified asset inventory exclude inventory classify asset note current asset total current asset investment property plant equipment cost land building machinery equipment office furnishing construction progress accumulate depreciation goodwill intangible net asset liabilitie equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable total current liability longterm debt defer income taxis noncurrent liability merck inc stockholders equity common stock par value authorize share issue share paidin capital retain earning accumulate comprehensive loss treasury stock cost share share total merck inc stockholders equity noncontrolle interest total equity accompany note integral consolidated financial statement table content consolidate statement equity merck inc subsidiary year end december millions share amount accumulate non common paidin retain comprehensive treasury control stock capital earning loss stock interest total balance january net income attributable merck inc comprehensive loss net tax cash dividend declare common stock share treasury stock share purchase astrazeneca option exercise net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc comprehensive income net tax cash dividend declare common stock share treasury stock share purchase change noncontrolle ownership interest net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc comprehensive loss net tax cash dividend declare common stock share treasury stock share purchase change noncontrolle ownership interest net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december accompanying note integral consolidated financial statement table content consolidate statement cash flow merck inc subsidiary year end december million cash flow operating activity net income adjustment reconcile net income net cash provide operating activity depreciation amortization intangible asset impairment charge charge relate settlement worldwide keytruda patent litigation foreign currency devaluation relate venezuela net charge relate settlement vioxx shareholder class action litigation gain divestiture merck consumer care business gain astrazeneca option exercise loss extinguishment debt equity income affiliate dividend distribution equity method affiliate defer income taxis sharebase compensation net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability net cash provide operating activity cash flow invest activity capital expenditure purchase security investment proceed sale security investment divestiture merck consumer care business net cash divest disposition business net cash divest proceed astrazeneca option exercise acquisition cubist pharmaceuticals inc net cash acquire acquisition idenix pharmaceuticals inc net cash acquire acquisition business net cash acquire acquisition bayer collaboration right cash inflow net investment hedge net cash investing activity cash flow financing activity net change shortterm borrowing payment debt proceed issuance debt purchase treasury stock dividend pay stockholder dividend pay proceed exercise stock option net cash financing activity effect exchange rate change cash cash equivalent net decrease increase cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement table content note consolidated financial statement merck inc subsidiarie million share amount nature operation merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product company operation principally manage product basis include operating segment pharmaceutical animal health healthcare service alliance segment pharmaceutical segment reportable segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity sale vaccine major european market market company sanofi pasteur msd spmsd joint venture termination december begin merck record vaccine sale european market previously joint venture company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer companys healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient merck alliance segment primarily include result company relationship astrazeneca termination relationship june note october company divest consumer care segment develop manufacture market overthecounter foot care sun care product note summary accounting policy principle consolidation consolidated financial statement include account company subsidiary control interest maintain intercompany balance transaction eliminate control interest determine majority ownership interest absence substantive thirdparty participate right case variable interest entity majority exposure expect loss residual return consolidate subsidiary merck ownership outside shareholder interest show noncontrolle interest equity investment affiliate company significant influence control interest interest entity own equally company party share control carry equity basis acquisition business combination acquisition method accounting require asset acquire liability assume record date acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency recognize fair value fair value reasonably estimate acquisition date fair value asset acquire liability assume arise contingency determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date acquisition company determine asset acquire meet table content definition business acquisition method accounting transaction account acquisition asset business combination goodwill record foreign currency translation net asset international subsidiary local currency determine functional currency translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation account include accumulate comprehensive income loss aoci reflect separate component equity subsidiary operate highly inflationary economy subsidiarie dollar determine functional currency nonmonetary foreign currency asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include income expense net cash equivalent cash equivalent comprise certain highly liquid investment original maturity month inventory inventory value low cost market cost substantial majority domestic pharmaceutical vaccine inventory determine lastin firstout lifo method financial report tax purpose cost inventory determine firstin firstout fifo method inventory consist currently market product certain inventory produce preparation product launch consider high probability regulatory approval evaluate recoverability inventory produce preparation product launch company consider likelihood revenue obtain future sale relate inventory status product regulatory approval process investment investment marketable debt equity security classify availableforsale report fair value fair value company investment determine quote market price active market identical asset liability quote price similar asset liability input observable corroborate observable market datum substantially term asset liability change fair value consider temporary report net tax comprehensive income oci decline fair value equity security consider otherthan temporary impairment loss charge income expense net company consider available evidence evaluate potential impairment investment include duration extent fair value cost equity security company ability intent hold investment debt security otherthantemporary impairment occur company expect recover entire amortize cost basis debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning record income expense net limited portion attribute credit loss remain portion otherthantemporary impairment relate factor recognize oci realize gain loss debt equity security include income expense net revenue recognition revenue sale product recognize title risk loss pass customer typically delivery recognition revenue require reasonable assurance collection sale proceed completion performance obligation domestically sale discount issue customer direct discount pointofsale indirectly intermediary wholesaler know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition revenue record net time value money discount collection account receivable expect excess year accrual chargeback reflect direct reduction account receivable accrual rebate record current liability accrue balance relative provision chargeback rebate include account receivable accrue current liability million billion respectively december million billion respectively december table content company recognize revenue sale vaccine federal government placement vaccine stockpile accordance security exchange commission sec interpretation commission guidance accounting sale vaccine bioterror countermeasure federal government placement pediatric vaccine stockpile strategic national stockpile depreciation depreciation provide estimate useful life asset principally straightline method tax purpose accelerate tax method estimate useful life primarily range year building year machinery equipment office furnishing depreciation expense billion billion billion advertising promotion cost advertising promotion cost expense incur company record advertising promotion expense billion billion billion respectively software capitalization company capitalize certain cost incur connection obtain develop internaluse software include external direct cost material service payroll cost employee directly involve software development capitalize software cost include property plant equipment amortize begin software project substantially complete asset ready intend use capitalize software cost associate project amortize year include company ongoing multiyear implementation enterprisewide resource planning system million million net accumulate amortization december respectively capitalize software cost amortize period range year cost incur preliminary project stage postimplementation stage maintenance training cost expense incur goodwill goodwill represent excess consideration transfer fair value net asset business acquire goodwill assign reporting unit evaluate impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying company conclude likely fair value report unit carrying quantitative fair value test perform acquire intangible acquire intangible include product product right tradename patent record fair value assign estimate useful life amortize primarily straightline basis estimate useful life range year note company periodically evaluate current fact circumstance indicate carry value acquire intangible recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference carry value intangible asset fair value determine base net present value estimate future cash flow acquire inprocess research development acquire inprocess research development iprd company acquire business combination represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project merck determination useful life intangible asset generally determine period substantial majority cash flow expect generate begin amortization company test iprd impairment annually frequently impairment indicator exist assess qualitative factor determine likely fair value iprd intangible asset carrying company conclude likely fair value carrying quantitative test compare fair value iprd intangible asset carrying value perform fair value carrying impairment loss recognize operating result table content contingent consideration certain company business acquisition involve potential future payment consideration contingent achievement performance milestone include product development milestone royalty payment future product sale fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probability weight cash flow subsequent acquisition date report period contingent consideration liability remeasure current fair value change expense income record earning change input result significantly different fair value adjustment research development research development expense incur upfront milestone payment party connection research development collaboration prior regulatory approval expense incur payment party subsequent regulatory approval capitalize amortize shorter remaining license product patent life amount collaborative partner relate development activity generally reflect reduction research development expense specific milestone achieve nonrefundable advance payment good service future research development activity expense activity perform good receive payment research development expense include restructure cost iprd impairment charge period addition research development expense include expense income relate change estimate fair value measurement liability contingent consideration sharebase compensation company expense sharebased payment employee requisite service period base grantdate fair value award restructuring cost company record liability cost associate exit disposal activity period liability incur accordance exist benefit arrangement employee termination cost accrue restructuring action probable estimable accrue cost company recognize range cost good estimate range range well estimate company recognize minimum range cost onetime termination benefit employee require render service termination order receive benefit recognize ratably future service period contingency legal defense cost company record accrual contingency legal defense cost expect incur connection loss contingency probable liability incur reasonably estimate taxis income defer taxis recognize future tax effect temporary difference financial income tax reporting base enact tax law rate company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement company recognize interest penalty associate uncertain tax position component taxis income consolidate statement income use estimate consolidated financial statement prepare conformity accounting principle generally accept united states gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection acquisition include initial fair value determination asset liability primarily iprd intangible asset contingent consideration subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset table content goodwill investment tax income uncertainty inherent estimate actual result differ estimate reclassification certain reclassification prior year amount conform current year presentation recently adopt accounting standard quarter company adopt accounting guidance issue financial accounting standard board fasb april require debt issuance cost present direct deduction carry debt balance sheet oppose present deferred charge approximately million debt issuance cost reclassify quarter result adoption new standard prior period amount recast conform new presentation second quarter company elect early adopt accounting standard update issue fasb march intend simplify accounting reporting employee sharebase payment transaction provision new standard require excess tax benefit deficiency arise vest exercise sharebase payment recognize income statement oppose previous guidance tax effect record paidincapital certain instance aspect new guidance require adopt prospectively result recognition million excess tax benefit tax income arise sharebase payment new guidance amend presentation certain sharebased payment item statement cash flow cash flow related excess income tax benefit classify operating activity include financing activity company elect adopt aspect new guidance prospectively standard clarify cash payment tax authority employee behalf share withhold present financing activity aspect guidance adopt retrospectively accordingly company reclassify million million payment operating activity financing activity consolidate statement cash flow year end december respectively conform current presentation company elect continue estimate impact forfeiture determine compensation cost recognize period account occur fourth quarter company elect early adopt accounting standard update issue fasb january intend clarify definition business objective add guidance assist entity evaluate transaction account acquisition disposal asset business substantially fair value gross asset include transaction concentrate single asset group similar asset asset represent business consider business asset transaction need include input substantive process significantly contribute ability create output prior adoption new guidance acquisition disposition consider business input process apply input ability create output entity permit apply update guidance transaction occur guidance issue long applicable financial statement issue accordingly company elect adopt guidance prospectively october recently issue accounting standard fasb issue amend accounting guidance revenue recognition apply contract customer objective new guidance improve comparability revenue recognition practice entity provide useful information user financial statement improve disclosure requirement august fasb approve oneyear deferral effective date make guidance effective interim annual period begin new standard permit method adoption retrospectively prior reporting period present retrospective method retrospectively cumulative effect adopt guidance recognize date initial application modify retrospective method company adopt new standard january currently plan use modify retrospective method majority company business ship bill primary revenue stream merck expect significant difference company analysis preliminary subject change merck complete assessment multiple element arrangement certain discount trade promotion program table content january fasb issue revise guidance accounting report financial instrument new guidance require equity investment readily determinable fair value currently classify available sale measure fair value change fair value recognize net income new guidance simplify impairment testing equity investment readily determinable fair value change certain disclosure requirement guidance effective interim annual period begin early adoption permit company currently assess impact adoption consolidate financial statement february fasb issue new accounting guidance accounting reporting lease new guidance require lessee recognize rightofuse asset lease liability record balance sheet lease lease meet definition shortterm lease lease classify operating finance operating lease result straightline expense income statement similar current operating lease finance lease result expense recognize early year lease term similar current capital lease new guidance effective interim annual period begin early adoption permit company currently evaluate impact adoption consolidate financial statement june fasb issue amend guidance accounting credit loss financial instrument scope guidance introduce expect loss model estimate credit loss replace incur loss model new guidance change impairment model availableforsale debt security require use allowance record estimate credit loss subsequent recovery new guidance effective interim annual period begin early application permit company currently evaluate impact adoption consolidate financial statement august fasb issue guidance classification certain cash receipt payment statement cash flow intend reduce diversity practice guidance effective interim annual period begin early adoption permit guidance apply retrospectively period present apply prospectively retrospective application impracticable company currently evaluate effect standard consolidate statement cash flow october fasb issue guidance accounting income tax consequence intraentity transfer asset inventory exist guidance recognition current defer income taxis intraentity asset transfer prohibit asset sell party new guidance require recognition income tax consequence intraentity transfer asset exception inventory intraentity transfer occur guidance effective interim annual period begin early adoption permit new guidance apply modify retrospective basis cumulativeeffect adjustment directly retain earning begin period adoption company anticipate adoption new guidance material effect consolidated financial statement november fasb issue guidance require amount generally describe restrict cash restrict cash equivalent include cash cash equivalent reconcile beginningofperiod endofperiod total amount show statement cash flow guidance effective interim annual period beginning apply retrospective transition method period present early adoption permit company currently evaluate effect standard consolidate statement cash flow january fasb issue guidance provide elimination step goodwill impairment test impairment charge recognize record carry exceed reporting unit fair value certain limitation new guidance effective interim annual period company anticipate adoption new guidance material effect consolidated financial statement table content acquisition divestiture research collaboration license agreement company continue acquire business establish external alliance research collaboration license agreement complement internal research capability arrangement include upfront payment expense reimbursement payment party milestone royalty profit share payment contingent occurrence certain future event link success asset development company review market product pipeline examine candidate provide value outlicense portfolio assessment process divest certain asset pro forma financial information acquire business present historical financial result acquire entity significant compare company financial result transaction july merck acquire afferent pharmaceutical afferent privately hold pharmaceutical company focus development therapeutic candidate target receptor treatment common poorlymanage neurogenic condition afferent lead investigational candidate selective nonnarcotic orallyadministere antagonist evaluate phase clinical trial treatment refractory chronic cough phase clinical trial idiopathic pulmonary fibrosis cough total consideration transfer million include cash pay outstanding afferent share million sharebase compensation payment settle equity award attributable precombination service cash pay transaction cost behalf afferent addition afferent shareholder eligible receive total additional million contingent attainment certain clinical development commercial milestone multiple indication candidate include transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value acquisition date company determine fair value contingent consideration million acquisition date utilize probabilityweighte estimate cash flow stream adjust expect timing payment appropriate discount rate dependent nature time milestone payment merck recognize intangible asset inprocess research development iprd million net defer tax liability million net asset million primarily consist cash acquire excess consideration transfer fair value net asset acquire million record goodwill allocate pharmaceutical segment deductible tax purpose fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probabilityadjuste future net cash flow reflect stage development project associate probability successful completion net cash flow discount present value discount rate actual cash flow likely different assume july merck wholly own subsidiary healthcare service solution llc acquire majority ownership interest staywell company llc staywell portfolio company vestar capital partner vestar staywell health engagement company help client engage educate people improve health business result term transaction merck pay million majority ownership interest additionally merck provide staywell million intercompany loan pay preexist thirdparty debt merck option buy vestar option require merck buy vestar remain ownership interest fair value begin year acquisition date transaction account acquisition business merck recognize intangible asset million defer tax liability million net liability million noncontrolle interest million excess consideration transfer fair value net asset acquire million record goodwill largely attributable anticipate synergy expect arise acquisition goodwill allocate healthcare service segment deductible tax purpose intangible asset recognize primarily relate customer relationship amortize year useful life medical information solution content amortize fiveyear useful life additionally july merck announce execute agreement acquire control interest valle valle lead privately hold producer animal health product brazil valle extensive portfolio product span parasiticide antiinfective vaccine include product livestock horse companion animal term agreement merck acquire approximately share valle approximately million base exchange rate time announcement agreement subject regulatory review certain closing condition table content june merck moderna therapeutics moderna enter strategic collaboration license agreement develop commercialize novel messenger rna mrnabase personalize cancer vaccine development program entail multiple study type cancer include evaluation mrnabase personalize cancer vaccine combination merck keytruda pursuant term agreement merck upfront cash payment moderna million record research development expense follow human proof concept study merck right elect additional payment moderna merck exercise right company equally share cost profit worldwide collaboration development personalize cancer vaccine moderna right elect copromote personalize cancer vaccine united states agreement entail exclusivity combination keytruda moderna merck ability combine mrnabase personalize cancer vaccine nonpd agents january merck acquire iomet pharma ltd iomet privately hold ukbased drug discovery company focus development innovative medicine treatment cancer particular emphasis field cancer immunotherapy cancer metabolism acquisition provide merck iomet preclinical pipeline ido indoleaminedioxygenase tdo tryptophandioxygenase dualacte idotdo inhibitors transaction account acquisition business total purchase consideration transaction include cash payment million future additional milestone payment million contingent certain clinical regulatory milestone achieve company determine fair value contingent consideration million acquisition date utilize probabilityweighte estimate cash flow stream adjust expect timing payment utilize discount rate merck recognize intangible asset iprd million net defer tax asset million excess consideration transfer fair value net asset acquire million record goodwill allocate pharmaceutical segment deductible tax purpose fair value identifiable intangible asset relate iprd determine income approach asset probabilityadjuste future net cash flow discount present value discount rate actual cash flow likely different assume transaction december company divest remain ophthalmic portfolio international market mundipharma ophthalmology product limited merck receive consideration approximately million recognize gain million record income expense net july merck acquire ccam biotherapeutics ltd ccam privately hold biopharmaceutical company focus discovery development novel cancer immunotherapy total purchase consideration transaction include upfront payment million cash future additional payment million associate attainment certain clinical development regulatory commercial milestone transaction account acquisition business merck recognize intangible asset iprd million relate monoclonal antibody liability contingent consideration million goodwill million net asset million result unfavorable efficacy datum company determine discontinue development pipeline program accordingly company record iprd impairment charge million relate reverse related liability contingent consideration fair value million time program discontinuation iprd impairment charge income relate reduction liability contingent consideration record research development expense july merck allergan plc allergan enter agreement pursuant allergan acquire exclusive worldwide right merck investigational small molecule oral calcitonin generelate peptide cgrp receptor antagonist develop treatment prevention migraine term agreement allergan acquire right upfront payment million million pay august closing transaction remain million pay april company record gain million income expense net relate transaction allergan fully responsible development cgrp program manufacturing commercialization approval launch product agreement merck entitle receive potential development commercial milestone payment royalty tiere doubledigit rate base commercialization table content program merck recognize gain million income expense net result payment allergan achievement research development milestone february merck ngm biopharmaceuticals inc ngm privately hold biotechnology company enter multiyear collaboration research discover develop commercialize novel biologic therapy wide range therapeutic area term agreement merck upfront payment ngm million include research development expense purchase equity stake ngm million merck commit million fund ngms effort initial fiveyear term collaboration potential additional funding certain condition meet prior merck initiate phase study license program ngm elect receive milestone royalty payment certain case cofund development participate global cost revenue share arrangement agreement provide ngm option participate copromotion cofunde program united states merck option extend research agreement additional twoyear term january merck acquire cubist pharmaceuticals inc cubist leader development therapy treat infection cause broad range bacteria total consideration transfer billion include cash pay outstanding cubist share billion sharebase compensation payment settle equity award attributable precombination service cash pay transaction cost behalf cubist sharebase compensation payment settle nonveste equity award attributable postcombination service recognize transaction expense addition company assume outstanding convertible debt cubist fair value approximately billion acquisition date merck redeem debt february transaction account acquisition business estimate fair value asset acquire liability assume cubist follows estimate fair value january cash cash equivalent account receivable inventory current asset property plant equipment identifiable intangible asset product product right year weightedaverage useful life iprd noncurrent asset current liability defer income tax liability longterm debt noncurrent liability total identifiable net asset goodwill consideration transfer include current liability noncurrent liability contingent consideration million million respectively goodwill recognize largely attributable anticipate synergy expect arise acquisition allocate pharmaceutical segment goodwill deductible tax purpose estimate fair value identifiable intangible asset relate currently market product determine income approach fair value estimate base market participant expectation asset discount project net cash flow company estimate project net cash flow consider historical project pricing margin expense level performance compete product applicable relevant industry therapeutic area growth driver factor current expect trend technology product life cycle extent time potential new product introduction company competitor life table content asset underlie patent net cash flow probabilityadjuste appropriate consider uncertainty associate underlie assumption risk profile net cash flow utilize valuation probabilityadjuste future net cash flow product discount present value utilize discount rate actual cash flow likely different assumed company record fair value incomplete research project surotomycin time acquisition reach technological feasibility alternative future use second quarter company receive unfavorable efficacy datum clinical trial surotomycin evaluation datum combine assessment commercial opportunity surotomycin result discontinuation program iprd impairment charge note connection cubist acquisition liability record potential future consideration contingent achievement future salesbase milestone fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probabilityweighte cash flow change input result different fair value measurement transaction close january accordingly result operation acquire business include company result operation begin date company incur million transaction cost directly relate acquisition cubist include sharebased compensation cost severance cost legal advisory fee reflect market administrative expense follow unaudited supplemental pro forma datum present consolidated information acquisition cubist complete january year end december sale net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder unaudite supplemental pro forma datum reflect historical information merck cubist adjust include additional amortization expense base fair value asset acquire additional interest expense incur borrowing fund acquisition transaction cost associate acquisition relate tax effect adjustment pro forma datum consider indicative result occur acquisition consummate january indicative future result transaction december merck acquire oncoethix privately hold biotechnology company specialize oncology drug development total purchase consideration transaction include upfront cash payment million future additional milestone payment million contingent certain clinical regulatory milestone achieve transaction account acquisition business merck recognize intangible asset iprd million relate otx investigational novel oral bet bromodomain inhibitor liability contingent consideration million net asset million result unfavorable efficacy datum company determine discontinue development accordingly company record iprd impairment charge million related reverse related liability contingent consideration fair value million time program discontinuation iprd impairment charge income relate reduction liability contingent consideration record research development expense october company complete sale merck consumer care mcc business bayer bayer billion billion net cash divest customary closing adjustment certain contingent amount hold payable manufacturing site transfer canada regulatory approval table content korea term agreement bayer acquire merck exist overthecounter business include global trademark prescription right claritin afrin company recognize pretax gain sale mcc billion recorded income expense net october company enter worldwide clinical development collaboration bayer bayer market develop soluble guanylate cyclase sgc modulator include bayer adempas riociguat approve treat pulmonary arterial hypertension chronic thromboembolic pulmonary hypertension company equally share cost profit collaboration implement joint development commercialization strategy collaboration include clinical development bayer vericiguat phase trial worsen heart failure optin right earlystage sgc compound development bayer merck turn available earlystage sgc compound similar term return broad collaboration right merck upfront payment bayer billion potential additional milestone payment billion achievement agreedupon sale goal agreement bayer lead commercialization adempas america merck lead commercialization rest world vericiguat potential optin product bayer lead rest world merck lead america product candidate include agreement company share development cost profit sale right copromote territory lead company determine merck payment access bayer compound constitute acquisition asset billion consideration pay merck million fair value relate adempas capitalize intangible asset subject amortization estimate useful life year remain million fair value relate vericiguat compound clinical development expense research development expense fair value adempas vericiguat determine income approach probabilityadjuste future net cash flow discount present value discount rate adempas vericiguat second quarter company determine probable adempas sale exceed threshold trigger million milestone payment merck bayer accordingly second quarter company record million liability correspond intangible asset recognize million cumulative amortization expense material production cost remain intangible asset june million amortize thenremaining estimate useful life year support project future cash flow subject impairment testing remain potential future milestone payment million accrue deem company probable time august merck complete acquisition idenix pharmaceuticals inc idenix approximately billion cash billion net cash acquire idenix biopharmaceutical company engage discovery development medicine treatment human viral disease primary focus development nextgeneration oral antiviral therapeutic treat hepatitis virus hcv infection transaction account acquisition business merck recognize intangible asset iprd billion related idx uprifosbuvir net defer tax liability million net liability million uprifosbuvir nucleotide prodrug clinical development evaluate treatment hcv infection excess consideration transfer fair value net asset acquire billion record goodwill allocate pharmaceutical segment deductible tax purpose fair value identifiable intangible asset relate iprd determine income approach asset probabilityadjuste future net cash flow discount present value discount rate company record billion iprd impairment charge relate uprifosbuvir result recent change product profile take change company expectation pricing market opportunity note merck enter agreement sell certain ophthalmic product santen pharmaceutical ltd santen japan markets europe asia pacific agreement provide upfront payment santen additional payment base define sale milestone santen purchase supply ophthalmology product cover agreement fiveyear period transaction closed market july remain market october company receive million upfront payment santen net certain adjustment recognize gain million transaction include income expense net table content march merck sell sirna therapeutics inc sirna subsidiary alnylam pharmaceuticals inc alnylam consideration million share alnylam common stock merck eligible receive future payment associate achievement certain regulatory commercial milestone royaltie future sale merck record gain million income expense net relate transaction excess merck tax basis investment sirna value receive result approximate million tax benefit record january merck sell marketing right saphris antipsychotic indicate treatment schizophrenia bipolar disorder adult forest laboratories inc forest term agreement forest upfront payment million record sale additional payment merck base define sale milestone addition transaction merck agree supply product forest subsequently acquire allergan patent expiry remicadesimponi subsidiary scheringplough enter licensing agreement centocor ortho biotech inc centocor johnson johnson company market remicade prescribe treatment inflammatory disease scheringplough subsidiary exercise option contract centocor license right develop commercialize simponi fully human monoclonal antibody company marketing right product europe russia turkey remicade lose market exclusivity major european market february company long market exclusivity marketing territory company continue market exclusivity simponi marketing territory profit derive merck distribution product country equally divide merck restructuring company incur substantial cost restructure program activity relate merck productivity cost reduction initiative connection integration certain acquire business company commence action global restructuring program design streamline cost structure action program include elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility company continue reduce global real estate footprint improve efficiency manufacture supply network nonfacility relate restructuring action program substantially complete remain activity primarily relate ongoing facility rationalization company record total pretax cost billion billion billion related restructuring program activity inception program december merck record total pretax accumulate cost approximately billion eliminate approximately position comprise employee separation elimination contractor vacant position company expect substantially complete remain action program end incur approximately million additional pretax cost company estimate approximately twothird cumulative pretax cost result cash outlay primarily relate employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest segment report restructuring charge unallocated expense table content follow table summarize charge related restructuring program activity type cost separation accelerate cost depreciation total year end december material production marketing administrative research development restructuring cost year end december material production marketing administrative research development restructuring cost year end december material production marketing administrative research development restructuring cost separation cost associate actual headcount reduction headcount reduction probable reasonably estimate position eliminate restructure program activity approximately position elimination comprise actual headcount reduction elimination contractor vacant position accelerate depreciation cost primarily relate manufacture research administrative facility equipment sell closed program accelerate depreciation cost represent difference depreciation expense recognize revise useful life asset base anticipate date site close divest equipment dispose depreciation expense determine utilize useful life prior restructure action site continue operate respective closure date future undiscounte cash flow sufficient recover respective book value merck record accelerate depreciation site asset anticipate site closure date particularly related manufacturing location continue adjust reflect change result regulatory factor activity include million million million respectively asset abandonment shutdown relate cost additionally activity include certain employeerelate cost associate pension postretirement benefit plan note share base compensation activity reflect net pretax loss result sale facility relate asset million million million table content follow table summarize charge spend relate restructure program activity separation accelerate cost depreciation total restructuring reserve january expense payment receipt net noncash activity restructuring reserve december expense payment receipt net noncash activity restructure reserve december remain cash outlay expect substantially complete end financial instrument derivative instrument hedging activity company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce variability cause change foreign exchange rate affect dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale forecast sale expect occur planning cycle typically year future company layer hedge time increase portion forecast sale hedge get close expect date forecast foreign currency denominate sale portion forecast sale hedge base assessment cost benefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument company manage anticipate transaction exposure principally purchase local currency option forward contract purchase collar option fair value derivative contract record asset gain position liability loss position consolidate balance sheet change fair value derivative contract record period current earning oci depend derivative designate hedge transaction type hedge transaction derivative designate cash flow hedge effective portion unrealize gain loss contract record aoci reclassify sale hedge anticipate revenue recognize hedge relationship highly effective hedge ineffectiveness minimis derivative designate cash flow hedge serve economic hedge forecast sale unrealize gain loss record sale period cash flow designate nondesignate contract report operating activity consolidate statement cash flow company enter derivative trade speculative purpose table content company manage operating activity net asset position local level order mitigate effect exchange monetary asset liability company use balance sheet risk management program mitigate exposure net monetary asset denominate currency subsidiary functional currency effect volatility foreign exchange instance merck principally utilize forward exchange contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument cash flow contract report operating activity consolidate statement cash flow monetary asset liability denominate currency functional currency give subsidiary remeasure spot rate effect balance sheet date effect change spot rate report income expense net forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception year company use forward exchange contract hedge net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation company hedge portion net investment certain foreign operation measure ineffectiveness base change spot foreign exchange rate record income expense net effective portion unrealize gain loss contract record foreign currency translation adjustment oci remain aoci sale complete substantially complete liquidation subsidiary cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci include cumulative translation adjustment pretax gain million million million eurodenominate note interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk interest rate swap notional amount million mature swap effectively convert company billion fixedrate note variable rate debt december company party payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note detailed table number interest rate total swap notional debt instrument par value debt swap hold note note note note note note table content interest rate swap contract designate hedge fair value change note attributable change benchmark london interbank offer rate libor swap rate fair value change note attributable change libor swap rate record interest expense offset fair value change swap contract cash flow contract report operating activity consolidate statement cash flow present table fair value derivative gross basis segregate derivative designate hedge instrument designate hedge instrument december fair value fair value derivative derivative dollar dollar balance sheet caption asset liability notional asset liability notional derivative designate hedge instrument interest rate swap contract asset interest rate swap contract accrue current liability interest rate swap contract noncurrent liability foreign exchange contract current asset foreign exchange contract asset foreign exchange contract accrue current liability foreign exchange contract noncurrent liability derivative designate hedge instrument foreign exchange contract current asset foreign exchange contract asset foreign exchange contract accrue current liability foreign exchange contract noncurrent liability table content note company record derivative gross basis consolidated balance sheet company master netting agreement financial institution counterpartie concentration credit risk follow table provide information company derivative position subject master netting arrangement present net basis allow right offset counterparty cash collateral exchange master agreement relate credit support annexe december asset liability asset liability gross amount recognize consolidated balance sheet gross subject offset master netting arrangement offset consolidated balance sheet cash collateral receive post net amount table provide information location pretax gain loss amount derivative designate fair value hedge relationship designate foreign currency cash flow hedging relationship iii designate foreign currency net investment hedge relationship designate hedge relationship year end december derivative designate fair value hedge relationship interest rate swap contract loss gain recognize income expense net derivative gain loss recognize income expense net hedge item derivative designate foreign currency cash flow hedging relationship foreign exchange contract gain reclassify aoci sale gain recognize oci derivative derivative designate foreign currency net investment hedging relationship foreign exchange contract gain recognize income expense net derivative loss gain recognize oci derivative derivative designate hedge relationship foreign exchange contract loss gain recognize income expense net derivative gain loss recognize sale million million million ineffectiveness hedge respectively ineffectiveness hedge represent exclude hedge effectiveness testing derivative contract mitigate change value remeasure foreign currency denominate monetary asset liability attributable change foreign currency exchange rate december company estimate million pretax net unrealize gain derivative mature month hedge foreign currency denominate sale period reclassify aoci sale ultimately reclassify sale differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity table content investment debt equity security information investment debt equity security december follow gross unrealized gross unrealize fair amortize fair amortize value cost gain loss value cost gain loss corporate note bond commercial paper government agency security assetbacke security mortgagebacke security foreign government bond equity security availableforsale debt security include shortterm investment total billion december remain debt security billion mature year december debt security pledge collateral fair value measurement fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date company use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset liability value determine pricing model discount cash flow methodology similar technique significant unobservable input asset liabilitie determination fair value require significant judgment estimation input measure financial asset liability fall level describe categorization base low level input significant fair value measurement instrument table content financial asset liability measure fair value recur basis financial asset liability measure fair value recur basis december summarize fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total asset investment corporate note bond commercial paper government agency security assetbacke security mortgagebacke security foreign government bond equity security asset government agency security corporate note bond mortgagebacke security assetbacke security foreign government bond equity security derivative asset purchase currency option forward exchange contract interest rate swap total asset liability liabilitie contingent consideration derivative liability forward exchange contract interest rate swap write currency option total liability primarily assetbacke security highlyrate standard poor rate aaa moodys investor service rating aaa secure primarily auto loan credit card student loan receivables weightedaverage live primarily year mortgagebacked security represent aaarate security issue unconditionally guarantee payment principal interest government agency increase investment include asset reflect certain asset previously restrict retiree benefit available fund certain health welfare benefit note fair value determination derivative include impact credit risk counterpartie derivative companys credit risk effect significant transfer level level december cash cash equivalent billion include billion cash equivalent consider level fair value hierarchy table content contingent consideration summarize information change liabilitie contingent consideration follow fair value january change fair value addition payment fair value december record research development expense material production cost change fair value largely attributable reversal liability relate program obtain connection acquisition ccam oncoethix smartcell note addition contingent consideration relate termination spmsd joint venture note acquisition iomet afferent note addition contingent consideration relate acquisition cubist ccam note payment contingent consideration relate commercial sale zerbaxa european union relate commercial sale zerbaxa united states fair value measurement company financial instrument cash cash equivalent receivables payable reflect balance sheet carrying value approximate fair value shortterm nature estimate fair value loan payable longterm debt include current portion december billion compare carry value billion december billion compare carry value billion fair value estimate recent observable market price consider level fair value hierarchy concentration credit risk ongoing basis company monitor concentration credit risk associate corporate government issuer security financial institution conduct business credit exposure limit establish limit concentration single issuer institution cash investment place instrument meet high credit quality standard specify company investment policy guideline majority company account receivable arise product sale united states europe primarily drug wholesaler retailer hospital government agency manage health care provider pharmacy benefit manager company monitor financial performance creditworthiness customer properly assess respond change credit profile company continue monitor economic condition include volatility associate international sovereign economy associate impact financial market business take consideration global economic condition ongoing sovereign debt issue certain european country december company total net account receivable outstanding year approximately million company expect writeoff adjustment account receivable material adverse effect financial position liquidity result operation company customer large account receivable balance mckesson corporation amerisourcebergen corporation cardinal health inc zuellig pharma ltd asia pacific aah pharmaceuticals ltd represent aggregate approximately total account receivable december company monitor creditworthiness customer grant credit term normal course business bad debt minimal company normally require collateral security support credit sale derivative financial instrument execute international swap derivative association master agreement master agreement company financial institution counterpartie include credit support annexe annexe contain provision require collateral exchange depend value derivative asset liability company credit rating credit rating counterparty table content december company receive cash collateral million million respectively counterpartie obligation return collateral record accrue current liability company advanced cash collateral counterpartie december inventory inventory december consist finished good raw material work process supply total approximate current cost increase lifo cost recognize inventory asset inventory value lifo method comprise approximately billion billion inventory december respectively amount recognize asset comprise entirely raw material work process inventory december amount include billion billion respectively inventory expect sell year addition amount include million million december respectively inventory produce preparation product launch goodwill intangible follow table summarize goodwill activity segment pharmaceutical total balance january acquisition divestiture impairment balance december acquisition impairment balance december include cumulative translation adjustment goodwill balance certain adjustment accumulate goodwill impairment loss december million million respectively addition goodwill pharmaceutical segment result primarily acquisition afferent iomet note termination spmsd joint venture treat stepacquisition accounting purpose note addition goodwill nonreportable segment relate acquisition staywell healthcare service segment note addition goodwill pharmaceutical segment result primarily acquisition cubist reduction result divestiture company remain ophthalmic business international market note impairment goodwill nonreportable segment relate certain business healthcare service segment table content intangible december consist gross gross carrying accumulate carry accumulate amortization net amortization net product product right iprd tradename acquire intangible include product product right tradename patent record fair value assign estimate useful life amortize primarily straightline basis estimate useful life increase intangible asset product product right primarily relate recognition intangible asset connection termination spmsd joint venture note company significant acquire intangible relate market product include product product right december include zerbaxa billion zetia billion sivextro million vytorin million implanonnexplanon million dificid million gardasilgardasil million nuvare million nasonex million company recognize intangible asset related adempas result formation collaboration bayer note carry value million december reflect table company record impairment charge relate market product intangible million million billion respectively material production cost company lower cash flow projection zontivity product reduction thrombotic cardiovascular event patient history myocardial infarction peripheral arterial disease follow business decision reduce sale expectation zontivity united states europe company utilize market participant assumption consider different scenario determine fair value intangible asset relate zontivity compare related carrying value result impairment charge million company wroteoff million capitalize connection inlicense product grastek ragwitek allergy immunotherapy tablet business reason company determine return licensor charge primarily relate impairment customer relationship tradename intangible certain business healthcare service segment record million relate pegintron million relate victrelis million relate rebetol product treatment chronic hcv infection development competitive hcv treatment market lead market share loss great company predict cause change cash flow projection pegintron victrelis rebetol indicate intangible asset value recoverable undiscounted cash flow basis company utilize market participant assumption determine good estimate fair value intangible asset relate pegintron victrelis rebetol compare related carry value result impairment charge note iprd company acquire business combination represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize iprd account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project company separate determination useful life asset begin amortization million million million respectively iprd reclassify product product right receipt marketing approval major market company record billion iprd impairment charge research development expense billion relate clinical development program uprifosbuvir nucleotide prodrug clinical development evaluate treatment hcv company determine recent change product profile change merck expectation pricing market opportunity take constitute trigger event require company evaluate uprifosbuvir intangible asset impairment utilize market participant assumption consider different scenario company conclude table content well estimate current fair value intangible asset relate uprifosbuvir million result recognition pretax impairment charge note iprd impairment charge include charge million million relate discontinuation program obtain connection acquisition ccam oncoethix respectively result unfavorable efficacy datum additional million relate program obtain connection smartcell acquisition follow decision terminate lead compound lack efficacy pursue backup compound reduce project future cash flow iprd impairment charge include million relate inlicense program house dust mite allergy business reason return licensor remain iprd impairment charge primarily relate deprioritize pipeline program deem alternative use period include million impairment charge investigational candidate contraception discontinuation delay certain clinical development program result reduction relate liability contingent consideration note company record million iprd impairment charge million relate surotomycin clinical development program company receive unfavorable efficacy datum clinical trial surotomycin evaluation datum combine assessment commercial opportunity surotomycin result discontinuation program iprd impairment charge note company record million iprd impairment charge primarily result change cash flow assumption certain compound obtain connection company joint venture supera farma laboratorio supera discontinuation certain animal health program iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate company recognize additional noncash impairment charge future relate market product pipeline program charge material aggregate amortization expense primarily record material production cost billion billion billion estimate aggregate amortization expense year follow billion billion billion billion billion joint venture equity method affiliate equity income affiliate reflect performance company joint venture equity method affiliate include spmsd termination december certain investment fund azlp termination company relationship azlp june equity income affiliate million million million include income expense net note investment affiliate account equity method total million december million december amount report asset amount joint venture include current asset million december million december sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur establish equallyowne joint venture spmsd market vaccines europe collaborate development combination vaccine distribution europe joint venture vaccine sale billion million billion december merck sanofi pasteur sanofi terminate spmsd end joint vaccine operation europe term termination merck acquire sanofis interest spmsd exchange consideration million comprise cash future royalty net sale merck product december company determine fair value million date table content termination company account transaction step acquisition require merck remeasure ownership interest previously account equity method investment fair value acquisition date merck turn sell sanofi intellectual property right hold spmsd exchange consideration million comprise cash future royalty net sale sanofi product december company determine fair value million date termination exclude arrangement potential future sale vaxeli jointly develop investigational pediatric hexavalent combination vaccine approve european commission february european marketing right vaxeli transfer separate equallyowne joint venture sanofi merck mcm net impact termination spmsd joint venture follow product product right year useful life account receivable income taxis payable deferred income tax liability net goodwill net asset acquire consideration payable sanofi net derecognition merck previously hold equity investment spmsd increase net asset merck share restructuring cost relate termination net gain termination spmsd joint venture goodwill allocate pharmaceutical segment deductible tax purpose record income expense net estimate fair value identifiable intangible asset relate product product right determine income approach fair value estimate base market participant expectation asset project net cash flow project net cash flow discount present value utilize discount rate actual cash flow likely different assume record product product right million relate gardasilgardasil fair value liability contingent consideration relate merck future royalty payment sanofi million reflect consideration payable sanofi net table determine acquisition date unobservable input input include estimate time project cash flow riskadjuste discount rate present value cash flow change input result different fair value measurement base exist accounting policy election merck record million estimate fair value contingent future royalty receive sanofi sale sanofi product recognize amount future period sale occur royalty earn company incur million transaction cost relate termination spmsd include marketing administrative expense pro forma financial information transaction present result significant compare company financial result astrazeneca merck enter agreement astra astra develop market astra product royaltybeare license merck total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami merck astra own share joint venture form develop market astra new prescription medicine united states merck astra complete restructure ownership operation joint venture merck acquire astras interest ami rename kbi inc kbi contribute kbis table content operate asset new limited partnership astra pharmaceutical partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca azlp astras merger zeneca group plc exclusive distributor product kbi retain right connection restructure ami merck assume billion par value prefer stock dividend rate annum carry kbi include noncontrolle interest merck earn revenue base sale kbi product revenue million primarily relate sale nexium prilosec addition merck earn certain partnership return azlp million record equity income affiliate june astrazeneca exercise option purchase merck interest kbi million cash million reflect estimate fair value merck interest nexium prilosec portion exercise price subject trueup base actual sale closing june defer recognize income million million million respectively income expense net contingency eliminate sale occur defer income fully amortize quarter company begin recognize income correspond receivable amount merck astrazeneca base sale performance nexium prilosec subject trueup june company recognize million income include income expense net remain exercise price million primarily represent multiple time merck average annual profit allocation partnership year prior exercise merck recognize million gain income expense net result astrazenecas option exercise company remain interest azlp redeem accordingly company recognize noncash gain approximately million income expense net result retirement billion kbi prefer stock elimination company billion investment azlp million reduction goodwill transaction result net tax benefit million primarily reflect reversal defer taxis azlp investment balance result astrazeneca exercise option july company long record equity income azlp supply sale azlp terminate summarize financial information azlp follow year end december sale material production cost expense net income taxis include result june termination date merck partnership return azlp generally contractually determine note base percentage income azlp respect mercks limited partnership interest loan payable longterm debt commitment loan payable december include million note million longdate note subject repayment option holder loan payable december include billion note million shortterm foreign borrowing million longdate note subject repayment option holder weightedaverage interest rate commercial paper borrowing year end december respectively table content longterm debt december consist note note note note note note note note eurodenominate note eurodenominate note note floatingrate borrow note note note floatingrate note note eurodenominate note eurodenominate note eurodenominate note note note note debenture debenture debenture floatingrate note present table include million million december respectively borrowing variable rate result effective interest rate zero respectively include foreign borrowing million december vary rate exception debenture note list table redeemable merck option time vary redemption price november company issue billion principal senior unsecured note consist million principal note million principal note company intend use net proceed offer billion general corporate purpose include limitation repayment outstanding commercial paper borrowing indebtedness upcoming maturity october company issue billion principal senior unsecured note net proceed offer billion repay debt validly tender connection tender offer launch company certain outstanding note debenture company pay billion aggregate consideration applicable purchase price accrue interest redeem billion principal table content debt november merck redeem additional billion principal senior unsecured note company record pretax loss million connection transaction effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date certain company borrowing require merck comply financial covenant include requirement total debt capitalization ratio define applicable agreement exceed december company compliance covenant aggregate maturity longterm debt year follow million billion billion billion billion june company terminate exist credit facility enter new billion fiveyear credit facility mature june facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility rental expense operating lease net sublease income million million million minimum aggregate rental commitment noncancellable lease follow million million million million million million company significant capital lease contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation certain additional matter include environmental matter opinion company unlikely resolution matter material company financial position result operation cash flow give nature litigation discuss complexity involve matter company unable reasonably estimate possible loss range possible loss matter company know factor claim survive dispositive motion practice extent claim include size potential class particularly damage specify indeterminate iii discovery process affect litigation settlement posture party litigation factor material effect litigation company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable company decision obtain insurance coverage dependent market condition include cost availability exist time decision company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance product liability effective august vioxx litigation product liability lawsuit previously disclose merck defendant number putative class action lawsuit allege economic injury result purchase vioxx settle settlement merck agree pay million resolve properly document claim submit class member approve attorney fee expense approve settlement notice cost certain administrative expense claim table content review process complete company pay approximately attorney fee pay determine merck defendant lawsuit abovereference lawsuit vioxx product liability lawsuit bring attorney general utah lawsuit pende utah state court utah allege merck misrepresented safety vioxx seek damage penalty utah false claim act trial date set merck recently reach agreement attorney general alaska montana settle state consumer protection act case company million million respectively result alaskas action dismiss prejudice september montanas action dismiss prejudice october shareholder lawsuit previously disclose addition vioxx product liability lawsuit putative class action individual lawsuit file merck certain employee allege defendant violate federal security law make alleged material misstatement omission respect cardiovascular safety vioxx vioxx security lawsuit vioxx security lawsuit coordinate multidistrict litigation district court district new jersey judge stanley chesler previously disclose merck reach resolution vioxx security class action reserve record merck create settlement fund million settlement class fund agree pay additional approve attorney fee expense million feeexpense fund june court approve settlement award attorney fee expense million remain feeexpense fund add settlement class fund company pay total settlement escrow april available fund certain insurance policy merck net cash payment settlement fee approximately million settlement cover claim relate vioxx settlement class member purchase merck security october settlement admission wrongdoe settlement agreement defendant continue deny allegation addition merck reach resolution reference individual security lawsuit file foreign domestic institutional investor consolidate vioxx security lawsuit insurance result previously disclose insurance arbitration company insurer pay insurance proceed approximately million connection settlement class action company director officer insurance coverage applicable vioxx security lawsuit remain state upper limit approximately million company receive dispute insurer availability company director officer insurance coverage claim amount actually recover director officer policy discuss paragraph state upper limit international lawsuit previously disclose addition lawsuit discuss merck name defendant litigation relate vioxx brazil europe collectively vioxx international lawsuit litigation jurisdiction generally procedural stage merck expect litigation continue number year reserve company immaterial reserve respect certain vioxx product liability lawsuit company establish liability reserve believe meritorious defense remain vioxx product liability lawsuit vioxx international lawsuit defend product liability litigation fosamax previously disclose merck defendant product liability lawsuit unite states involve fosamax fosamax litigation december approximately case file pende table content merck federal state court approximately action plaintiff allege thing suffer osteonecrosis jaw onj generally subsequent invasive dental procedure tooth extraction dental implant andor delay healing association use fosamax addition plaintiff approximately action generally allege sustained femur fracture andor bone injury femur fracture association use fosamax case allege onj andor jaw relate injury august judicial panel multidistrict litigation jpml order certain fosamax product liability case pende federal court nationwide transfer consolidated multidistrict litigation fosamax onj mdl coordinated pretrial proceeding december merck reach agreement principle plaintiff steer committee psc fosamax onj mdl resolve pende onj case appeal fosamax onj mdl state court aggregate million merck psc subsequently formalize term agreement master settlement agreement onj master settlement agreement execute april include plaintiff july merck elect proceed onj master settlement agreement reduce funding level million participation level approximately merck fully fund onj master settlement agreement escrow agent agreement make settlement payment qualify plaintiff onj master settlement agreement effect case allege femur fracture discuss discovery currently ongoing approximately remain onj case pende federal state court company intend defend lawsuit case allege femur fracture march merck submit motion transfer jpml seek federal case allege femur fracture consolidate multidistrict litigation coordinate pretrial proceeding motion transfer grant federal case involve allegation femur fracture transfer multidistrict litigation district new jersey femur fracture mdl bellwether case try date femur fracture mdl glynn merck jury return verdict merck favor addition june femur fracture mdl court grant merck motion judgment matter law glynn case hold plaintiff failure warn claim preempt federal law august femur fracture mdl court enter order require plaintiff femur fracture mdl cause case assert claim femur fracture injury take place prior september dismiss base court preemption decision glynn case pursuant cause order march femur fracture mdl court dismiss prejudice approximately case preemption ground plaintiff approximately case appeal decision court appeal circuit circuit femur fracture mdl court dismiss prejudice approximately case pende plaintiff appeal preemption rule circuit june circuit hear oral argument plaintiff appeal preemption rule party await decision addition june femur fracture mdl court grant merck summary judgment gaynor merck case find merck update january fosamax label atypical femur fracture adequate matter law merck adequately communicate change plaintiff gaynor appeal court decision circuit august merck file motion request court enter order require plaintiff femur fracture mdl claim fosamax label inadequate proximate cause allege injury cause case dismiss base court preemption decision rule gaynor case november court grant merck motion enter request cause order december seven case pende femur fracture mdl exclude case dismiss prejudice preemption ground pende appeal case dismiss prejudice pende aforementioned appeal table content december approximately case allege femur fracture file new jersey state court pending judge jessica mayer middlesex county party select initial group case review fact discovery additional group case review fact discovery select november march respectively group case review fact discovery select merck july merck continue select additional case review fact discovery december approximately case allege femur fracture file pende california state court petition file seek coordinate femur fracture case file california state court single judge orange county california petition grant judge thierry colaw currently preside coordinate proceeding march court directed group discovery pool case review fact discovery subsequently schedule galper merck case plaintiff select trial galper trial begin february jury return verdict merck favor april plaintiff appeal verdict california appellate court oral argument plaintiff appeal galper hold november party await decision femur fracture trial california schedule begin april stay plaintiff request new trial date set additionally femur fracture case pende state court discovery ongoing femur fracture mdl state court femur fracture case pende company intend defend lawsuit januviajanumet previously disclose merck defendant product liability lawsuit unite states involve januvia andor janumet december approximately product user claim serve merck alleging generally use januvia andor janumet cause development pancreatic cancer injury complaint file different state federal court claim file consolidated multidistrict litigation proceed district court southern district california call incretinbase therapy product liability litigation mdl mdl include federal lawsuit allege pancreatic cancer use follow medicine januvia janumet byetta victoza product manufacture pharmaceutical company majority claim file mdl file superior court california county los angeles california state court december product user claim pende merck state court california state court november mdl california state court separate opinion grant summary judgment defendant ground preemption approximately serve product user claim ruling result dismissal approximately product user claim plaintiff appeal mdl california state court preemption ruling addition claim note company agree december toll statute limitation approximately additional claim company intend continue defend lawsuit propeciaproscar previously disclose merck defendant product liability lawsuit unite states involve propecia andor proscar december approximately lawsuit file plaintiff allege experience persistent sexual effect follow cessation treatment propecia andor proscar approximately plaintiff allege propecia proscar cause cause prostate cancer testicular cancer male breast cancer lawsuit file federal court state court new jersey federal lawsuit consolidate pretrial purpose federal multidistrict litigation judge brian cogan eastern district new york matter pende state court new jersey consolidated judge jessica mayer middlesex county addition matter pende state court california matter pende state court new york matter pende state court ohio company intend defend lawsuit table content governmental proceeding previously disclose company receive civil investigative demand attorney office southern district new york request information relate company contract service payment pharmacy benefit manager respect maxalt levitra january present company cooperate investigation previously disclose company receive subpoena office inspector general department health human service behalf attorney office district maryland civil division department justice doj request information relate company marketing singulair dulera inhalation aerosol certain marketing activity january present company cooperate investigation previously disclose company receive civil investigative demand attorney office eastern district pennsylvania request information relate company contract pricing dulera inhalation aerosol certain pharmacy benefit manager medicare plan company cooperate investigation august company learn underlie qui tam complaint unseal voluntarily dismiss prejudice relator prejudice government doj inform company matter inactive current investigation previously disclose company receive letter doj sec seek information activity number country reference foreign corrupt practice act company cooperate agency request believe inquiry broad review pharmaceutical industry practice foreign country previously disclose company advise doj base information receive closed inquiry matter relate company company recently advise sec close inquiry matter relate company previously disclose company subsidiary china receive continue receive inquiry operation chinese governmental agency inquiry relate matter involve multinational pharmaceutical company chinese entity business company company policy cooperate authority provide response appropriate time time company receive inquiry subject preliminary investigation activity competition authority market outside united states certain inquiry activity lead commencement formal proceeding proceeding determine adversely company monetary fine andor remedial undertaking require commercial litigation kdur antitrust litigation previously disclose june january scheringplough corporation scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle respectively relate generic version scheringplough longacte potassium chloride product supplement cardiac patient lederle upshersmith file abbreviate new drug application anda follow commencement administrative proceed federal trade commission allege anticompetitive effect settlement resolve schering plough favor putative class nonclass action suit file behalf direct indirect purchaser kdur scheringplough upshersmith lederle consolidated multidistrict litigation district court district new jersey suit claim violation federal state antitrust law state statutory common law cause action seek unspecified damage april indirect purchaser voluntarily dismiss case february district court deny company motion summary judgment relate direct purchaser claim concern settlement upshersmith grant company motion summary judgment relate direct purchaser claim concern settlement lederle anticipation trial party file motion exclude certain expert opinion evidence defendant file motion summary judgment table content february merck upshersmith reach settlement principle class direct purchaser optout class merck contribute approximately million aggregate overall settlement formal settlement agreement class optout execute settlement class subject approval district court sale force litigation previously disclose kelli smith file complaint company district court district new jersey behalf putative class female sale representative putative subclass female sale representative child claim discriminatory policy practice selection promotion advancement disparate pay differential treatment hostile work environment retaliation federal state discrimination law plaintiff sought grant leave file amend complaint january plaintiff file amend complaint add additional name plaintiff october court deny company motion dismiss strike class claim premature september plaintiff file additional motion include motion conditional certification equal pay act motion amend pleading seek add erisa constructive discharge claim company subsidiary name defendant motion equitable relief merck file paper opposition motion april court grant plaintiff motion conditional certification deny plaintiff motion extend liability period equal pay act claim june result liability period date april early april magistrate judge grant plaintiff request amend complaint add follow company subsidiary corporate defendant erisa claim iii individual constructive discharge claim name plaintiff approximately individual optedin action optin period close qui tam litigation previously disclose june district court eastern district pennsylvania unseal complaint file company federal false claim act employee allege thing company defraud government falsify datum connection clinical study conduct mump component company mmr vaccine complaint allege fraud take place government right participate prosecution lawsuit notify court decline exercise right employee pursue lawsuit involvement government addition previously disclose putative class action lawsuit behalf direct purchaser mmr vaccine charge company misrepresent efficacy mmr vaccine violation federal antitrust law state consumer protection law pende eastern district pennsylvania september court deny merck motion dismiss false claim act suit grant deny motion dismiss thenpende antitrust suit result false claim act suit antitrust suit proceed discovery company intend defend lawsuit merck kgaa litigation january protect longestablished brand rights united states company file lawsuit merck kgaa darmstadt germany kgaa operating emd group united states allege improperly use merck united states kgaa file suit company france united kingdom germany switzerland mexico india allege breach party coexistence agreement unfair competition andor trademark infringement december paris court instance issue judgment find certain activity company direct france constitute trademark infringement unfair competition activity find infringe company kgaa appeal decision appeal schedule hear january high court issue judgment find company breach coexistence agreement infringe kgaas trademark right result certain activity direct base use word merck promotional information activity note decision find base company use sign merck connection sale product material pharmaceutical business transact company kgaa appeal decision appeal schedule hear june table content patent litigation time time generic manufacturer pharmaceutical product file anda food drug administration fda seek market generic form company product prior expiration relevant patent own company protect patent right company file patent infringement lawsuit generic company certain product company product market agreement company currently involve patent infringement litigation united states include cancidas invanz nasonex noxafil nuvare similar lawsuit defend company patent right exist country company intends vigorously defend patent believe valid infringement company attempt market product prior expiration patent litigation assurance outcome adverse result significantly shorten period exclusivity product respect product acquire acquisition potentially significant intangible asset impairment charge cancidas february patent infringement lawsuit file united states xellia pharmaceuticals aps xellia respect xellias application fda seek prepatent expiry approval market generic version cancidas june district court find xellia infringe company patent order xellias application approve patent expire september include pediatric exclusivity xellia appeal decision appeal hear march party reach settlement xellia launch generic version august early certain condition august patent infringement lawsuit file united states fresenius kabi usa llc fresenius respect freseniuss application fda seek prepatent expiry approval market generic version cancidas december party reach settlement fresenius launch generic version august early certain condition invanz july patent infringement lawsuit file united states hospira respect hospiras application fda seek prepatent expiry approval market generic version invanz trial matter hold april october district court rule patent valid infringe august patent infringement lawsuit file united states savior lifetec corporation savior respect savior application fda seek prepatent expiry approval market generic version invanz lawsuit automatically stay fda approval savior application november adverse court decision whichever occur early nasonex july patent infringement lawsuit file united states teva pharmaceuticals usa inc teva pharma respect teva pharmas application fda seek prepatent expiry approval market generic version nasonex trial matter hold june november district court rule patent valid infringe company appeal decision march patent infringement lawsuit file united states amneal pharmaceutical llc amneal respect amneal application fda seek prepatent expiry approval market generic version nasonex trial matter hold june january district court rule patent valid infringe company appeal decision previous decision issue june hold merck patent teva pharma amneal lawsuit cover mometasone furoate monohydrate valid infringe apotex corps propose product april patent infringement lawsuit file apotex inc apotex corp apotex respect apotexs nowlaunche product company believe differ generic version previous lawsuit noxafil august company file lawsuit actavis laboratory inc actavis united states respect company application fda seek prepatent expiry approval sell generic version noxafil lawsuit automatically stay fda approval actaviss application december adverse court decision whichever occur early trial matter currently schedule begin july march company file lawsuit roxane laboratories inc roxane united states respect company application fda seek prepatent expiry approval sell generic version noxafil lawsuit automatically stay fda approval roxane application august adverse court decision whichever occur early february company file lawsuit par sterile product llc par pharmaceutical inc par pharmaceutical company inc par pharmaceutical holdings inc collectively par united states respect company application fda seek pre table content patent expiry approval sell generic version noxafil october party reach settlement par launch generic version january early certain condition nuvare december company file lawsuit subsidiary allergan plc united states respect company application fda seek prepatent expiry approval sell generic version nuvare trial matter hold january august district court rule patent invalid company appeal decision september company file lawsuit teva pharma united states respect company application fda seek prepatent expiry approval sell generic version nuvare base rule allergan plc matter district court dismiss company lawsuit december company appeal decision company involve ongoing litigation canada apotex concern company patent relate lovastatin alendronate norfloxacin litigation settle conclude consequence conclusion litigation company record net gain million include income expense net note antipd antibody patent opposition litigation previously disclose ono pharmaceutical ono european patent broadly claim use antipd antibody company immunotherapy keytruda treatment cancer ono previously license commercial right antipd antibody bristol myers squibb bms certain market bms ono european patent grant broadly claim antipd antibody include keytruda previously disclose company bms ono engage worldwide litigation include united states validity infringement patent patent equivalent january company announce enter settlement license agreement bms ono resolve worldwide patent infringement litigation relate use antipd antibody treatment cancer keytruda settlement license agreement company onetime payment million record expense company financial result bms pay royalty worldwide sale keytruda nonexclusive license market keytruda market approve global net sale keytruda company pay royalty follow net sale occur january include december net sale occur january include december party agree dismiss claim worldwide relevant legal proceeding october pdl biopharma pdl file lawsuit united states company allege manufacture keytruda infringe patent patent expire december patent claim platform technology creation manufacture recombinant antibody pdl seek damage preexpiry infringement patent july company file declaratory judgment action united states genentech city hope seek rule patent cabilly iii patent claim platform technology creation manufacture recombinant antibodie invalid keytruda bezlotoxumab infringe cabilly iii patent july company file petition uspto inter parte review ipr certain claim patent cabilly patent claim platform technology creation manufacture recombinant antibody own genentech city hope invalid december uspto deny petition allow company join ipr file previously party gilead patent litigation opposition august gilead sciences inc gilead file lawsuit district court northern district california seek declaration company patent invalid infringe sale sofosbuvir contain product solvadi harvoni company file counterclaim sale table content product infringe patent seek reasonable royalty past present future sale product march conclusion jury trial patent find invalid infringe jury award company million royalty sale product december conclusion jury trial court hold bench trial equitable defense raise gilead june court find gilead determined merck collect jury award patent unenforceable respect gilead company appeal court decision gilead ask court overturn jurys decision validity court hold hear gilead motion august court subsequently reject gilead request company pay net legal fee damage royalty receive ionis pharmaceuticals inc company idenix pharmaceuticals inc subsidiary pende litigation gilead united states norway canada germany france australia base different patent estate infringe gilead sale product gilead opposed european patent epo trial united states hold december jury return verdict company award damage billion company currently brief posttrial motion include issue enhance damage future royalty gilead briefing posttrial motion judgment matter law australia canada company initially unsuccessful case currently appeal norway patent hold invalid appeal file epo opposition division revoke european patent company appeal decision case france germany stay pende final decision epo litigation pende legal proceeding involve company principally product liability intellectual property lawsuit feasible predict outcome proceeding opinion company likelihood loss remote reasonably possible loss associate resolution proceeding expect material company financial position result operation cash flow individually aggregate legal defense reserve legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate environmental matter previously disclose merck facility oss netherlands inspect province brabant province pursuant dutch hazard major accident decree site environmental permit province issue penalty allege violation regulation govern prevent manage accident hazardous substance government issue fine allege environmental violation oss facility total thousand company subsequently advise criminal investigation initiate base certain issue form basis administrative enforcement action province company intend defend enforcement action result investigation environmental protection agency conduct air compliance evaluation company pharmaceutical manufacturing facility elkton virginia result investigation company table content recently issue notice noncompliance cause notification relate certain federally enforceable requirement applicable elkton facility company attempt resolve allege violation way settlement defend settlement reach company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability minimis final cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial position result operation liquidity capital resource company company take active role identify accrue cost amount include reduction anticipate recovery cleanup cost site owner operator recalcitrant potentially responsible party management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year equity merck certificate incorporation authorize share common stock share prefer stock capital stock summary common stock treasury stock transaction share millions follow common treasury common treasury common treasury stock stock stock stock stock stock balance january purchase treasury stock issuance balance december issuance primarily reflect activity sharebase compensation plan sharebase compensation plan company sharebase compensation plan company grant restrict stock unit rsus performance share unit psus certain management level employee company issue rsus employee certain company equity method investee addition employee nonemployee director grant option purchase share company common stock fair market value time grant plan approve company shareholder table content december million share collectively authorize future grant company sharebase compensation plan award settle primarily treasury share employee stock option grant purchase share company stock fair market value time grant award generally vest year threeyear period contractual term year rsus stock award grant employee entitle holder share common stock award vest fair value stock option rsu award determine fix grant date base company stock price psus stock awards ultimate number share issue contingent company performance preset objective set objective fair value psu determined date grant base company stock price rsus psus dividend declare vest period payable employee vest psu performance period number share stock expect issue adjust base probability achievement performance target final compensation expense recognize base ultimate number share issue rsu psu distribution share company stock end vest performance period generally year subject term applicable award total pretax sharebase compensation cost record million million million respectively relate income tax benefit million million million respectively company use blackschole option pricing model determine fair value option grant apply model company use historical datum current market datum estimate fair value option blackschole model require assumption include expect dividend yield riskfree interest rate volatility term option expect dividend yield base historical pattern dividend payment riskfree rate base rate grant date zerocoupon treasury notes term equal expect term option expect volatility estimate blend historical imply volatility historical component base historical monthly price change imply volatility obtain market datum company trade option expect life represent time option grant expect outstanding base historical forecast exercise behavior weight average exercise price option grant option respectively weight average fair value option grant option respectively determine follow assumption year end december expect dividend yield riskfree interest rate expect volatility expect life year summarize information relative stock option plan activity option thousand follows weight weight average average remain aggregate number exercise contractual intrinsic option price term year value outstanding january grant exercise forfeit outstanding december exercisable december table content additional information pertain stock option plan provide table year end december total intrinsic value stock option exercise fair value stock option vest cash receive exercise stock option summary nonveste rsu psu activity share thousand follow rsus psus weight weight average average number grant date number grant date share fair value share fair value nonveste january grant vested forfeited nonveste december december million total pretax unrecognized compensation expense relate nonveste stock option rsu psu award recognize weight average period year segment report sharebased compensation cost unallocated expense pension postretirement benefit plan company define benefit pension plan cover eligible employee united states certain international subsidiary addition company provide medical benefit principally eligible retiree dependent postretirement benefit plan company use december yearend measurement date pension plan postretirement benefit plan net periodic benefit cost net periodic benefit cost pension postretirement benefit plan consist follow component pension benefit international postretirement benefit year end december service cost interest cost expect return plan asset net amortization termination benefit curtailment settlement net periodic benefit credit cost change net periodic benefit credit cost year year pension plan largely attributable change discount rate affect net amortization decrease net periodic benefit cost postretirement benefit plan compare largely attributable change retiree medical benefit approve company december connection restructuring action note termination charge record pension postretirement benefit plan relate expand eligibility certain employee exit merck connection restructuring activity curtailment record pension table content postretirement benefit plan settlement record certain international pension plan reflect table obligation fund status summarize information change plan asset benefit obligation fund status amount record december follow pension benefit postretirement international benefit fair value plan asset january actual return plan asset company contribution effect exchange rate change benefit pay settlement asset long restrict payment postretirement benefit fair value plan asset december benefit obligation january service cost interest cost actuarial loss gain benefit pay effect exchange rate change plan amendment curtailment termination benefit settlement benefit obligation december fund status december recognize asset accrue current liability noncurrent liability result certain allowable administrative action occur june million plan asset previously restrict payment postretirement benefit available fund certain health welfare benefit actuarial loss actuarial gain primarily reflect change discount rate decline postretirement benefit obligation result plan amendment primarily reflect change merck retiree medical benefit approve company december change provide beginning merck provide access retiree health insurance coverage supplement governmentsponsore medicare private insurance marketplace december accumulate benefit obligation billion billion respectively pension plan billion billion respectively relate pension plan table content information relate fund status select pension plan december follow international pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset plan asset entity require use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset value determine pricing model discount cash flow methodology similar technique significant unobservable input instrument determination fair value require significant judgment estimation december million million respectively approximately respectively company pension investment categorize level asset input measure financial asset fall level describe categorization base low level input significant fair value measurement instrument table content fair value companys pension plan asset december asset category follow fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total pension plan asset cash cash equivalent investment fund develop market equities emerge market equity equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacke security investment net asset fair value hierarchy investment measure nav practical expedient plan asset fair value international pension plan asset cash cash equivalent investment fund develop market equities emerge market equity government agency obligation corporate obligation fix income obligation real estate equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacke security investment insurance contract net asset fair value hierarchy investment measure nav practical expedient plan asset fair value certain investment measure net asset value nav share equivalent classify fair value hierarchy fair value amount present table intend permit reconciliation fair value hierarchy fair value plan asset december plans level investment real estate fund generally value market appraisal underlie investment fund plan level investment insurance contract generally value credit rate approximate market return invest underlying security market value unobservable determine pricing model discount cash flow methodology similar technique table content table provide summary change fair value include transfer andor financial asset measure fair value significant unobservable input level company pension plan asset insurance real insurance real contract estate total contract estate total pension plan balance january actual return plan asset relate asset hold december relate asset sell year purchase sale net balance december international pension plan balance january actual return plan asset relate asset hold december purchase sale net transfer level balance december fair value company postretirement benefit plan asset december asset category follow fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total asset cash cash equivalent investment fund develop market equities emerge market equity government agency obligation equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacked security net asset fair value hierarchy investment measure nav practical expedient plan asset fair value certain investment measure net asset value nav share equivalent classify fair value hierarchy fair value amount present table intend permit reconciliation fair value hierarchy fair value plan asset december company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation table content plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest international pension plan target investment portfolio varies base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline expect contribution expect contribution approximately million pension plan approximately million international pension plan approximately million postretirement benefit plan expect benefit payment expect benefit payment follow international pension postretirement pension benefit benefit benefit expect benefit payment base assumption measure benefit obligation include estimate future employee service amount recognize comprehensive income net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption net loss amount excess certain threshold amortize net periodic benefit cost average remain service life employee follow amount reflect component oci pension plan postretirement international benefit plan year end december net loss gain arise period prior service cost credit arise period net loss amortization include benefit cost prior service credit cost amortization include benefit cost estimate net loss gain prior service cost credit amount amortize aoci net periodic benefit cost million million respectively pension plan million million respectively relate pension plan million million respectively postretirement benefit plan table content actuarial assumption company reassesse benefit plan assumption regular basis weight average assumption determine pension postretirement benefit plan international pension plan information follow pension postretirement benefit plan international pension plan december net periodic benefit cost discount rate expect rate return plan asset salary growth rate benefit obligation discount rate salary growth rate pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay determine plan basis develop expect rate return plan longterm historical return datum consider actual return plan asset capital market experience reference information longterm return expectation asset category weight average expect return plan target portfolio develop accord allocation investment category expect portfolio performance reflect contribution active management appropriate expect rate return company pension postretirement benefit plan range compare range health care cost trend rate assumption postretirement benefit plan follow december health care cost trend rate assume year rate cost trend rate assume decline year trend rate reach ultimate trend rate percentage point change health care cost trend rate follow effect percentage point increase decrease effect total service interest cost component effect benefit obligation saving plan company maintain define contribution saving plan united states company match percentage employee contribution consistent provision plan employee eligible total employer contribution plan million million million respectively table content income expense net income expense net consist year end december interest income interest expense exchange loss equity income affiliate net high exchange loss compare relate primarily venezuelan bolvar second quarter evaluation evolve economic condition venezuela volatility country combine decline transaction settle official cencoex rate vef bolvar fuerte dollar company determine unlikely outstanding net monetary asset settle cencoex rate accordingly second quarter company record charge million devalue net monetary asset venezuela represent company estimate dollar ultimately collect quarter company record additional exchange loss million aggregate reflect ongoing effect translate transaction net monetary asset consistent second quarter fourth quarter result deterioration economic condition venezuela continue decline transaction settle official rate company begin simadi rate report venezuelan operation company revalue remain net monetary asset simadi rate subsequently replace dicom rate result additional charge fourth quarter million january venezuela designate hyperinflationary result local foreign operation remeasure dollar impact record result operation decline equity income affiliate compare drive primarily low equity income certain research investment fund net present table include charge million settle worldwide patent litigation relate keytruda note gain million relate settlement patent litigation note gain million result receipt milestone payment license migraine clinical development program note million income relate astrazenecas option exercise note net include million net charge relate settlement vioxx shareholder class action litigation note expense million contribution investment equity securities merck foundation partially offset million gain sale certain migraine clinical development program note million gain divestiture merck remain ophthalmic business international market note recognition million defer income relate astrazenecas option exercise net include billion gain divestiture mcc note gain million relate astrazenecas option exercise million gain divestiture certain ophthalmic product international market note gain million relate sale sirna note recognition million defer income relate astrazenecas option exercise partially offset million loss extinguishment debt note million goodwill impairment charge relate company joint venture supera interest pay million million million table content tax income reconciliation effective tax rate statutory rate follow tax rate tax rate tax rate statutory rate apply income taxis differential arise foreign earning unremitte foreign earning tax settlement astrazeneca option exercise sale sirna therapeutics inc impact purchase accounting adjustment include amortization foreign currency devaluation relate venezuela state taxis restructure health care reform legislation divestiture merck consumer care include tax effect contingency reserve research credit miscellaneous item foreign earning tax rate differential tax rate reconciliation primarily reflect impact operation jurisdiction different tax rate united states particularly ireland switzerland singapore puerto rico operate tax incentive grant earning indefinitely reinveste yield favorable impact effective tax rate compare statutory rate foreign earning tax rate differential include impact intangible asset impairment charge amortization purchase accounting adjustment restructure cost item present separately represent significant separately disclose pretax cost charge substantial portion item relate jurisdiction low tax rate united states impact record expense item low tax rate jurisdiction unfavorable impact effective tax rate compare statutory rate company effective tax rate reflect impact protect americans tax hike act sign law december extend research credit permanently control foreign corporation lookthrough provision year company effective tax rate reflect impact tax increase prevention act sign law december extend research credit control foreign corporation lookthrough provision year income taxis consist year end december domestic foreign table content taxis income consist year end december current provision federal foreign state defer provision federal foreign state defer income taxis december consist asset liability asset liability intangible inventory relate accelerated depreciation unremitte foreign earning pension postretirement benefit compensation relate unrecognized tax benefit net operating loss tax credit carryforward subtotal valuation allowance total defer taxis net deferred income taxis recognize asset defer income taxis company net operating loss nol carryforward jurisdiction december million defer taxis nol carryforward relate foreign jurisdiction individually significant valuation allowance million establish foreign nol carryforward foreign defer tax asset addition company million defer tax asset relate tax credit carryforward nol carryforward expect fully utilize prior expiry income taxis pay billion billion billion respectively income taxis pay reflect approximately billion taxis pay divestiture mcc tax benefit relate stock option exercise million million million table content reconciliation begin end unrecognized tax benefit follow balance january addition relate current year position addition relate prior year position reduction tax position prior year settlement lapse statute limitation balance december amount reflect settlement irs discuss company recognize unrecognized tax benefit billion december income tax provision reflect favorable net impact billion company examination numerous tax authority jurisdiction globally company believe reasonably possible total unrecognized tax benefit december decrease billion month result audit closure settlement expiration statute limitation ultimate finalization company examination relevant tax authority include formal administrative legal proceeding significant impact time reversal unrecognized tax benefit company believe reserve uncertain tax position adequate cover exist risk exposure item currently discussion internal revenue service irs relate examination company conclude position sustain audit item result unfavorable outcome settlement material adverse impact company financial position liquidity result operation expense interest penalty associate uncertain tax position amount million million million amount reflect beneficial impact tax settlement include discuss liability accrue interest penalty million million december respectively irs currently conduct examination company tax return year irss examination company federal tax return conclude prior issue relate refund claim remain open issue resolve company receive refund approximately million exceed receivable previously record company result tax benefit million addition state foreign tax examination progress significant tax jurisdiction state foreign company income tax return open examination period december foreign earning billion retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability addition company subsidiary operate puerto rico singapore tax incentive grant begin expire table content earning share calculation earning share share millions follow year end december net income attributable merck inc average common share outstanding common share issuable average common share outstanding assume dilution basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder issuable primarily sharebased compensation plan million million million respectively common share issuable sharebased compensation plan exclude computation earning common share assume dilution effect antidilutive comprehensive income loss change aoci component follow employee cumulative accumulate benefit translation comprehensive derivative investment plan adjustment income loss balance january net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis relate foreign currency cash flow hedge reclassify aoci sale represent net realize gain loss sale availableforsale investment reclassify aoci income expense net include net amortization prior service cost actuarial gain loss include net periodic benefit cost note include pension plan net loss billion billion december respectively postretirement benefit plan net loss million million december respectively pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december respectively table content segment reporting company operation principally manage product basis comprise operating segment pharmaceutical animal health healthcare service alliances animal health healthcare service alliance segment material separate reporting pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity large component pediatric adolescent vaccine sale center disease control prevention vaccine child program fund government additionally company sell vaccine federal government placement vaccine stockpile sale vaccine major european market market company spmsd joint venture termination december note company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer company change composition animal health segment result inclusion certain revenue cost previously include nonsegment revenue profit prior period recast reflect change comparable basis company healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient merck alliance segment primarily include result company relationship azlp termination relationship june note october company divest consumer care segment develop manufacture market overthecounter foot care sun care product note table content sale company product follow year end december primary care womens health cardiovascular zetia vytorin diabete januvia janumet general medicine women health nuvare implanonnexplanon dulera follistim hospital specialty hepatitis zepati hiv isentress hospital acute care cubicin noxafil invanz cancidas bridion primaxin immunology remicade simponi oncology keytruda emend temodar diversify brand respiratory singulair nasonex cozaarhyzaar arcoxia fosamax zocor vaccine gardasilgardasil proquadmmr iivarivax zostavax rotateq pneumovax pharmaceutical total pharmaceutical segment sale segment sale total segment sale sale cubicin represent sale subsequent cubist acquisition date sale cubicin reflect sale japan pursuant previously exist licensing agreement amount reflect sale vaccine sell major european market company joint venture spmsd result reflect equity income affiliate include income expense net amount reflect supply sale spmsd december merck sanofi terminate spmsd joint venture note pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately represent nonreportable segment animal health healthcare service alliance consumer care divestiture october note alliance segment include revenue company relationship azlp termination june note primarily comprise miscellaneous corporate revenue include revenue hedging activity thirdparty manufacture sale include approximately million million respectively connection sale marketing right certain product table content consolidated revenues geographic area derive follow year end december united states europe middle east africa asia pacific japan latin america reconciliation total segment profit consolidate income taxis follow year end december segment profit pharmaceutical segment segment total segment profit profit unallocate interest income interest expense equity income affiliate depreciation amortization research development amortization purchase accounting adjustment restructure cost gain sale certain migraine clinical development program charge relate settlement worldwide keytruda patent litigation gain divestiture certain ophthalmic product foreign currency devaluation relate venezuela net charge relate settlement vioxx shareholder class action litigation gain divestiture merck consumer care gain astrazeneca option exercise loss extinguishment debt unallocated net segment profit comprise segment sale standard cost certain operating expense directly incur segment internal management reporting present chief operating decision maker merck allocate material production cost standard cost majority research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit addition cost related restructuring activity amortization purchase accounting adjustment allocate segment profit primarily comprise miscellaneous corporate profit operate profit relate thirdparty manufacturing sale unallocate net include expense corporate manufacturing cost center goodwill intangible asset impairment charge gain loss sale business expense income relate change estimate fair value contingent consideration miscellaneous income expense item table content equity income affiliate depreciation amortization include segment profit follow pharmaceutical total year end december include segment profit equity income affiliate depreciation amortization year end december include segment profit equity income affiliate depreciation amortization year end december include segment profit equity income affiliate depreciation amortization property plant equipment net geographic area locate follow december united states europe middle east africa asia pacific latin america japan company disaggregate asset product service basis internal management report information present table content report independent register public accounting firm board director shareholders merck inc opinion accompany consolidated balance sheet relate consolidated statement income comprehensive income equity cash flow present fairly material respect financial position merck inc subsidiaries december december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso company management responsible financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include management report item responsibility express opinion financial statement company internal control financial reporting base integrated audits conduct audits accordance standard public company accounting oversight board united states standard require plan perform audits obtain reasonable assurance financial statement free material misstatement effective internal control financial reporting maintain material respect audits financial statement include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp florham park new jersey february table content supplementary datum select quarterly financial datum contain condense interim financial datum table condense interim financial datum unaudite million share amount sale material production marketing administrative research development restructuring cost income expense net loss income taxis net loss income attributable merck inc basic loss earning common share attributable merck inc common shareholder loss earning common share assume dilution attributable merck inc common shareholder sale material production marketing administrative research development restructuring cost income expense net income taxis net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder amount include charge settle worldwide patent litigation relate keytruda note amount reflect net charge relate settlement vioxx shareholder class action litigation note foreign exchange loss relate venezuela note gain sale company remain ophthalmic business international market note amount include gain sale certain migraine clinical development program note amount include foreign exchange loss relate devaluation company net monetary asset venezuela note amount reflect acquisition divestiturerelated cost note impact restructuring action note table content item change disagreement accountant account financial disclosure applicable item control procedure management company participation chief executive officer chief financial officer evaluate effectiveness company disclosure control procedure base evaluation end period cover company chief executive officer chief financial officer conclude company disclosure control procedure define rule securities exchange act amend act effective management responsible establish maintain adequate internal control financial reporting term define rule act management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december pricewaterhousecooper llp independent register public accounting firm perform assessment effectiveness company internal control financial reporting attestation report include filing management report management responsibility financial statement responsibility integrity objectivity company financial statement rest management financial statement report management stewardship company asset statement prepare conformity generally accept accounting principle accordingly include amount base management good estimate judgment nonfinancial information include annual report prepare management consistent financial statement assure financial information reliable asset safeguard management maintain effective system internal control procedure important element include careful selection training development operate financial manager organization provide appropriate division responsibility communication aim assure company policy procedure understand organization staff internal auditor regularly monitor adequacy application internal control worldwide basis ensure personnel continue understand system internal control procedure policy concern good prudent business practice annually employee company require complete code conduct training include financial stewardship training reinforce importance understand internal control review key corporate policy procedure system addition company compliance program include ethical business practice program reinforce company longstanding commitment high ethical standard conduct business financial statement financial information include annual report fairly present material respect companys financial condition result operation cash flow formal certification security exchange commission include filing management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule securities exchange act company internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle united states america management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december table content inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear kenneth frazier robert davis chairman president executive vice president global services chief financial chief executive officer officer item information table content iii item director executive officer corporate governance require information director nominee incorporate reference discussion proposal election director company proxy statement annual meeting shareholder hold information executive officer set forth document require information compliance section security exchange act incorporate reference discussion head section beneficial ownership report compliance company proxy statement annual meeting shareholder hold company code conduct value standard applicable employee include principal executive officer principal financial officer principal accounting officer controller code conduct available company website wwwmerckcomaboutcodeofconductpdf company intend disclose future amendment certain provision code conduct waivers code conduct grant executive officer director website business day follow date amendment waiver merck employee responsible adhering business practice accordance law ethical principle reflect high standard corporate individual behavior print copy send charge shareholder request write chief ethic compliance officer merck inc galloping hill road kenilworth require information identification audit committee audit committee financial expert incorporate reference discussion head board meeting committee companys proxy statement annual meeting shareholder hold item executive compensation information require executive compensation incorporate reference discussion heading compensation discussion analysis summary compensation table compensation table grant planbase award table outstanding equity award table option exercise stock vest table pension benefit table nonqualifie defer compensation table potential payment termination change control include discussion subheading separation change control footnote information table company proxy statement annual meeting shareholder hold require information director compensation incorporate reference discussion head director compensation relate director compensation table schedule director fee table company proxy statement annual meeting shareholder hold require information heading compensation benefit committee interlock insider participation compensation benefit committee report incorporate reference company proxy statement annual meeting shareholder hold table content item security ownership certain beneficial owner management relate stockholder matter information respect security ownership certain beneficial owner management incorporate reference discussion head stock ownership information company proxy statement annual meeting shareholder hold equity compensation plan information follow table summarize information option warrant right equity compensation company equity compensation plan close business december table include information tax qualify plan merck saving plan number number security remain security available future issue weightedaverage issuance equity exercise exercise price compensation plan outstanding outstanding exclude option warrant option warrant security right right reflect column plan category equity compensation plan approve security holder equity compensation plan approve security holder total include option purchase share company common stock right follow shareholderapprove plan merck sharp dohme incentive stock plan merck inc nonemployee directors stock option plan merck inc scheringplough stock incentive plan exclude approximately share restrict stock unit performance share unit assume maximum payout merck sharp dohme incentive stock plan exclude share phantom stock defer msd employee deferral program share phantom stock defer merck inc plan defer payment director compensation item certain relationship relate transaction director independence require information transaction relate person incorporate reference discussion head related person transaction company proxy statement annual meeting shareholder hold require information director independence incorporate reference discussion head independence director company proxy statement annual meeting shareholder hold item principal accountant fee service information require item incorporate reference discussion proposal ratification appointment independent register public accounting firm begin caption preapproval policy service independent register public accounting firm fee service provide independent register public accounting firm company proxy statement annual meeting shareholder hold table content item